Subtypes of small-diameter sensory neurons in the rat knee joint by Ivanavicius, Stefan Paul
        
University of Bath
PHD








Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 14. May. 2019
SUBTYPES OF SMALL-DIAMETER SENSORY NEURONS 
IN THE RAT KNEE JOINT
By
STEFAN PAUL IVANAVICIUS
A Thesis Submitted for the Degree of Doctor of Philosophy
University of Bath 
School for Health 
September 2005
Copyright
Attention is drawn to the fact that copyright of this thesis rests with its author. 
This copy of the thesis has been supplied on condition that anyone who consults it is 
understood to recognise that its copyright rests with its author and that no quotation 
from the thesis and no information derived from it may be published without the prior
written consent of the author.
The Thesis may be made available for consultation within the University Library and 
may be photocopied or lent to other libraries for the purpose of consultation.
UMI Number: U207229
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U207229
Published by ProQuest LLC 2014. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
» s t  YAt'>
Declaration
I declare that this thesis was composed entirely by myself and that the work on which 
it is based is my own with the following exceptions:
Injection of retrograde nerve tracers was performed by Dr. Paul Mapp at the 
University of Bath for the experiments described in Chapter 2.
Knee joint injections were performed by Dr. Sharon Bingham and Iain Strickland at 





I would like to thank all of my supervisors for their guidance and advice during the 
various stages throughout my PhD studentship.
From the University of Bath I thank; Dr. Paul Mapp for his expertise and direction 
during the early stages of my studentship, Dr. Cliff Stevens for stepping in as my 
surrogate supervisor when things looked bleak and for his advice and late nights in 
The Huntsman Bar, and Prof. David Blake for our infrequent but always useful 
meetings.
From Neurology CEDD, GlaxoSmithKline I thank, Dr. Iain Chessell who has been 
my one supervisor from start to finish, who has been encouraging, dedicated and 
thorough throughout and to whom I owe a great deal (including several beers). In 
addition, I thank Dr. Sharon Bingham for the helpful discussions and support (and 
frequent lifts to and from GSK sites) during a critical period of my work.
I would like to extend my thanks to a number of other colleagues and friends, who 
have helped, encouraged or provided me with welcome distractions along the way. 
These include, from the University of Bath; Ms. Emma Roberts, Dr. Nick Shenker 
and Dr. James Hewinson for their friendship, support inside the lab and for acting as 
excellent guides to the city of Bath and bars therein, from GSK; Mr. Stephen 
Medhurst, Dr. Alex Wilson and Mr. Iain Strickland for all of their help and for 
making my move to the Harlow area much more enjoyable than anticipated.
Dedication
I would like to dedicate this thesis to all of my family and friends for their love and 
support over recent years and the years that stretch beyond the duration of my PhD 
studentship. In particular, my Mother, Father, Sister and Grandparents, without whom 
there would be no beginning, middle or end to this thesis. I also thank Laura, for 
making my life complete and for keeping me sane during the hours spent writing this 
thesis. This small passage does not even begin to express how much you all mean to 
me and how much I appreciate you all.
Abstract
Small diameter primary afferent neurons (C-fibres) are thought to contribute 
significantly in the pathology of chronic inflammatory joint pain. C-fibres are 
nociceptive afferent neurons and can be separated into at least two distinct neuronal 
subtypes based on a host of distinguishing properties. One subtype expresses the pro- 
inflammatory peptides, calcitonin gene-related peptide (CGRP), and substance P 
(SP). This C-fibre population exhibit trophic dependency towards nerve growth factor 
(NGF) and express the high affinity NGF receptor, tyrosine receptor kinase (trk) A. 
The second population of C-fibres are a non-peptidergic population that express cell 
surface glycoconjugates, which selectively bind the plant lectin Griffonia 
simplicifolia Isolectin B4 (IB4). IB4-binding C-fibres are dependent on the trophic 
factor glial derived neuronal factor (GDNF) for survival and express the GDNF 
family receptor (GFR)a subunit. A number of other distinguishing features have also 
become apparent over recent years, in particular their differential expression of cell 
surface receptors, such as the purine receptor, P2 X3, and transient receptor potential 
vanilloid receptor 1 (TRPV1; VR1). All of these characteristics imply potential 
differences in the relative contributions to nociception and disease pathogenesis by C- 
fibre subtypes.
Whilst numerous distinguishing features separating the C-fibre subtypes have been 
identified, their distributions in synovial joints and respective roles in the 
pathogenesis of chronic joint pain have not been investigated thoroughly and 
therefore are not entirely understood. Greater understanding of the roles elicited by 
the C-fibre subtypes may facilitate the development of novel pharmaceuticals for the 
treatment of chronic inflammatory joint pain. In this thesis, retrograde nerve tracing, 
in vivo models of pain, fluorescent histochemistry and behavioural techniques were 
used to test the hypotheses that (i) IB4-binding neurons are not present within the rat 
knee joint during normal or pathophysiological conditions and (ii) that knee joint 
specific CGRP-expressing neurons increase in number during a model of chronic 
inflammatory joint pain.
Investigations described in this thesis demonstrate, unequivocally, that IB4-binding 
neurons are entirely absent from the rat knee joint at the level of the ipsilateral L3 and 
L4 DRG under normal and pathophysiological conditions induced by intra-articular 
(i.art) administration of FCA. In addition, the data demonstrate that CGRP- 
immunoreactive joint afferent neurons increase in number during the early, 
intermediate and latter stages of pathophysiological conditions. Data derived from 
this thesis support the notion of separate roles for C-fibre subtypes in both normal 
physiology and their potential contributions in disease pathology and thus, may have 
implications for the development of novel pharmaceuticals for the treatment of pain.
Publications
IVANAVICIUS, S. BLAKE, D. R. CHESSELL, I. P. AND MAPP, P. I. (2004). 
Isolectin B4 binding neurons are not present in the rat knee joint. Neuroscience. 128, 
555-560.





ANOVA Analysis of variance
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Rene Descartes once described pain in the terms of an alarm bell ringing in a bell 
tower to alert an individual of harm or potential harm (Main and Spanswick, 2000). 
This protective sensory function is echoed in modem day understanding and 
definitions of pain. The current definition of pain, as determined by the International 
Association for the Study of Pain (IASP) is “an unpleasant sensory and emotional 
experience normally associated with tissue damage or described in terms of such 
damage” (Merskey et al., 1986).
Chronic inflammatory pain affects millions of people worldwide and is regarded by 
the World Health Organisation (WHO) as a major reason for health related absence 
from work. Chronic inflammatory pain is a severe symptom of diseases such as 
fibromyalgia syndrome (FMS), rheumatoid arthritis (RA) and osteoarthritis (OA) 
(Loeser and Melzack, 1999). Insomnia, depression, anxiety and an array of other 
psychological problems can occur as a result of chronic pain conditions which often 
have detrimental effects on the quality of life and social responsibilities of affected 
individuals (Gureje et al., 1998; Ashbum and Staats, 1999). Pain is referred to as 
chronic when it lasts beyond the normal time required for healing following tissue 
trauma or when it is associated with a pathological condition that does not heal. In 
many cases chronic pain may arise in the absence of an external trigger, such as the 
onset of RA and FMS (Kidd and Urban, 2001; Staud, 2004).
Decades of research have identified several classes of afferent neurons, a number of 
which mediate pain sensation and which are stimulated by countless mediators and 
networks of inflammation, contributing significantly to conditions of chronic pain.
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Over recent years, afferent neurons have been implicated not only in the mediation of 
pain during conditions such as RA, but also in the pathogenesis of such diseases. 
Thus, the specific innervation of areas affected by diseases such as RA are of 
considerable medical interest, particularly in terms of understanding chronic 
inflammatory pain states and in developing new targets for novel pharmaceuticals to 
treat such conditions.
In this introductory chapter primary afferent neurons will be discussed throughout. 
Several of the mechanisms associated with chronic inflammatory pain will also be 
described with particular focus on cytokines, prostaglandins and neurogenic factors. 
A detailed account of the vertebrate knee joint will also be covered in the context of 
normal and pathophysiological states, in particular RA. Finally, animal models of 
pain and the literature detailing current treatments for chronic inflammatory joint pain 
will be reviewed.
1.2 NOCICEPTION
The idea that pain can be physically detected through specific pain sensing receptors 
was first documented almost a century ago by Sherrington (1906). Sherrington 
proposed that a “nocicipient” system was present within organisms that was able to 
detect stimuli capable of compromising its integrity. Thus, the terms nociception and 
nociceptor were coined (Burgess and Perl, 1967). Despite the dawn of 
electrophysiological techniques in the 1920’s and considerable other research efforts, 
no conclusive evidence of Sherrington’s noci-receptors was found until the late 
I960’s. Identification of a small diameter, thinly myelinated neuronal population (A6 - 
fibres) in cat skin confirmed the presence of nociceptive afferent neurons by
3
responding to noxious thermal and mechanical stimuli (Burgess and Perl, 1967). 
Furthermore, another small diameter, unmyelinated neuronal population (C-fibres), 
which responded to intense thermal, mechanical and chemical stimulation was also 
identified in cat skin (Bessou and Perl, 1969). Thus, the presence of nociceptor 
subclasses had been discovered.
1.2.1 Classification of nociceptors
Nociceptive afferent fibres are often classified in two fashions. There is an 
alphabetical classification, which includes A and C-fibres and there is also a Roman 
numeral classification system, designated as group I, II, III and IV fibres (Freeman 
and Wyke, 1967). The alphabetical system categorizes afferents according to size, 
generally there are Aa, Ap, AS and C-fibres, largest to smallest (see table 1.1) 
(Gasser and Erlanger, 1927). Ay and B-fibres are also part of the alphabetical 
classification although these are motor and sympathetic fibres, respectively. Whilst 
some overlap between the alphabetical and numerical system does exist, for example, 
AS and C-fibres roughly correspond to group III and IV afferents, this overlap can 
cause some confusion. Therefore, from hereonin sensory afferents will be referred to 
using the alphabetical system.
1.2.2 A-delta and C-fibres
AS and C-fibres are nociceptive afferent neurons that mediate pain information from 
various peripheral locations. A8 -fibres are small diameter lightly myelinated neurons 
with a conductance velocity of action potentials ranging between 12-30 m/s. C-fibres 
are an unmyelinated class of nociceptor with a smaller axonal diameter than A8 -fibres
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and slower conductance velocities, approximately 0.5-2 m/s (Caterina and Julius, 
1999; Hunt and Mantyh, 2001; Julius and Basbaum, 2001). C-fibre subtypes, 
potential functions and roles in chronic pain are discussed in more detail later in this 
chapter. It is also important to mention that whilst Ap-fibres generally mediate 
proprioception and light touch they also mediate a degree of pain sensation, 






Aa and Ap-fibres 10-20 Aa = 70-120 
A3 = 30-70
Proprioception and light 
touch
A8-fibres 3 12-30 Nociception (chemical, 
thermal, mechanical)
C-fibres <1 0.5-2 Nociception (chemical, 
thermal, mechanical)
Table 1.1 Summary of sensory afferent fibre properties. (Gasser and Erlanger, 1927; 
Julius and Basbaum, 2001).
1.2.3 Classifying pain
Pain can generally be classified as nociceptive, inflammatory or neuropathic 
depending on the type of injury sustained (Mackey, 2004). Nociceptive pain is the 
pain in which normal nociceptive afferent neurons transmit information to the central 
nervous system (CNS) about trauma to tissue. Inflammatory pain is pain precipitated 
by an insult to the integrity of tissues at a cellular level. Neuropathic pain is pain in 
which there are structural and/or functional nervous system maladaptations secondary 
to injury, that take place either in the peripheral or central nervous system (Ranney, 
2001).
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Pain states are associated with increases in the sensitivity of the normal physiological 
pain pathways. These aberrations of the nociceptive pathways include hyperalgesia; 
an increased amount of pain due to a mild noxious stimuli and allodynia; pain evoked 
by a non-noxious stimulus (Rang et al., 2003). Increases in sensitivity occur as a 
result of plasticity in the sensory pathways which are mediated by the processes 
involved in peripheral and/or central sensitisation (Rang et al., 1996; Zhang et al., 
2003).
1.2.4. Peripheral sensitisation
Tissue injury is, for the large part, the immediate cause of pain. This is mainly due to 
local release of inflammatory mediators from damaged cells which activate peripheral 
nociceptors directly or via initiation of biochemical and/or immune pathways. Cations 
(K+, H+), bradykinin, 5-hydroxytryptamine (5-HT), adenosine triphosphate (ATP) and 
nitric oxide (NO) are all released from damaged tissue and all produce pain via action 
on ion channels or their appropriate receptor complexes (Grubb, 1998; Kidd and 
Urban, 2001). Inflammatory mediators influence the recruitment of immune cells to 
the site of injury, thereby promoting the release of inflammatory cytokines and 
growth factors. Activation of the arachidonic acid pathway leads to the release of 
prostaglandins and leukotrienes. In addition, nerve growth factor (NGF) is released, 
and A8  and C-fibres exert a neurogenic inflammatory effect through the release of 
substance P and calcitonin gene related peptide (CGRP), which are both potent 
inflammatory neuropeptides (See figure 1.1 for summary of peripheral sensitisation). 
In the presence of inflammatory mediators the normal responses of primary afferent 




Cytokines are soluble proteins that are released by a variety of cells, such as 
fibroblasts, synoviocytes and mast cells (Watkins et al., 1995; Buch and Emery, 
2002). Cytokines are chemical messengers that regulate the balance between cell- 
mediated and humoral (antibody) mediated immune responses. Essentially, they 
produce either an inflammatory or an anti-inflammatory response. In addition, 
cytokines can stimulate the release of other inflammatory mediators, particularly 
prostaglandins, which influence the neurogenic inflammatory properties of A8  and C- 
fibres.
Inflammatory cytokines include tumour necrosis factor alpha (TNFa), interleukin-1 
(IL-1), IL- 6  and IL-8 . The actions of anti-inflammatory cytokines are not as well 
understood as the inflammatory cytokines. IL-10 has received the most attention of 
all the anti-inflammatory cytokines and is referred to as anti-inflammatory due to a 
macrophage suppression function and an ability to reduce hyperalgesia evoked by 
TNFa, IL-1 and IL- 6  when administered in models of neuropathic pain (Okamoto et 
al., 2001). Cytokines are discussed in the context of RA later in this chapter.
1.2.4.2. Prostaglandins
Prostaglandins are derivatives of arachidonic acid, the most abundant polyunsaturated 
fatty acid component of cell membranes which is released from membrane 
phospholipids in response to phospholipase-A2 (PLA-2) and phospholipase-C (PLC) 
activity (Bertolini et al., 2001). The released arachidonic acid serves as the precursor
7



























Figure 1.1 Tissue damage that often precedes pain leads to the local release of 
numerous inflammatory mediators from various sources. These act alone or more 
often in synergy with each other to regulate the processes of inflammation and pain 
via direct action on receptors located on A8  or C-fibres or indirectly as sensitising 
agents. NGF, nerve growth factor; TrkA, tyrosine receptor kinase A; BK2, bradykinin 
2 receptor; ATP, adenosine triphosphate; P2 X3, purine receptor; H+, proton; VR1, 
vanilloid receptor 1; PGE2, prostaglandin E2 . Adapted from Julius and Basbaum 
(2001).
Two human isoforms of COX, COX-1 and COX-2, have been identified and well 
documented since the early 1990s. Both isoforms have similar active sites for their 
natural substrate, arachidonic acid, and exhibit approximately 60% sequence
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homology (Bertolini et al., 2001). COX-1 is constitutively expressed in most tissues 
and is involved in maintaining gut integrity by reducing gastric acid secretions and 
stimulating the production of viscous mucus. Prostaglandins synthesised via COX-1 
also exert an effect on the regulation of renal blood flow by dilating vascular beds and 
enhancing organ perfusion. COX-2 is an inducible isoform that is only constitutively 
expressed in certain regions of the CNS and renal cortex (Chopra et al., 2000). During 
inflammatory states, levels of COX-2 are upregulated via a number of immuno- 
inflammatory pathways, including stimulation through IL-1 and TNFa release, thus, 
levels of prostaglandins are substantially increased (Ebersberger et al., 1999; 
Goldenberg, 1999).
Intermediate compounds are formed from the catalysis of arachidonic acid which are 
converted to prostaglandins G2 (PGG2), PGD2, PGF2 and PGI2. PGG2 is rapidly 
converted to PGE2 and PGF2 depending on the cell type. Prostaglandins are important 
mediators of inflammation and pain, especially PGE2 . In some circumstances 
prostaglandins can contribute to pain by directly activating nociceptors. However, 
most of their actions are mediated via PG receptors (EP1-4) which are located on a 
variety of sensory neurons (Bley et al., 1998). Prostaglandin receptors utilise a 
number of second messenger pathways to mediate their inflammatory actions, 
including activation of protein kinase C (PKC) via diacylglycerol (DAG) and 
activation of protein kinase A (PKA) via activation of cyclic adenosine 
monophosphate (cAMP). These pathways activate cell surface ion channels thus, 
propagating action potentials, which promote further release of arachidonic acid and 
neuropeptides and cause increased sensitisation of primary afferent neurons to 
bradykinin (see figure 1 . 2  for summary of prostaglandin synthesis and receptor
9
mediated effects; Bley et al., 1998; Kidd and Urban, 2001). A number of 
pharmaceuticals that disrupt this pathway have been developed in attempts to treat 
chronic inflammatory pain and are discussed later in this chapter.
arachidonic acid 
COX-1/COX-2 >k NSAIDs 

















Figure 1.2 Summary of prostaglandin synthesis and EP receptor mediated effects. 
PG’s synthesised from arachidonic acid via COX-1 and -2 act on EP and IP receptors 
located on nearby sensory neurons. EP and IP receptor activation stimulates 
adenylate cyclase and/or PLC activity. Hence, cAMP dependent protein kinase (PKA) 
and protein kinase C (PKC) are activated. This results in the modulation of voltage- 
gated and ligand-gated ion channels, culminating with increased action potentials and 
transmitter release. Non-steroidal anti-inflammatory drugs (NSAIDs) and COX 
inhibitors which disrupt this pathway are discussed later in this chapter. Adapted from 
Bley et al (1998).
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1.2.5.3. Neurogenic factors
In addition to cytokine release and prostaglandin synthesis at the site of tissue injury, 
expression of NGF is also increased, by cells such as mast cells, lymphocytes and 
eosinophils (Pan et al., 2000; Bonini et al., 2003; Butowt and Bartheld, 2003). NGF is 
a trophic factor that regulates the survival of at least one population of primary 
afferent neurons. Afferents that express neuropeptides and the high affinity NGF 
receptor tyrosine receptor kinase (trk) A have shown NGF dependence (Calza et al.,
1998). NGF exerts a considerable and long-lasting effect within several of the pain 
and inflammation pathways. During acute stages of an inflammatory response NGF 
activates trkA receptors which leads to tyrosine phosphorylation of intracellular 
proteins including ion channels, thus adding to the sensitisation of nociceptive 
afferent neurons. Over time, NGF activates mast cells and other inflammatory cells, 
which leads to further release of inflammatory mediators (Lewin and Mendell, 1993; 
McMahon et al., 1995). Moreover, NGF regulates the expression of SP and CGRP 
from trkA-expressing neurons. Although SP and CGRP are thought to make little, if 
any, direct contributions to nociceptor activity during inflammation these 
neuropeptides are known to potentiate the inflammatory response by increasing 
capillary permeability, inducing the release of PGE2 and acting as chemotactic agents 
for endothelial cells and fibroblasts. Collectively the actions of inflammatory 
neuropeptides released by neurons are referred to as neurogenic inflammation. Whilst 
neurogenic inflammation is predominantly mediated by A8- and C-fibres evidence 
exists which suggests that Ap-fibres contribute by switching their phenotype to one 
resembling nociceptors (Neumann et al., 1996).
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1.2.5 Central sensitisation
In the same way that the peripheral terminals of nociceptors can become sensitised, 
excitability of the dorsal horn of the spinal cord can also be chronically increased. 
Central sensitisation occurs when repetitive or continuous activation of AS- and/or 
C-fibres terminating in laminae I, II and V of the dorsal horn produce changes in 
central neurogenic pathways (Woolf and Salter, 2000; Bolay and Moskowitz, 2002). 
Release of SP, CGRP and glutamate (GLU) from primary afferent neurons within the 
dorsal horn leads to activation of receptors located on nociresponsive neurons in the 
dorsal horn. In particular (+/-)-a-amino-3-hydroxy-5-methylisoxazole-4-propionic 
acid (AMPA) and N-methyl-D-aspartate (NMDA) receptors become activated (see 
figure 1.3 for summary). AMPA and NMDA receptors mediate long-lasting changes
4^*in spinal excitability due to increased Ca ion influx and phosphorylation of 
intracellular proteins. These actions cause exaggerated responses to normal stimuli, 
expansion of receptive field size and reduced thresholds for activation from novel 
inputs (Levine et al., 1993; Grubb, 1998; Woolf and Salter, 2000; Kidd and Urban, 
2001). Thus, central sensitisation is responsible for amplification of peripheral inputs 
from regions beyond the inflamed or injured tissue and secondary hyperalgesia. It is 
also postulated that when Ap-fibres undergo phenotypic switch to resemble 
nociceptors that they may be sufficient enough to maintain the responses to 















Figure 1.3 Repeat activation of primary afferent neurons leads to synaptic release of 
transmitters within the dorsal horn. These act at several postsynaptic receptor 
complexes, including the excitatory amino acid receptors NMDA and AMPA 
receptors. SP and CGRP are also thought to act at autoreceptors on peptide 
expressing primary afferent neurons. Adapted from Levine et al., 1993.
In addition to the well established processes described above, recent evidence has 
demonstrated that central sensitisation is also facilitated by a number of mediators 
that have been predominately associated with peripheral sensitisation. These include 
several cytokines and COX-2 products, in particular PGE2 . Increased expression of 
COX-2 in the CNS is thought to occur in response to IL-lp release by endothelial 
cells of the cerebral vasculature (Samad et al., 2001). The subsequent increase in 
spinal PGE2 influences synaptic release of neuropeptides by binding to presynaptic 
endings of nociceptors and may be one of several mediators responsible for long-term 
activation of spinal cord microglia and dorsal horn neurons (Staud, 2004; Woolf, 
2004; McMahon et al., 2005). It is postulated that activation of microglia, which are
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macrophage-like cells, in response to peripheral injury are a source of many cytokines 
that act on surrounding neurons and glia. Indeed, activation of peripheral glia after 
nerve injury are thought to influence neighbouring injured and non-injured sensory 
neurons via the release of TNFa (Woolf, 2004).
Numerous painful conditions can be easily explained in terms of increased release 
and expression of inflammatory mediators and cell activation. However, in conditions 
of chronic inflammatory pain there may be no easily identifiable external trigger to 
cause tissue trauma. In fact many conditions of chronic inflammatory pain are of 
uncertain aetiology, RA is a prime example of this. Despite the uncertainty 
concerning the aetiology of RA, research has uncovered an abundance of knowledge 
regarding this disease and other chronic inflammatory pain states that effect synovial 
joints.
1.3 SYNOVIAL JOINTS
Synovial joints are the body’s most numerous, most mobile and most anatomically 
complex joints. Synovial joints cushion many bones and absorb considerable pressure 
exerted on them during locomotion making them very sensitive structures that are 
often subject to injury, wear and tear or disease conditions such as RA and OA.
In order to discuss diseases that effect synovial joints in detail it is essential to 
describe the anatomy of synovial joints. For anatomical investigation the knee joint is 
a relatively large and easily accessible synovial joint that is examined frequently in 
numerous species. Studies described in this thesis only examined the knee joint
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therefore the knee joint will be used to illustrate key features of synovial joints 
throughout this introductory chapter.
1.3.1 Anatomy of the vertebrate knee joint
Typically, synovial joints are comprised of a number of key structures. These include 
subchondrial bone, articular cartilage, fibrous capsule and the synovial membrane 
(see figure 1.4.A).
B
Figure 1.4 Normal and chronically inflamed knee joint. A, illustrates the basic 
structure of the vertebrate knee joint and a number of key structures that comprise 
synovial joints. B, illustrates the vertebrate knee joint during a chronic inflammatory 
state, highlighting several structural abnormalities and immune cells recruited to the 
synovium during such conditions. Adapted from Smolen and Steiner (2003).
Subchondrial bone is found at the epiphyses of the bone and is filled with the soft 
connective tissue, red marrow. Articular cartilage is a thin layer of hyaline cartilage 
that covers and cushions the joint surfaces of bones which prevents rubbing of the 
subchondrial bone. The joint capsule is a complete fibrous casing that surrounds the 















synovial membrane or synovium is a slippery membrane that lines the inner surface 
of the joint capsule. Synovium is usually only a few cells (synoviocytes) thick and the 
inner membrane secretes synovial fluid into the joint space, lubricating the joint.
1.3.2 Innervation of the knee joint
Most investigations of knee joint innervation have been made in rodents, although 
some studies have also been performed in cat and man. Despite some interspecies 
differences the similarities appear to be more prominent. Constant in all three species 
are the two main articular nerves supplying the vertebrate knee joint, the medial 
articular nerve and the posterior articular nerve (MAN and PAN respectively) 
(Freeman and Wyke, 1967; Johansson et al., 1991). The PAN is the largest articular 
nerve and arises from the posterior tibial nerve and innervates the posterior aspect of 
the knee joint capsule. The MAN arises in the antro-medial region of the thigh as a 
branch of the saphenous and/or the obturator nerves and innervates the antro-medial 
aspect of the joint capsule. All knee joint structures receive innervation from articular 
nerves except for hyaline cartilage. Although additional innervation of the joint 
comes from smaller intramuscular articular nerves, which arise in muscles from 
branches of the main muscle nerves, the majority of innervation comes from the 
MAN and PAN. Together these two articular nerves account for 80-90% of knee joint 
innervation and are comprised of both myelinated and unmyelinated fibres (Salo,
1999).
Approximately 20% of axons from the MAN and PAN are myelinated and consist of 
large diameter, thickly myelinated mechanoreceptors and smaller diameter, thinly
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myelinated, rapid conducting nociceptors. The remaining 80% are unmyelinated 
axons, almost half are sympathetic and the rest are C-fibres (Salo, 1999).
1.3.3 Articular mechanoreceptors
Ruffini end organs, Pacinian corpuscles and Golgi tendon organs are the 3 different 
morphological types of sensory nerve endings of A a and Af-fibres. These sensory 
nerve endings respond to different degrees of pressure, they are responsible for 
proprioception and are located throughout synovial joints. Although each of the 
sensory nerve endings do exhibit similar functional characteristics they are generally 
found in different joint structures and have distinct morphologies (Heppelmann et al., 
1995; Salo, 1999).
1.3.4 Articular nociceptors
Synovial joints are predominantly innervated by AS and C-fibres, the latter being the 
most abundant (Langford and Schmidt, 1987; Salo, 1999). Articular nociceptors are 
located in all areas of the joint except in the hyaline cartilage and respond to noxious 
thermal, mechanical and chemical stimuli. Growing evidence implies that there is a 
significant C-fibre involvement in the pathogenesis and progression of chronic 
inflammatory joint pain (Kidd et al., 1990; Mapp et al., 1990). Extreme changes in 
neuronal plasticity, such as phenotypic switching, have been noted in C-fibres at their 
peripheral terminations, in their cell bodies located in the dorsal root ganglia (DRG), 
in their spinal cord connections and in the neurons supplying the contralateral joint 
(Mapp et al., 1993). One of the key neurogenic components involved in inflammation 
includes the release of NGF from sites of tissue damage which stimulates the release
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of SP and CGRP from trkA-expressing neurons, as described above. However, this is 
only one mechanism that C-fibres are thought to utilize in the mediation of normal 
and pathophysiological pain.
1.4 C-FIBRE SUBTYPES
Until two decades ago C-fibres were thought to be comprised exclusively of trkA- 
expressing fibres and were regarded as a single subclass of nociceptor. However, in 
the early 1980s Nagy and Hunt (1982) noted another subclass of C-fibre that 
contained the enzyme fluoride-resistant acid phosphatase (FRAP) and bound the plant 
lectin Grijfonia simplicifolia I Isolectin B4 (IB4; Nagy and Hunt, 1982). Since the 
early 1980s the differences between the two C-fibre subclasses have become more 
and more apparent, especially with regards to their trophic dependencies, expression 
of neurochemicals and neurochemical receptors and their anatomy and innervation 
territories (Bennett et al., 1998; Guo et al., 1999; Stucky and Lewin, 1999).
1.4.1 Trophic dependency
During early embryonic development most, if not all C-fibres in rat are dependent on 
NGF (Zwick et al., 2002). For trkA-expressing C-fibres this NGF dependence 
continues throughout the entire of postnatal and adult life. However, approximately 
half of all C-fibres undergo a complete phenotypic switch during the first three weeks 
after birth, becoming dependent on glial derived neuronal factor (GDNF; Bennett et 
al., 1996b; Molliver et al., 1997; Bennett et al., 1998; Zwick et al., 2002). These C- 
fibres develop into IB4-binding neurons.
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Just as trkA receptors are expressed by NGF dependent C-fibres, the IB4-binding 
subclass express the GDNF high affinity receptor components, GDNF-family 
receptors (GFR)al-4 and c-ret (Bennett et al., 1998; Bennett et al., 2000; Orozco et 
al., 2 0 0 1 ) which act as ligand binding domains and a signal transducing domain 
respectively. Together these receptor domains are believed to mediate the passage of 
nociceptive information within IB4-binding neurons.
Whilst NGF is thought to predominantly promote survival in trkA-expressing neurons 
it has been demonstrated that some NGF dependent neurons also bind IB4 (Kashiba 
et al., 2001). These observations may imply the presence of a further subtype within 
C-fibre populations which may be confirmed using appropriate marker substances 
raised against, as yet, unidentified targets. This overlap also suggests that the 
distinction between trophic dependencies is not as clear as previous studies have 
indicated, thus, a combined effect of NGF and GDNF may be required for the 
survival of certain C-fibres.
1.4.2 Expression of neurochemicals and receptors
As described above, NGF dependent C-fibres express SP and CGRP. Therefore, they 
are referred to as being peptidergic. IB4-binding neurons are generally non- 
peptidergic although some co-localization with SP and CGRP has been noted 
(Bergman et al., 1999). All IB4-binding neurons are thought to express a variety of 
enzymes, cell surface receptors and other cell surface products such as a-D-galactose 
groups. These are glycoconjugates that specifically bind the plant lectin, IB4, hence 
the name IB4-binding neurons.
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The main enzymes expressed by IB4-binding neurons are FRAP and thiamine mono­
phosphatase (TMP). FRAP and TMP are assumed to be identical enzymes, only 
regarded as separate enzymes due to differences in the organelles they are 
concentrated within and moderately different enzyme kinetics (Knyihar-Csillik et al., 
1986). The functions of these enzymes are not entirely understood, but it has been 
postulated that they act as neurotransmitter metabolizing enzymes (Nagy and Hunt, 
1982). Despite this lack of understanding about the roles of these enzymes the fact 
that they act as useful markers for IB4-binding neurons is established and employed 
in research.
Arguably the most important receptors, other than the growth factor receptors, 
expressed by IB4-binding neurons, with regards to nociception and potential 
pharmacological intervention are the capsaicin receptor and purine receptor, vanilloid 
receptor 1 (TRPV1; VR1) and P2 X3 respectively. In addition, a number of voltage 
gated sodium channels (VGSCs) located on IB4-binding neurons have been identified 
and are thought to contribute significantly in nociceptive transmission, particularly in 
inflammatory pain (Fjell et al., 1999).
1.4.3 Transient receptor potential Vanilloid receptor 1
TRPV1 or VR1 can be activated by endogenous ligands such as anandamide and 
leukotriene B4, the exogenous ligand capsaicin, which is the pungent agent in hot 
chilli peppers and by heat (>43 °C) and acidic pH (<5.3) (Veronesi and Oortgiesen, 
2006). Intradermal and topical administration of capsaicin often results in a 
hyperalgesia, mainly associated with the release of SP and CGRP (Caterina and 
Julius, 2001). IB4-binding neurons do not express SP or CGRP, thus it is probable
20
that the hyperalgesia induced by capsaicin occurs via activation of a VR1 population 
on another subset of neurons. Indeed, there is evidence that does suggest this, as VR1 
receptors have been identified on both subclasses of C-fibre and even on a small 
population of A8 -fibres (Guo et al., 1999; Guo et al., 2001). Nevertheless it has been 
postulated that the relationship between VR1 and IB4-binding neurons could indicate 
the possibility of more complex mechanisms for the release of peptides such as SP 
and CGRP in response to capsaicin.
The expression of VR1 on IB4-binding neurons appears to differ between species. In 
rat 65-75% of IB4-binding neurons express VR1 (Guo et al., 1999) whereas in mice 
percentages as low as 2-3% of IB4-binding/VR 1 co-localization in DRG cell bodies 
have been reported (Zwick et al., 2002). However, other authors have noted 
approximately 24% IB4-binding/VRl co-localization in naive mice DRG (Breese et 
al., 2005). Despite this, it is apparent that a large species difference in IB4- 
binding/VRl co-localization exists. To date, the relationship between IB4-binding 
and VR1 co-expression in human is currently unconfirmed and therefore which 
species most closely resembles the human IB4-binding/VRl profile is unknown. 
Exactly how VR1 receptors co-localized with IB4-binding neurons influence 
nociception also remains unclear. However, the observation that IB4-binding/VRl 
co-localization increases from 24% to 80% in mice DRG, two days following 
inflammation of the hind paw (Breese et al., 2005) suggests that a crucial function for 
VR1 on IB4-binding neurons exists in the inflammatory process, despite the species 
difference in naive animals.
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1.4.4 Purine receptor P2X3
P2X receptors are a family of ion channels that are activated by ATP. Although there 
are several members of the P2X family, the main member of significance regarding 
IB4-binding neurons is P2 X3. This is because approximately 94% of IB4-binding 
neurons express the P2 X3 receptor (Vulchanova et al., 1998) whereas only 3% of 
trkA-expressing neurons are P2 X3 positive. Thus, expression of P2 X3 is almost 
exclusive to C-fibres and implicates this receptor in the process of nociception.
Release of ATP, from sites of tissue damage, can promote the development of 
inflammation through a combination of actions via receptors other than P2 X3, such as 
release of histamine from mast cells, provoking production of prostaglandins and the 
synthesis and release of cytokines from immune cells (Bumstock, 2002). It is thought 
that ATP can directly activate P2 X3 receptors on IB4-binding neurons causing 
increased firing frequency and evoking a depolarizing response, resulting in pain 
sensation (Honore et al., 2002). The depolarizing currents produced by P2 X3 
receptors in response to ATP vary depending on whether or not the channel is a 
homomeric or heteromeric complex (Caterina and Julius, 1999). Research efforts 
have identified heteromeric complexes derived from both P2 X3 and P2 X2 receptor 
subunits which elicit distinct electrophysiological profiles following exposure to ATP 
or ATP analogues (Radford et al., 1997). The significance of this phenotypic variance 
has yet to be fully established.
A number of experiments have illustrated the potential of P2 X3 receptor antagonists 
as treatments for chronic pain. For example, Honore et al induced a chronic 
inflammatory state in the hind paw of rats using complete Freund’s adjuvant then
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administered a P2 X3 antisence oligonucleotide over a period of seven days to block 
receptor expression (Honore et al., 2002). This produced a significant decrease in 
behavioural measurements of nociception. In addition, P2 X3 receptor antagonists have 
demonstrated reductions in mechanical allodynia and thermal hyperalgesia in models 
of neuropathic and chronic inflammatory pain (North, 2003b). Hence, the P2 X3 
receptor is currently a major area of investigation within the pharmaceutical industry
1.4.5 Voltage gated sodium channels
VGSCs are fundamental determinants of neuronal excitability and may play a 
significant role in inflammatory pain (Fjell et al., 1999). Nociceptive afferent neurons 
are generally endowed with both VGSCs that are sensitive to tetrodotoxin (TTX-S), 
and VGSCs that are relatively resistant to tetrodotoxin (TTX-R) (Caterina and Julius, 
1999). Molecular cloning and electrophysiological investigations have identified that 
two TTX-R sodium channels, Nav1.8 and Nav1.9 are present in both IB4-binding and 
trkA-expressing neurons (Wu and Pan, 2004). The distribution of Nav1.8 channels 
appears to be relatively even between the two neuronal subtypes, whereas Nav1.9 
channels are preferentially expressed in IB4-binding neurons (Fjell et al., 1999). 
Whilst the exact nature of this molecular heterogeneity and relative distributions in C- 
fibre subtypes have not yet determined the respective contributions of Nav1.8 and 
Nav1.9 in nociception, several studies have provided encouraging data. In vitro 
studies using transected sciatic nerve have identified that down regulation of Nav1.8 
and Nav1.9 channels and the subsequent reduction in TTX-R currents, as seen in 
nerve damage, can be rescued by treatment with NGF and GDNF respectively, 
demonstrating that these neurotrophins differentially regulate VGSCs (Fjell et al., 
1999). In addition, mouse knockout studies have shown that mice without Nav1.8
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exhibit deficits in certain thermal and mechanically evoked nociceptive responses, as 
well as delays in the development of inflammation-induced hyperalgesia, suggesting 
a critical role of Nav1.8 in normal nociception (Caterina and Julius, 1999). Future 
studies of this nature will undoubtedly offer further detail regarding the significance 
of VGSCs in specific aspects of nociception.
1.4.6 Anatomy and innervation territories
Further distinguishing features that separate the two C-fibre subclasses can be 
illustrated by their anatomical differences. Both C-fibre populations terminate in the 
superficial dorsal horn of the spinal cord (Stucky and Lewin, 1999). Although these 
points of termination overlap, they are also somewhat distinct. TrkA-expressing C- 
fibres project to lamina I and outer lamina II, whereas IB4-binding neurons terminate 
predominately in inner lamina II (see figure. 1.5; Silverman and Kruger, 1990).
The significance of these anatomical differences is not yet understood but it almost 
certainly has functional implications as the distinct layers of the superficial dorsal 
horn have been implicated in different aspects of nociception, such as the quality of 
nociceptive information received and transmitted and in several features of 
nociceptive behavior (Malmberg et al., 1997a; Mantyh et al., 1997; Stucky and 
Lewin, 1999).
The innervation territories of the two C-fibre subclasses are also distinct. Most trkA- 
expressing fibres appear to innervate visceral structures, whereas IB4-binding 
neurons generally innervate more superficial structures (Lu et al., 2001; Ambalavanar 
et al., 2003). For example, approximately 70% of all neurons innervating the
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epidermis of the rat footpad were IB4-binding, but did not express trkA (Lu et al., 
2001). Other investigations support these findings having identified a greater 
proportion of IB4-binding neurons in cutaneous structures rather than trkA- 
expressing fibres. Conversely, far more visceral afferents have been identified as 
trkA-expressing and IB4 negative (Bennett et al., 1996a).
Despite identifying a cutaneous and visceral link with IB4-binding and trkA- 
expressing neurons respectively, detail regarding their individual innervation of deep 
somatic structures such as synovial joints remains relatively sparse. Thus, exactly 
how IB4-binding and trkA-expressing neurons influence the mediation of joint pain 
in normal and pathophysiological conditions such as RA is unknown.
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Figure 1.5 Distinct regions of the superficial dorsal horn where IB4-binding neurons 
and trkA-expressing neurons terminate. Adapted from Hunt and Mantyh (2001).
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1.5 RHEUMATOID ARTHRITIS
RA is a chronic, progressive and systemic autoimmune disease that affects synovial 
joints. Typically, RA is a symmetrical arthritis that manifests in the synovial joints of 
the hands and feet and then with decreasing frequency, the wrists, ankles, knees, 
shoulders, elbows and hips (Freemont, 1995; Buch and Emery, 2002). It affects 
approximately 1 % of adults worldwide and is three times more prevalent in the 
female population (Goemaere et al., 1990; Firestein, 2001; Buch and Emery, 2002). 
As a systemic disease, RA can affect tissues or body systems other than the synovial 
joints, causing extra articular conditions such as scleritis and anemia (Mclnnes and 
Sturrock, 1995). However, the essential pathophysiology of RA is characterized by 
inflammation of the synovium and increased proliferation of synoviocytes, leading to 
formation of a tissue called pannus, a disorganized mass of cells made up of 
macrophages, fibroblasts, chondrocytes and vascular fibrous tissue (see figure 1.4 B; 
Edwards, 1995). Pannus is considered to be the most damaging element affecting the 
diseased joint. It is associated with the expression of destructive matrix 
metalloproteinases (MMPs) and the degradation of the soft-tissue constraints (joint 
capsule and ligaments) and of the articular cartilage (Woolley, 1995; Buch and 
Emery, 2002).
RA is associated with inflammatory and neuropathic pain, which is characterized by 
spontaneous pain and hyperalgesia (Salo, 1999; Zhang et al., 2003). Spontaneous pain 
may occur when the joint is at rest and hyperalgesia usually occurs when the joint is 
being moved in its normal working range and/or when gentle pressure is applied. The 
pain associated with the RA causes an enormous burden on the quality of life and self
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perception of individuals suffering with the disease (Gureje et al., 1998: Ashbum and 
Staats, 1999).
Determining the etiology of RA is currently a matter of considerable research and has 
been for many years. Evidence suggests that RA may be caused by interactions 
between environmental agents and a background of genetic susceptibility which 
together give rise to a persistent immunological response. A number of genetic and 
infectious factors (viral and bacterial) have been implicated with the onset of RA in 
numerous studies, but proof is still lacking (Ebringer and Wilson, 2000; Silman and 
Pearson, 2002). In addition, the reasons for joint-specific immuno-inflammatory 
responses exhibited in RA are also unknown. Without knowing the exact disease 
etiology it is difficult to explain the initiation. However, it is possible to describe 
many of the pathological changes that occur at a cellular level during the progression 
of RA.
1.5.1 Histological changes in RA
Numerous cell types have been associated with the pathogenesis of RA. These 
include T cells, antigen presenting cells, endothelial cells and B cells which are 
thought to mediate the progression of RA via a variety of immune responses and 
biological mechanisms. A major feature of RA pathology is an increase in cells 
recruited from the circulation to the synovial membrane and increased retention of 
cells already located there. This increase in cellularity is believed to be, in part, the 
result of expression of various adhesion molecules by rheumatoid synovial 
endothelial cells. Endothelial leukocyte adhesion molecule-1 (E-selectin), 
intercellular adhesion molecule (ICAM)-l and very late activation antigen (VLA)-4
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are just a few of the adhesion molecules known to be involved in the pathology of 
RA. It is understood that interactions between these adhesion molecules are pivotal in 
the cellular migration of T-cells into the synovium (Oppenheimer-Marks and Lipsky, 
1995) and that these interactions possibly enhance T-cell retention too.
T-cells are strongly implicated in the maintenance of RA, as they make up around 30- 
50% of the cell population in the synovium of a rheumatoid joint, considerably more 
than in the normal joint (Maini et al., 1995). Approximately 50% of T-cells in 
rheumatoid synovium express human leukocyte antigen (HLA) class II. Over­
expression of HLA class II is believed to induce an autoimmune reaction, 
perpetuating an immune response and resulting in damage to the host tissues. 
However, as yet, there is no proven role for this mechanism in RA. Moreover, many 
T-cells in the rheumatoid synovium are cluster of differentiation positive (CD4+), 
which can differentiate into T-helper (Th)l-cells and Th2-cells, thus producing pro- 
and anti-inflammatory cytokines respectively (Delgado et el., 1999).
T-cells, B-cells, endothelial cells and antigen-presenting cells such as macrophages 
and monocytes all produce pro-inflammatory cytokines. Whilst most of these cells 
express a mixture of IL-1, IL-6 , IL- 8  and TNFa, T-cell’s express additional cytokines 
which include interferon (IFN)-y (Chabaud et al., 1999; Maini et al., 1995).
This network of cytokines is thought to contribute significantly to the pathogenesis of 
RA. INF-y has been shown to induce macrophage activation and expression of HLA 
class II which is a critical feature in the generation of an inflammatory or immune 
reaction (Firestein, 2001). Also, TNFa and IL-1 are abundant in rheumatoid
28
synovium and receptors for these cytokines, TNF-R and type I IL-1 receptor 
respectively, are highly expressed on rheumatoid synovial cells, chondrocytes and 
pannus cells. Thus, it is probable that TNFa and IL-1 induce tissue destruction via 
pannus cells and direct actions on chondrocytes. TNFa appears to be one of the major 
cytokines involved in the pathogenesis of RA. Literature notes that TNFa is a potent 
inducer of adhesion molecules such as ICAM-1 and has been directly linked with the 
onset of synovitis and cartilage degeneration, which has been demonstrated following 
intra-articular (i.art) injection of TNFa into the rabbit knee joint (reviewed by Maini 
et al., 1995). Manipulation of cytokine networks and individual cytokines, in 
particular TNFa, have been key in the discovery and development of new compounds 
available for the treatment of RA, a number of these disease-modifying antirheumatic 
drugs (DMARDs) are discussed later in this chapter.
1.5.2 Articular innervation and RA
Whilst the immune response is believed to play a fundamental role in the onset of RA 
it is the subsequent inflammatory processes that liberate inflammatory mediators, 
described above, which are thought to propagate the disease. C-fibres that supply 
synovial joints are thought to contribute significantly to the network of inflammation 
seen in RA through processes such as neurogenic inflammation.
Detail regarding primary afferent innervation of synovial joints is limited and has 
generally been conducted at the level of the joint itself (Mapp et al., 1990; Hukkanen 
et al., 1992; Theriault et al., 1993). As synovial joints become amassed with cellular 
outgrowth during joint inflammation and enzymatic degradation of marker proteins
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often occurs, identification of specific neuronal populations is difficult and findings 
are often contradictory. Thus, exactly how C-fibre subtypes, their associated receptors 
and products of expression, are involved in the pathogenesis of RA is currently 
unknown. Examination of the afferent cell bodies in the DRG has provided much 
more consistent, albeit limited, data (Hanesch et al., 1997; Salo and Theriault, 1997). 
Upregulation of trkA has been identified in both the lumbar DRG and dorsal horn 
during animal models of arthritis, particularly during the latter stages of a chronic 
model of joint inflammation (Wu et al., 2000; Pezet et al., 2001). This may suggest 
that trkA-expressing neurons play a significant role in the maintenance of chronic 
joint inflammation. In addition, Salo and Theriault used retrograde nerve tracing 
techniques to label all knee joint afferent neurons in naive rats (Salo and Theriault, 
1997). Upon examination of the DRG they found that 10% and 33% of the knee joint 
afferents were positive for SP and CGRP immunoreactivity (IR) respectively. Thus, 
approximately one-third of all rat knee joint afferents appear to be trkA-expressing 
neurons. Unfortunately, little else is known about joint specific C-fibre innervation 
which leaves numerous questions unanswered. In particular, questions relating to 
IB4-binding neurons, such as, are IB4-binding neurons present in the naive rat knee 
joint, and if so why have they not been identified, and what happens to this 
population of C-fibres during chronic joint inflammation? Furthermore, what happens 
to joint specific peptide-expressing neurons, in terms of peptide expression and 
number of cell bodies during chronic joint inflammation?
Investigation of joint specific neurons and their involvement in conditions such as RA 
are not beyond the scope of current research. Using animal models of chronic
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inflammatory joint pain we have already gained great insight into numerous 
mechanisms concerning the pathogenesis of arthritic diseases.
1.6 MODELS AND MEASUREMENTS OF CHRONIC INFLAMMATORY 
JOINT PAIN
1.6.1 Historical perspective
Early models of chronic inflammatory joint pain used an injection of substance, to 
induce an immuno-inflammatory response (adjuvant), into the tail base of rats which 
resulted in a polyarthritis and inflammatory joint pain (Pircio et al., 1975). Joint 
swelling was generally observed ten days subsequent to injection when 
hypersensitivity was deemed to be at its greatest. Long term studies using tail base 
injection of adjuvant demonstrated that the hypersensitivity lasted for over sixty days 
and therefore was an appropriate model for chronic inflammatory joint pain (De 
Castro Costa et al., 1981). However, induction of a polyarthritis is associated with a 
number of distressing side effects. These include physical effects such as lesions of 
the eyes, ears, nose and genitals which may eventually lead to behavioural effects 
such as disruption of eating patterns and severe weight loss (Millan et al., 1987; Stein 
C et al., 1988). These systemic side effects not only fuel the already heated debate 
over the ethical implications of causing pain to animals in the name of research but 
also raise concerns over the validity of the model. This is because of the difficulties in 
attributing the hypersensitivity solely to the joint inflammation when there are a 
number of other conditions that may be affecting the animal.
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1.6.2 Unilateral monoarthritis models
The development of a technique whereby adjuvant was injected directly into a joint, 
usually the ankle or knee, proved to be a much better model of chronic inflammatory 
joint pain in terms of fewer side effects and ethical concerns (Grubb et al., 1988; 
Donaldson et al., 1993). In addition, the observed hypersensitivity associated with 
this unilateral, monoarthritis model of joint pain was deemed clinically appropriate 
for a model of chronic pain (Attal et al., 1988).
This technique is currently the method of choice for assessing conditions of joint pain 
experimentally. There are a number of agents that can be used to initiate the 
inflammation. These include kaolin and carrageenan, monosodium iodoacetate (MIA) 
and Freund’s complete adjuvant (FCA; Donaldson et al., 1993; Radhakrishnan et al., 
2003; Combe et al., 2004). All produce significant joint inflammation and 
hypersensitivity via distinct mechanisms and require the use of strict guidelines. For 
studies described in this thesis only FCA was used, therefore, only FCA is discussed 
further.
1.6.3 Freund’s complete adjuvant
FCA is a mixture of non-metabolisable oil (mineral oil), heat killed Mycobacterium 
(Mycobacterium tuberculosis or Mycobacterium butyricum) and monooleate (a 
surfactant) (Freund, 1951). FCA is a potent adjuvant that stimulates both humoral and 
cell-mediated immune responses, preferably by stimulating antibodies against 
epitopes on denatured proteins located on the bacterial cell surface. FCA is prepared 
as an oil and water emulsion which enables the antigen to be distributed over a large 
surface area, thus, increasing interaction with appropriate cells and stimulating the
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immune response. The immune response is initiated due to non-specific immuno- 
potentiation of macrophages by the Mycobacterium which increases antibody 
production and produces inflammation at the site of administration. This is 
maintained due to a depot effect by the FCA mixture following administration, 
producing a cycle of antibody production, potentially mimicking the immune 
response associated with RA.
The use of FCA is subject to numerous guidelines as the routes of administration and 
immune responses that it promotes can produce discomfort and unwanted side effects. 
For example, intramuscular injection may cause permanent lameness and intravenous 
injection may damage the lungs. In addition causing pain to animals is an ethically 
serious matter which must be justified in every instance and never result it severe 
discomfort or suffering to the animal.
1.6.4 Measuring chronic inflammatory joint pain
The measurement of pain in animals is not simple and often subjective. A number of 
behavioural measurement techniques can be employed together in order to give as 
accurate and consistent measurements of pain as possible. Techniques used to assess 
pain in animal models include tail flick latency and paw withdrawal from a source of 
pressure or thermal stimuli such as Von Frey hairs or a Hargreaves (hotplate) 
machine respectively (Chillingworth and Donaldson, 2003). However, to specifically 
quantify joint pain the use of weight bearing measurements and chronic inflammation 
measurements are usually used together. The technique of weight bearing developed 
by Clayton et al (1997) requires the use of a specifically designed incapacitance tester 
(Clayton et al., 1997). This allows an animal to be placed upon a set of force
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transducers and the weight distributed on each hind limb to be measured. Thus, any 
subsequent shift in weight bearing during a chronic inflammatory time course, due to 
hypersensitivity or reduction of hypersensitivity can be quantified. Weight bearing is 
described in detail in Section 3.3.3 and illustrated in figure 3.1. Chronic joint 
inflammation is usually quantified by measuring the diameter of the inflamed joint.
Animal models of pain are used widely in the pharmaceutical industry for the routine 
screening and manipulation of novel and existing pharmaceuticals. As evident from 
the numerous mechanisms involved in chronic inflammatory pain, which provide 
many biological systems for drugs to target. Thus, a variety of compounds exist that 
can are prescribed and taken in an attempt to treat chronic inflammatory pain 
conditions.
1.7 TREATING CHRONIC INFLAMMATORY JOINT PAIN
Many chronic inflammatory pain conditions are of unknown aetiology therefore 
prevention of, or cures for such diseases currently remain elusive. Fortunately, 
through the expansion in pain research, numerous drug compounds have been 
identified, developed and put to use in the treatment of chronic inflammatory pain. 
Diseases such as RA are generally treated using two principal approaches. The first 
approach consists of symptomatic treatment using compounds that reduce pain via 
interference with particular aspects of the inflammatory cascade, in particular the 
prostaglandin pathway; these compounds are comprised of numerous non-steroidal 
anti-inflammatory drugs (NSAIDs). The second approach aims to modify the disease 
by interfering with the underlying immuno-inflammatory actions, collectively these 
compounds are known as disease-modifying antirheumatic drugs (DMARDs). This
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section is intended to give a brief overview of current NSAIDs and DMARDs, 
therefore only key drugs, compounds or targets are described.
1.7.1 Non-steroidal anti-inflammatory drugs
NSAIDs are compounds designed to block the active sites of COX-1 and COX-2 in 
order to prevent the conversion of arachidonic acid to prostaglandins and therefore 
reduce the subsequent inflammatory events. NSAIDs are the most commonly used 
remedy in the treatment of chronic inflammatory pain (Scott and Lamb, 1999) and 
include a variety of over the counter (OTC) medicines such as aspirin and ibuprofen 
and prescription only medicines (POMs) such as indomethacin and diclofenac. 
Unfortunately NSAIDs are associated with a number of adverse effects which induce 
damage of the gastric and intestinal mucosa (Trevethick et al., 1995) and cardiorenal 
effects (Bertolini et al., 2001). Arguably the most alarming side effect with NSAIDs 
is their potential to induce gastric ulceration. NSAID-induced ulcers have been shown 
histologically to extend down to the muscularis mucosa (Trevethick et al., 1995). The 
major risk from such deep ulceration is the potential of damage to surrounding blood 
vessels and the possibility of fatal heamorrhage. NSAID-induced gastric injury can be 
reduced when administered with gastroprotective agents such as misoprostol, 
histamine LL-receptor antagonists or proton pump inhibitors. These drugs can 
counteract the damaging effects of suppressing prostaglandin synthesis (Bertolini et 
al., 2001). However, combination therapies are associated with a multitude of 
pharmacokinetic and toxic concerns and decreased patient compliance.
As COX-2 is induced by inflammatory stimuli it has been suggested that the anti­
inflammatory effects of NSAIDs are due primarily to inhibition of COX-2 and the
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unwanted side effects due to the inhibition of COX-1. Support for this hypothesis has 
grown since the advent of selective COX-2 inhibitors which allow COX-1 to 
maintain gastric integrity whist removing the inflammatory aspects of COX-2. Based 
on such information selective COX-2 inhibitors may appear to be ideal solutions to 
the problems seen with NSAIDs. Unfortunately COX-2 inhibitors are not without 
their own drawbacks.
1.7.2 Selective COX-2 inhibitors
Selective COX-2 inhibitors (coxibs) have been the most recent breakthrough 
medicine to come to market for the treatment of RA and OA. The theory behind these 
drugs is based on the principle that COX-2 is responsible for prostaglandin synthesis 
at sites of inflammation and COX-1 is involved in the synthesis of prostaglandins in 
the context of homeostatic functions. Vioxx (rofecoxib) and Celebrex (celecoxib) 
were the main coxibs to be marketed since the discovery of COX-2 in 1991 (Mamett 
and Kalgutkar, 1999). Although classic NSAIDs block both isoforms of COX, most 
compounds show at least a small degree of preference for one isoform. Only 
diclofenac is thought to exhibit near equipotency in its effects on COX-1 and COX-2 
(Bertolini et al., 2001). Rofecoxib and celecoxib have shown up to 800-fold and 375- 
fold more selectivity for COX-2 respectively (Bertolini et al., 2001).
Patients treated with coxibs have, as expected, noted considerably fewer gastric 
complaints while relief from symptomatic pain associated with chronic inflammatory 
joint disease is comparable to classic NSAIDs (Bianchi and Broggini, 2003). 
Experimental models of pain and clinical trails have unequivocally demonstrated that 
coxibs provide significant anti-inflammatory and analgesic effects (reviewed by
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Goldenberg, 1999). However, a number of side effects have raised concerns over the 
safety of these relatively new compounds and recently lead to the withdrawal of 
Vioxx by Merck in September 2004, after only five years on the market (FitzGerald, 
2004). These side effects include potential gastric injury and renal damage, although, 
cardiovascular complications associated with coxibs have proven to be the most 
disturbing unwanted effects.
Long-term studies have suggested that coxibs increase the risk of thromboembolic 
events, such as stroke and myocardial infarction (MI) by a factor of 3.9 (FitzGerald, 
2004). It has been suggested that the increased risk of thromboembolic events may be 
due to suppression of COX-2-dependent synthesis of PGI2 . PGI2 is thought to be the 
predominant prostaglandin in endothelium and has been demonstrated to inhibit 
platelet aggregation and vasodilation. Until recently PGI2 formation was assumed to 
be converted by COX-1, however, studies investigating the actions of coxibs later 
proved this assumption to be incorrect (FitzGerald, 2004). Thus, coxib-induced 
suppression of PGI2 would be expected to elevate blood pressure, accelerate 
atherogenesis and predispose patients to exaggerated thrombotic responses.
Despite the array of side effects associated with NASIDs and coxibs these compounds 
remain the best and most prescribed treatments for symptomatic relief of chronic 
inflammatory joint pain. However, the current interest and escalating number of 
targets for DMARDs brings new promise to the treatment of chronic inflammatory 
joint pain, which may see conventional treatments eventually become redundant.
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1.7.3 Disease-modifying antirheumatic drugs
DMARDs are agents that reduce both pain and inflammation and can retard the joint 
destruction associated with RA. Many DMARDs require several weeks before any 
relief becomes apparent, but once an effect is evident pain is significantly reduced 
and disease progression halted. In clinical practice between 20-25% of patients 
treated with DMARDs show signs of remission (Smolen and Steiner, 2003). These 
antirheumatic drugs can be separated into two main types, small molecule DMARDs 
and biological agents.
Small molecule DMARDs include methotrexate (MTX), the most commonly used 
DMARD, which currently maintains the highest level of efficacy for this class of 
DMARD. MTX and other small molecule DMARDs generally exert their actions via 
interference with pyrimidine synthesis, possibly by increasing endogenous adenosine 
levels (Cronstein et al., 1996). This subsequently affects the generation of cytokines, 
cell proliferation and migration. Although some patients respond well to this type of 
DMARD treatment, particularly during the early stages of disease onset, others show 
little if any response at all (Ranganathan et al., 2003). Thus, questions have been 
raised over the efficacy of small molecule DMARDs. Understandably, 
pharmacological meddling with such fundamental biological processes also results in 
a number of side effects and risk of toxicity. Many patients discontinue the use of 
MTX due to the toxicity associated with its long term effects (Ranganathan et al., 
2003). These include serious and sometimes fatal liver disease, pneumonitis and 
gastrointestinal symptoms such as vomiting, diarrhea and abdominal cramps 
(Borchers et al., 2004). Fortunately, with careful monitoring, folate supplementation 
can significantly reduce the risk of MTX toxicity in many patients.
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As with small molecule DMARDs, biological agents aim to disrupt pro-inflammatory 
cytokine networks. However, these agents are designed to alter cytokine pathways 
more specifically and directly. To date the key target for biological DMARDs has 
been TNFa; new therapies aim to reduce the levels of this cytokine during chronic 
inflammatory states. Biological agents include monoclonal antibodies, soluble 
receptors, anti-inflammatory cytokines and antibodies raised against differentiation 
associated antigens (Smolen and Steiner, 2003). Approved anti-TNF agents include 
infliximab (Remicade) and adalimumab (Humira) which are both antibodies raised 
against TNF, and etanercept (Enbrel) which is a fusion protein of the TNF receptor II. 
These three agents have been shown to be extremely efficacious in the treatment of 
RA (Flendrie et al., 2005), not only have significant improvements in the 
symptomatic pain of RA been observed, many patients have also demonstrated halted 
progression of joint destruction. Whilst treatment with these biological agents have 
been efficacious in many patients not all patients respond, and although these agents 
are remarkably well tolerated they do pose a few significant side effects. These 
include nerve demyelination, thus multiple sclerosis type effects, systemic lupus 
erythematosus and possibly tuberculosis (TB; Roberts and McColl, 2004; Flendrie et 
al., 2005). Although these side effects appear to be rare careful patient monitoring is 
again essential for patients treated with biological DMARDs and in some cases prior 
screening for latent TB may also be necessary.
Due to the extensive nature of the cytokine network many other potential targets have 
been identified and numerous drug agents specifically designed to exploit these sites. 
One such area of interest is the development of MMP inhibitors. MMPs are
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associated with the formation of pannus and comprise a variety of potentially 
damaging enzymes including collagenases, gelatinases and adamalysins. Several 
compounds that have been developed to target specific MMPs have shown good 
results in experimental models of RA but have been discontinued following clinical 
trials due to safety concerns (reviewed by Smolen and Steiner, 2003).
1.8 SUMMARY
The enigmatic pathogenesis of diseases such as RA suggests that no single drug will 
ever provide sufficient therapy for all sufferers. C-fibres have been implicated within 
the vast combination of contributing factors and may provide a variety of therapeutic 
avenues. Indeed, VR1, P2 X3, and VGSCs are already regarded as putative targets for 
drug action. Whilst manipulation of these receptors and ion channels are unlikely to 
provide any significant disease modifying effect they may potentially offer alternative 
symptomatic/analgesic relief. Greater understanding of the anatomy, innervation 
territories and function of C-fibre subtypes in normal and pathophysiological states 
may provide key information for pharmacological manipulation of neurochemical 
products and surface receptors located within and on C-fibres. Consequently, until the 
causes of RA are understood and causative therapies become available the aim will be 
to examine and interfere with the known processes involved in such conditions. The 
potential for current and novel drug agents is vast and it is likely that with the correct 




For this thesis, models of joint pain, retrograde nerve tracing techniques and * 
behavioural and immunofluorescence approaches were used to investigate the 
neuroanatomy of the rat knee joint, in terms of innervation by IB4-binding and 
peptide-expressing neurons.
The hypotheses that IB4-binding neurons are not present within the rat knee joint 
during normal or pathophysiological conditions were tested during the first series of 
investigations, and the hypothesis that knee joint specific peptidergic neurons 
increase in number during a model of chronic inflammatory joint pain was also 
examined. The effect of celecoxib on FCA-induced joint pain was also measured at a 
behavioural level and at a histological level, with regards to the effects on joint- 
specific CGRP expression.
The overall aim of this thesis was to contribute to the understanding of C-flbre 
subtypes, in particular, their innervation territories and potential functions in normal 
physiological states and in conditions of chronic inflammatory joint pain induced by 
i.art injection of FCA.
41
CHAPTER 2
Potential innervation of the normal rat knee joint by IB4-binding 
neurons
2.1 INTRODUCTION
Retrograde nerve tracing is a technique that can be utilized for the histological 
examination of specific neuronal populations in a given location, for example, 
afferent neurons that project from the knee joint. This technique incorporates the 
administration of a marker substance, usually a fluorescent dye, such as Fast Blue 
(FB; Hanesch and Heppelmann, 1995) or Fluoro-gold (FG; Salo and Theriault, 1997) 
which can be taken up by the neuronal population at one site and traced back over a 
time course to another anatomical location, thus labelling and identifying the neuronal 
pathway for a particular subset of neurons.
FB and FG have been used previously to label cutaneous, visceral and deep somatic 
afferents in various studies examining afferent co-localisation with IB4-binding 
neurons and peptidergic neurons (Bennett et al., 1996b; Salo and Theriault, 1997). 
Retrograde nerve tracing studies described in this thesis used FG as the fluorescent 
marker to identify knee joint afferent neurons in the lumbar DRG. FG was deemed an 
appropriate marker for the current studies due to its long survival period following 
injection. Optimal fluorescence for FG is thought to occur between days four and 28 
post-injection (Schmued and Fallon, 1986) with some fading noted 90 days post­
injection (Puigdellivol-Sanchez et al., 2002). Once mounted on microscope slides, an 
intense (bright gold coloured) emission can be observed using fluorescence 
microscopy under a filter appropriate for FG-illumination, even following repeated 
ultra violet exposure (Schmued and Fallon, 1986). In addition, previous usage of FG 
for identification of knee joint specific afferents in rats has been documented (Salo 
and Theriault, 1997).
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C-fibres can be separated into at least two distinct subtypes based on their chemical 
and physical properties, including anatomy and innervation territories. IB4-binding 
neurons are thought to predominantly innervate the more superficial structures such 
as the skin and project to the inner portion of LII in the dorsal horn (Lu et al., 2001). 
TrkA-expressing neurons generally innervate more visceral structures and terminate 
in LI and the outer portion of LII in the dorsal horn (see figure 1.5) (Silverman and 
Kruger, 1990; Bennett et al., 1996a). Based on such differences it has been postulated 
that their physiological roles in the mediation of nociceptive information differ. 
Furthermore it is also possible that their contributions to conditions of chronic 
inflammatory joint pain may not be equal or at least represent different aspects of 
nociception. Studies have suggested that the two populations of C-fibres may 
represent different modalities of chronic pain; chronic pain derived from tissue 
inflammation has been associated with trkA-expressing neurons, whereas 164- 
binding neurons have been associated with chronic pain derived from nerve injury 
(Malmberg et al., 1997a; Malmberg et al., 1997b).
Despite a number of studies having identified several innervation territories of 164- 
binding and trkA-expressing neurons, little is documented regarding their projection 
from deep somatic structures such as synovial joints, in particular the knee joint. 
Using retrograde nerve tracing Salo and Theriault (1997) labelled all articular afferent 
neurons in the rat knee joint, at the level of the lumbar DRG. Upon examination of 
the DRG they found that 10% and 33% of the knee joint afferent neurons were 
positive for SP and CGRP respectively. This finding indicates that approximately 
one-third of all rat knee joint afferent neurons are trkA-expressing. Whilst trkA- 
expressing neurons have been identified in the knee joint of at least two species, rat
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(Salo and Theriault, 1997) and cat (Hanesch et al., 1997) there are no data, we are 
aware of, to suggest that IB4-binding neurons are also present within this deep 
somatic structure.
IB4-binding neurons are implicated as a key population in nociception and the 
receptors expressed on this neuronal subtype are potential avenues for novel 
pharmaceuticals. P2 X3 receptors are almost exclusively located on IB4-binding 
neurons (Vulchanova et al., 1998) and have been acknowledged as a significant 
mediator of inflammatory and neuropathic pain (North, 2003a; North, 2003b). Thus, 
pharmacological manipulation of P2 X3 receptors for the treatment of chronic pain is 
now a target of considerable interest for pharmaceutical companies. In addition, VR1 
receptors and VGSCs located on IB4-binding neurons are also under scrutiny and 
may provide suitable sites for drug intervention. Therefore, increased focus on the 
innervation and properties of IB4-binding neurons is essential for the discovery and 
developmental processes.
2.2 AIMS
For the current study retrograde nerve tracing with FG was utilized to label all rat 
knee joint afferents at the level of the ipsilateral L3 and L4 DRG. Fluorescent 
histochemistry techniques using an IB4-FITC conjugate were also used to identify 
IB4-binding neurons. The overall aim of the study was to determine whether or not 
there exists a population of IB4-binding neurons in the normal/naive rat knee joint.
In addition, retrograde labeling of rat knee joint afferent neurons with FG was 
observed in a twenty-eight day study. This was to determine whether or not the
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quality of FG-labelling and the number and size of FG-labelled cell bodies were 
comparable in DRG removed twenty-eight days post-i.art administration of FG and in 
DRG removed seven days post-i.art. administration, thus establishing if FG could be 
used in future studies for up to twenty-eight days.
2.3 METHODS
2.3.1 Animals
Female Wistar rats (University of Bath) in the weight range of 250-300g and aged 
between 10-11 weeks were used in studies described in this chapter (number of 
animals used per investigation is given in Section 2.4). Animals were housed in cages 
of 3, 4 or 5 in a room with a 12 hour light/dark cycle maintained at 20°C (+/- 2°C). 
All animals had access to tap water and a standard rat diet (SDS Ltd., Witham, UK) 
ad libitum. A period of 5 days was given for animals to acclimatize to new 
surroundings following movement from cages and rooms before any experimentation 
commenced. These experiments were carried out at the University of Bath (Project 
licence, PPL30/1594; Personal licence, PIL70/7762) in accordance with the Animals 
(Scientific Procedures) Act 1986 (UK). In addition, every effort was made to 
minimize animal suffering and reduce the number of animals used.
2.3.2 Retrograde nerve labeling
2.3.2.1 Intra-articular (knee joint) injection
Retrograde labelling of knee joint afferents was carried out using a technique 
described previously (Salo and Theriault, 1997; Catre and Salo, 1999). Animals were
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anaesthetized with Isoflurane (3%; O2 at 1.5L/min) and their right knee shaved and 
swabbed with industrial methylated spirit (IMS). Using a sterile scalpel blade a small 
(~5 mm) skin incision was made over the patellar ligament of the right hind limb. A 
gauge 27 needle, as part of a SURFLO® winged infusion set (Terumo, NJ, US) 
connected to 100 pi Hamilton syringe was introduced through the tendon into the 
space between the patellar groove of the distal femur. Then 15 pi of 0.1% Fast Green 
(Sigma, UK) dissolved in 0.1 M phosphate buffer saline (PBS) was drawn up into the 
infusion tube, followed by 5 pi of air and 5 pi of 2% FG, the air separated the two 
solutions. This order ensured that when the solutions were injected into the joint 
space that all of the FG entered the joint and none became trapped in the dead space 
of the needle as the Fast Green could be observed entering the joint last. Following 
injection the needle was withdrawn, the incision irrigated with saline and sealed with 
non-toxic glue.
2.3.2.2 Intra-dermal (skin) injection
Animals were restrained under isoflurane anaesthesia as described above and a gauge 
27 needle, as part of a SURFLO® winged infusion set connected to 100 pi Hamilton 
syringe was inserted into an area of skin over the medial aspect of the knee. Then 15 
pi of 0.1% Fast Green dissolved in 0.1M phosphate buffer and 5 pi of 2% FG was 
administered intradermally.
2.3.2.3 Intra-venous (tail vein) injection
Tail vein injections were performed in the same way as for knee joint and skin 
injections except animals were restrained in a cylindrical restraint device that left the
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tail exposed. Also, injection of FG (5 pi, 2%) into the tail vein was carried out in the 
absence of Fast Green. Fast Green was not necessary to see extravasation from this 
site.
2.3.3 Histology
2.3.3.1 Fixation and termination
On the final day of retrograde nerve labelling studies, days 7 and 28 subsequent to FG 
injection, animals were deeply anaesthetized with intra-peritoneal (i.p) sodium 
pentobarbital (-120 mg). Incisions were made to open the thoracic cavity and expose 
the heart. A small incision was made in the left ventricle and a cannula attached to a 
perfusion pump, inserted into the aorta and clamped in place. The vena cava was cut 
to allow bleeding and the perfusion pump switched on. Phosphate Buffered Saline 
(PBS; 500ml, 0.1 M) and ice-cold fresh paraformaldehyde (PFA; 500ml, 4%) in 0.1 
M PBS were then pumped through the heart. Where perfusion fixing was unnecessary 
animals were euthanased using a rising concentration of carbon dioxide.
2.3.3.2 Preparation of tissue
Following the fixing process or confirmation of death, the sciatic nerve in the hind 
limb ipsilateral to the FG injection was exposed and used to trace and locate the 
lumbar DRG. Ipsilateral and contralateral lumbar DRG L3 and L4 were then 
removed. Ganglia were post-fixed in 4% PFA overnight and cryoprotected in 20% 
sucrose solution for another 24 hours. Single ganglia were then embedded and 
oriented (in the plane perpendicular to the long axis of the ganglia) in OCT tissue
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Tec, rapidly frozen in liquid nitrogen/isopentane or on dry ice and stored at -80°C 
until sectioning.
2.3.4 Fluorescent histochemistry
IB4-binding neurons were examined using the direct method of fluorescent 
histochemistry. The direct method of labelling is a one step staining process. Using a 
labelled antibody or protein, for example, fluorescein isothiocyanate (FITC) 
conjugated antiserum, the antibody or protein can react directly with its target and be 
identified by the labelling chemical (VanNoorden, 1986).
2.3.4.1 IB4-binding: Direct method of fluorescent histochemistry
Frozen tissue samples were cut into 10pm sections on a Bright or a LEICA cm3050s 
cryostat and thaw-mounted onto BDH Superfrost microscope slides in a regular grid 
formation. Slides were left to air dry for 30 minutes then immersed in acetone for 3-5 
minutes. Slides were then rehydrated in PBS twice, 5 minutes each time. 
Subsequently, tissue sections were treated with an IB4-FITC conjugate (10 pg/ml; 
Sigma, UK) for 40 minutes. Slides were then rinsed in PBS twice for 10 minutes and 
mounted with fluorescent mounting medium (DAKO, US) and covered with glass 
cover slips. Slides were left to dry for over an hour in the dark before microscopic 
analysis. Unconjugated-FITC (Sigma, UK) was used with control slides.
2.3.5 Microscopic analysis
All slides were observed under a Zeiss microscope using filters appropriate for FG 
illumination (excitation: 365/12 nm; emission: 397 nm) and FITC/Alexa 488
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illumination (excitation: 450-490 nm; emission: 515-565 nm). Digital images were 
generated of every section for all DRG and analysis performed on every third section. 
The outline of FG-labelled neurons was digitized using pre-programmed image 
analysis software (Zeiss KS 300 image analyzer). The image analysis software 
calculated the total number of FG-labelled neurons per section and their mean, feret 
diameter (diameter measured every 10 degrees with the mean recorded). Only 
neurons with a nucleus showing were included in the counts.
2.4 EXPERIMENTAL PROCEDURES
Data described in this chapter is taken from two studies. Both studies examined the 
distribution of FG-labelled knee joint afferent neurons and their potential co­
localization with IB4-binding neurons over different durations, seven and twenty- 
eight days. In addition to these studies a number of preliminary experiments were 
conducted.
2.4.1 Preliminary experiments
Preliminary experiments were carried out prior to the larger (seven and twenty-eight 
day) studies described in this chapter. Preliminary experiments used a total of 10 
female Wistar rats. All animals received injection of FG (i.art) into the right knee 
joint. All animals were euthanased 7 days post-FG injection.
2.4.2 Seven day study; retrograde labelling of joint and skin afferents
Ten female Wistar rats were used in this study. Animals received either a knee joint 
injection (n = 4), skin injection (n = 3) or tail vein injection (n = 2) of FG. One animal 
remained naive. All animals were perfusion fixed 7 days post-FG injection.
2.4.3. Twenty-eight day study; retrograde labeling of knee joint afferents
Four female Wistar rats were used in this study. All animals received i.art injection of 
FG into the right knee joint. All animals were euthanased 28 days post-FG injection.
2.5 RESULTS
2.5.1 Preliminary experiments
Preliminary experiments optimized the technique for knee joint injection, ensuring 
that accurate positioning of the needle into the joint could be achieved and that joint 
afferents showed quality labeling when viewed using fluorescence microscopy. 
Moreover, preliminary experiments improved dissection techniques considerably. 
Thus, the correct lumbar DRG were removed for analysis on every occasion.
No FG-labelled cell body counts were derived from the tissue acquired during these 
early experiments. However, the tissue was used to work-up the optimal fluorescent 
histochemistry technique, appropriate fluorescent marker, dilutions and duration of 
incubation with marker.
No images were taken from these early experiments or from the fluorescent 
histochemistry work-up experiments. However, preliminary experiments identified
51
that the fluorescent marker IB4-FITC conjugate consistently identified IB4-binding 
neurons best at a concentration of 10 jig/ml following incubation for 30 minutes to 1 
hour.
2.5.2 Seven day study; retrograde labeling of joint and skin afferents
2.5.2.1 Animals
Due to preliminary experiments all injections of FG were deemed accurately placed 
therefore no animals were excluded from studies described in this chapter as a result 
of injection into none-joint space structures or leakage of tracer from the injection 
site.
2.5.2.2 Retrograde nerve labelling
Only L3 and L4 DRG were examined, as approximately 8 8 % of knee joint afferents 
are found here (Salo and Theriault, 1997). Therefore, searching for approximately 
12% of FG-labelled cell bodies in the remaining lumbar DRG (LI, L2, L5 and L6 ) 
was deemed unnecessary for the purpose of this investigation. Intense FG-labelled 
neuronal profiles were easily identifiable in the ipsilateral L3 and L4 DRG of animals 
which received FG injections to the knee joint (Figure 2.1.A and C). Contralateral L3 
and L4 DRG were also removed and examined for control purposes. No FG-labelled 
profiles were seen in any of the contralateral DRG (Figure 2.2.A).
Intense FG-labelled neuronal profiles were also seen in the ipsilateral L3 and L4 
DRG of animals that received a skin injection of FG (Figure 2.3.A and C). No FG- 
labelled neuronal profiles were seen in contralateral DRG from skin injected animals
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(data not shown) and no FG-labelled neuronal profiles were seen in the tail vein 
injected animals or the naive control animal (Figure 2.2.B).
Figure 2.1 Images of rat L4 DRG following fluoro-gold (FG) injection in the knee 
joint and fluorescent histochemistry. The two sections were each photographed 
alternately under filters appropriate for FG (A and C) and FITC (B and D). Arrows 
indicate neurons labelled only with FG. Scale bar, 100 pm.
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Figure 2.2 Images of control rat DRG viewed under a filter appropriate for FG 
illumination. Image A is a contralateral L4 DRG following an ipsilateral knee joint 
injection of FG. Image B is an L4 DRG following injection of FG into the tail vein. 
Scale bar, 100pm.
Figure 2.3 Images of rat L4 DRG following fluoro-gold (FG) injection in the skin 
over the medial aspect of the knee joint and fluorescent histochemistry. The two 
sections were each photographed alternately under filters appropriate for FG (A and 
C) and FITC (B and D). Arrows indicate FG- and FITC-double labelled neurons. 
Scale bar, 100 pm.
54
A B
Figure 2.4 Images of rat L3 DRG viewed under a filter appropriate for FITC 
illumination, following incubation with non-conjugated FITC. Scale bar, 100pm.
2.5.2.3 Fluorescent histochemistry
IB4-binding neurons labelled with FITC were readily identifiable. None of the 
neurons were double-labelled with both FG and FITC in any of the animals that 
received a knee joint injection of FG (Figure 2.1.B and D). FG and FITC double­
labelled neurons were easily identifiable in DRG from the skin injected animals 
(Figure 2.3.B and D). Forty-eight percent of FG-labelled skin afferents were double­
labelled with FITC (Table 2.1.). No labelling was seen in any sections following 
incubation with non-conjugated FITC (Figure 2.4).
2.5.2.4 Number and size of joint afferents
Digital images were generated of every third section for all DRG. The outline of all 
FG-labelled neurons was digitized using pre-programmed image analysis software 
(Zeiss KS 300 image analyzer). The image analysis software calculated the total 
number of FG-labelled neurons per section and their mean, feret diameter (diameter 
measured every 10 degrees with the mean recorded). Only neurons with a nucleus
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showing were included in the counts. Numbers of FG-labelled afferents varied 
between DRG (Table. 2.1 and 2.2). Somal diameters of joint and skin afferents were 
broadly distributed across a range of sizes (Figure. 2.4 and 2.6 respectively). The 
count technique was tested by an independent observer (Emma Roberts) to ensure 
that the method was reproducible.
Animal L3 L4
Total FG-
labelled Total FG/FITC double­
cell bodies labelled cell bodies
Percentage
co-localization
Rat skin 1 96 111 207 71 34
Rat skin 2 76 197 273 127 47
Rat skin 3 42 263 305 177 58
Totals 214 571 785 375 48
Table 2.1 Counts of FG-labelled cell bodies in the L3 and L4 DRG of skin injecti 
animals.






Rat knee 1 36 34 70 0 0
Rat knee 2 109 107 216 0 0
Rat knee 3 89 237 326 0 0
Rat knee 4 273 211 484 0 0
Totals 507 589 1096 0 0
Table 2.2 Counts of FG-labelled cell bodies in the L3 and L4 DRG of knee joint 
injected animals.
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Figure 2.5 Size distribution of FG-labelled knee joint afferent cell bodies in L3 and 
L4 DRG together (n = 4).
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Figure 2.6 Size distribution of FG-labelled skin afferent cell bodies in L3 and L4 
DRG together (n = 3).
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2.5.3 Twenty-eight day study; retrograde labeling of knee joint afferents
2.5.3.1 Retrograde nerve labelling
As seen in the previous study intense FG-labelled neuronal profiles were easily 
identifiable in the ipsilateral L3 and L4 DRG of animals which received FG injections 
to the knee joint (data not shown).
2.5.3.2 Fluorescent histochemistry
IB4-binding neurons labelled with FITC were also readily identified. None of the 
neurons were double-labelled with both FG and FITC in any of the animals that 
received a knee joint injection of FG (Table 2.3).
2.5.3.3 Number and size of joint afferents
Numbers of FG-labelled afferents varied between DRG (Table 2.3). Somal diameters 
of joint afferents were broadly distributed across a range of sizes (Figure 2.6).






Rat 1 74 23 97 0 0
Rat 2 19 91 110 0 0
Rat 3 23 62 85 0 0
Rat 4 107 48 155 0 0
Totals 223 224 447 0 0
Table 2.3 Counts of FG-labelled cell bodies in the L3 and L4 DRG of knee joint 
injected animals taken 28 days post-FG injection.
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Figure 2.7 Size distribution of FG-labelled knee joint afferent cell bodies in L3 and 
L4 DRG together, taken 28 days post-FG injection (n = 4).
2.6 DISCUSSION
Using retrograde nerve tracing with FG rat knee joint afferent neurons were labelled 
at the level of the lumbar DRG. None of the knee joint afferents identified were 164- 
binding neurons. Previous studies examining the innervation of deep somatic 
structures have also noted low numbers of IB4-binding neurons. In the rat trigeminal 
masticatory muscle only 5% of sensory afferents show IB4 binding (Ambalavanar et 
al., 2003). Also, our finding that 48% of cutaneous afferents are IB4-binding neurons 
is in agreement with previous results. Approximately 44% and 43% of cutaneous 
afferents from the vibrissal pad area and medial ankle respectively, show IB4 binding 
(Ambalavanar et al., 2003; Bennett et al., 1996b). Also, this suggests that IB4-binding 
neurons transport FG at a similar rate as other sensory afferent neurons. Thus, it is 
unlikely that FG and FITC double-labelled neurons have not been identified in the rat 
knee joint due to slower transport of FG to the lumbar DRG. Moreover, we identified
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no FG and FITC double-labelled neurons in lumbar DRG removed twenty-eight days 
subsequent to rat knee joint injection with FG (Table 2.3). As expected with a 
systemic injection of FG we saw no labelling of lumbar DRG cell bodies following a 
tail vein injection of FG, indicating that the labelling we saw following knee joint and 
skin injections was from the site of injection only and not due to systemic spread of 
FG. In addition no FG-labelled neurons were identified in the naive control or in any 
contralateral DRG, indicating that there is no cross over of FG at a spinal level from a 
unilateral knee joint injection.
The number of FG-labelled afferent neurons in the L3 and L4 DRG were somewhat 
lower than numbers counted in previous studies (Salo and Theriault, 1997). This may 
be due to differences in counting techniques and the image analysis software used. 
Although most neurons that were labelled with FG showed good quality, bright gold 
labelling, some appeared to be faintly labelled, giving a more granular appearance. It 
is possible that by using different colour thresholds to identify FG-labelled neurons 
some software may outline cells that we deemed as borderline. Therefore, only 
neurons that were brightly labelled were included in the cell counts.
The low counts may also represent difficulties with the reproducibility of manual 
injections into the rat knee joint. This is particularly apparent with rat knee joint 1 
(Table 2.2). Numbers of labelled cell bodies from this animal, in both L3 and L4 
DRG were much lower than in any other animal from the group. It is unlikely that 
this animal actually did have much fewer knee joint afferents than the other animals 
as they came from the same litter and were maintained under the same environment.
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The only variability was with the knee joint injection, despite attempts to keep all 
injections as accurate as possible.
Total numbers of FG-labelled cell bodies in animals from the twenty-eight day study 
were significantly lower than the seven-day study (P <0.05, Mann-Whitney rank sum 
test, see appendix 2.1). Again this may be due to variability in the joint injections. 
However, it is also possible that the FG started to degrade at this point in the study, as 
the period between four and twenty-eight days post-injection is believed to provide 
the optimum fluorescence (Schmued and Fallon, 1986). If the FG had started to 
degrade, it is possible that some cell-bodies that had previously been brightly labelled 
would have had a more faded profile by the twenty-eighth day. Thus, fewer labelled 
somata would have been identified by the image analysis software.
Although the numbers of FG-labelled knee joint afferents differed between the 
individual ganglia, the size distribution profile (Figure 2.5) constructed from the total 
number of FG-labelled neurons was consistent with previous size distribution profiles 
of knee joint afferents (Salo and Theriault, 1997). FG-labelled skin afferents showed 
a similar size distribution profile to the FG-labelled knee joint afferents after seven 
days (Figure 3.6). However, the size distribution profile derived from DRG removed 
from the twenty-eighth day study showed a different pattern with lower numbers of 
labelled afferents and a broader spectrum of sizes (Figure 2.7). Again, this may be 
due to the possibility of FG-fading. If FG-labelling had started to fade within joint 
afferent cell bodies it is possible that degradation occurred more prominently within a 
particular size group. Even if all size groups were affected the counts would still be 
low and the distribution profile altered.
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Identification of IB4-binding neurons with an IB4-FITC conjugate was consistently 
good throughout these investigations. Negative controls using non-conjugated FITC 
showed no labelling of IB4-binding neurons. During preliminary experiments a 
number of fluorescent histochemistry work up procedures were performed to optimise 
identification of IB4-binding neurons, including application of the avidin-biotin 
complex (ABC) method. This method requires the use of a binding agent-avidin 
conjugate and a marker-biotin conjugate. The binding agent locates the target and the 
biotin forms a complex with avidin, leaving the marker substance to be identified 
(Coggi et al., 1986). In the current study an IB4-avidin conjugate (Sigma, UK) and 
FITC-biotin conjugate (Sigma, UK) were used. However, reliable labelling could not 
be achieved using this method despite revising many aspects of the protocol including 
various dilution solutions, concentrations of both conjugates and duration of 
incubations (data not shown). Thus, use of the IB4-FITC conjugate was a 
contingency method adopted following the failure of the ABC method.
Results described in this chapter further support the notion of different functional 
roles for the C-fibre populations in normal physiology and disease pathology. If, as 
the data suggest, IB4-binding neurons are entirely absent in the normal rat knee joint, 
it becomes increasingly likely that trkA-expressing neurons are the important 
population of C-fibres in chronic inflammatory conditions such as RA. However, a 
more comprehensive analysis would have been achieved through examination of the 
normal and inflamed knee joint. This may have identified a number of differences 
between normal and pathophysiological states, for example, potential phenotypic 
switching from peptidergic neurons to non-peptidergic neurons.
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A number of studies have suggested that the anatomical signatures of IB4-binding 
neurons and trkA-expressing neurons may produce differential contributions to the 
initiation and maintenance of pain. Neurons within the inner and outer portions of 
lamina II of the dorsal horn are associated with different levels of nociceptive 
transmission. Protein kinase C-gamma (PKCy)-expressing intemeurons in lamina II 
inner, where IB4-binding neurons terminate, have been implicated in both 
inflammatory and neuropathic pain (Malmberg and Basbaum, 1998). Lamina V 
intemeurons, where A5-fibres terminate, require PKCy in order to induce the 
hyperexcitability associated with prolonged injury. Thus, suggesting that stimulation 
of IB4-binding neurons, increases levels of PKCy in lamina II inner, which may 
promote central sensitisation type responses in lamina V. Analysis of nociceptive 
behaviours in PKCy-knockout mice have suggested that IB4-binding neurons may be 
more involved with the processes of chronic pain derived from nerve injury 
(Malmberg et al., 1997a; Malmberg et al., 1997b) whereas chronic pain derived from 
tissue inflammation has been associated with trkA-expressing neurons.
In contrast, IB4-binding neurons have also been implicated in the nociception of 
acute pain. When IB4-binding neurons are selectively destroyed with the nerve toxin 
saporin, animals show behavioural signs of decreased sensitivity to thermal and 
mechanical acute pain (Vulchanova et al., 2001). Although acute pain is mainly 
ascribed to the larger diameter, A8 -fibres, C-fibres are still thought to contribute, as a 
degree of pain can still be felt following a pin prick to the skin even after loss of A8 - 
fibre function (Magerl et al., 2001). Finally, the expression of P2 X3 receptors on IB4- 
binding neurons and the abundance of this C-fibre subclass in the skin support the 
observations that cutaneous nerves are more sensitive to ATP in conditions of acute
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inflammation (Hamilton et al., 2001). Thus, it is possible that EB4-binding neurons 
mediate both chronic pain derived from nerve injury and acute pain, albeit secondary 
to A-fibres.
In conclusion, these studies have identified that IB4-binding neurons are not present 
within the normal rat knee joint, at the level of the L3 and L4 DRG. However, before 
sizeable involvement of IB4-binding neurons in chronic inflammatory joint pain can 
be inferred or ruled out a more comprehensive examination should be conducted via 
examination of the inflamed rat knee joint.
Data derived from this chapter has subsequently been published in 
Neuroscience. (2004). 128, 555-560. See appendix 2.
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CHAPTER 3
Potential innervation of the hypersensitive rat knee joint by IIM- 
binding neurons
3.1 INTRODUCTION
Findings from the previous chapter suggest that IB4-binding neurons are completely 
absent in the rat knee joint during normal physiological states and are only present to 
a small extent in other deep somatic structures (Ambalavanar et al., 2003; Ivanavicius 
et al., 2004). IB4-binding neurons appear to be more predominant within cutaneous 
structures and several authors have suggested that these neurons may be more 
involved in the mediation of acute pain (Bennett et al., 1996b; Vulchanova et al., 
2001). The absence of IB4-binding neurons in the rat knee joint suggests that trkA- 
expressing neurons are the only C-fibre subtype present. Thus, it is likely that trkA- 
expressing neurons are the more prominent population of C-fibres associated with 
chronic inflammatory joint diseases such as RA. However, the possibility of IB4- 
binding neurons being present in the rat knee joint during a chronic inflammatory 
state cannot be ruled out based on these findings alone.
Phenotypic switching within neuronal populations is known to occur during the 
course of chronic inflammatory conditions (Neumann et al., 1996). Switches in 
neuronal phenotype typically consist of changes in the size distribution profiles of the 
population and/or fluctuations in the number of neurons expressing a particular 
peptide within a population. Phenotypic switching of trkA-expressing neurons to 164- 
binding neurons has been acknowledged previously in rat pups during the first three 
weeks after birth (Bennett et al., 1996b; Molliver et al., 1997; Bennett et al., 1998). 
However, no further phenotypic switching or sprouting of IB4-binding neurons into 
previously IB4-negative areas has been reported in adult rats. It is possible that under 
the extreme conditions associated with chronic inflammation that IB4-binding 
neurons may develop within the rat knee joint. It has also been postulated that
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transitions from inflammatory to neuropathic pain may occur in experimental models 
of arthritis (Calza et al., 1998) and thus, may suggest a transition from pain mediated 
by trkA-expressing neurons to pain mediated by IB4-binding neurons. Crucially, 
examination of IB4-binding neurons in the chronically inflamed rat knee joint has not 
yet been performed. Consequently, before inference about the role of IB4-binding 
neurons in conditions such as RA can be made, joint specific innervation in a model 
of monoarthritis is essential.
Experimental models of chronic pain are utilised regularly within research and have 
been for many years. Early models used an injection of adjuvant into the tail base of 
rats which resulted in a measurable polyarthritis (Pircio et al., 1975). However, as 
described in Section 1.4, this model caused a multitude of unwanted side affects 
which not only questioned the validity of the model but also caused unnecessary 
suffering for the animals (Millan et al., 1987; Stein et al., 1988). The later 
development of monoarthritic models by direct injection of adjuvant into the ankle or 
knee joint provided a more appropriate model of chronic pain, both in terms of model 
validity and ethical approval. Since the introduction of the monoarthritis model in the 
late 1980s (Grubb et al., 1988) injection of agents, such as FCA, into joints have been 
characterized and used as tools in pharmacological studies of pain and inflammation 
(Donaldson et al., 1993; Radhakrishnan et al., 2003; Combe et al., 2004).
Studies described in this thesis used injection of FCA into the rat knee joint. The knee 
joint provides an accessible site for monoarthritis induction as this joint has a 
relatively large infrapatellar ligament through which a needle can easily be inserted. 
The properties and use of FCA in experimental models of pain and inflammation are
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described in Section 1.6.3. Briefly, FCA is a water, oil and Mycobacterium emulsion 
that can be used to stimulate an immune response by initiating a non-specific 
immuno-potentiation of macrophages which increases antibody production and 
produces inflammation at the site of administration.
The inflammation and hypersensitivity of a joint injected directly with FCA is dose 
related (Donaldson et al., 1993). A number of investigations have identified that FCA 
injection into the rat knee joint at volumes of 150 pi produce a significant and 
sustained inflammatory response with minimal leakage from the site of injection 
(Dowd et al., 1998). Therefore, studies of chronic joint inflammation described in this 
thesis used i.art injection of FCA at volumes that did not exceed 150 pi.
Assessing pain and inflammation caused by FCA-induced monoarthritis is generally 
carried out using a combination of behavioural measurements, in particular weight 
bearing and/or joint diameter measurements. Weight bearing and joint diameter 
measurement have been described briefly in Sections 1.6.4 and are covered in detail 
in sections 3.3.3 and 4.3.3.2, respetively. Monoarthritis studies discussed in this thesis 
were quantified using weight bearing alone or by weight bearing and joint diameter 
measurements together if drugs were being administered (as described in Chapter 4).
3.2 AIMS
For the current study FCA was used to induce a unilateral joint inflammation. 
Retrograde nerve tracing with FG, was also administered to label all knee joint 
afferents at the level of the L3 and L4 DRG. Weight bearing apparatus was used to 
measure joint hypersensitivity and fluorescent histochemistry techniques using an
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IB4-FITC conjugate were utilized to identify IB4-binding neurons within the same 
DRG. The overall aims of this study were i) to evaluate behavioural responses 
indicative of pain during chronic inflammation of the joint and ii) to determine 
whether or not there exists a population of IB4-binding neurons in the rat knee joint 
under chronic pathophysiological conditions.
3.3 METHODS
3.3.1 Animals
Female Wistar rats (Charles Rivers, UK) in the weight range of 150-200g and aged 
between 5 and 6  weeks were used in the studies described in this chapter (number of 
animals used per investigation is given in Section 3.4). Animals were housed in cages 
of 3 or 4 in a room with a 12 hour light/dark cycle (06.00h-18.00h) and were 
maintained at 21°C (+/- 3°C) and 55% (+/- 15%) humidity. All animals had access to 
tap water and a standard rat diet ad libitum. A period of 5 days was given for animals 
to acclimatize to new surroundings following movement from cages and rooms 
before any experimentation commenced. These experiments were carried out at 
GlaxoSmithKline (GSK) Stevenage (PPL 80/1688; PIL 80/9066) in accordance with 
the Animals (Scientific Procedures) Act 1986 (UK).
3.3.2 Injection of FCA and FG
Retrograde nerve labelling and induction of hypersensitivity and inflammation were 
performed together using the same technique as described in Section 2.3.2.1. Briefly, 
animals anaesthetized under Isoflurane (3%; O2 at 1.51/min) had their left knee 
shaved and swabbed with Hibiscrub and industrial methylated spirit (IMS) providing
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a sterile injection site. Using a 29-gauge needle and insulin syringe combination, 
solution containing saline (130 pi) or FCA (130 pi, lmg/ml heat killed 
Mycobacterium Tuberculosis suspended in mineral oil, Sigma, UK), 0.1% Fast Green 
(15 pi) and 2% FG (5 pi) was injected into the joint. Animals were given time to 
recover from the anesthetic in a heated recovery cage with soft paper bedding before 
being returned to their original cage.
3.3.3. Measurement of hypersensitivity
Hypersensitivity derived from FCA injection was measured using an incapacitance 
meter (Linton Instruments, UK). The incapacitance meter (weight bearing apparatus) 
consisted of two separate force transducer panels which measure the weight 
distribution exerted by an individual animal through each hind limb (Clayton et al., 
1997). Animals were placed into a Perspex chamber over the force transducer panels 
and given adequate time to settle. Once settled, facing forward and with both hind 
paws on the appropriate panel, a reading was taken (see figure 3.1). A digital readout 
of the mean weight exerted on each panel, over a period of 3 seconds, was taken for 
each animal and measured in grams. Three readouts were recorded for each animal on 
every occasion and the mean used for final analysis.
3.3.4 Histology
Animals were euthanased using a rising concentration of CO2 and DRG were 
removed and post-fixed in PFA as described in Section 2.3.3.
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Figure 3.1 Photograph of a random hooded rat inside a Perspex box on top of the 
incapacitance tester, used to measure hypersensitivity in rats with a unilateral 
inflammation of the foot pad or knee joint.
3.3.5 Fluorescent histochemistry
Identification of IB4-binding neurons was performed as described in Section 2.3.4.1.
3.3.6 Microscopic analysis
Microscopic analysis was carried out as described in Section 2.3.5.
3.3.7 Analysis of hypersensitivity
Data derived from weight bearing measurements were expressed as a percentage 
difference (of ipsilateral over contralateral values; +/- SEM). Equal weight bearing 
distributed across both limbs equated to 100%. Therefore, lower percentage values 
correspond to greater degrees of hypersensitivity of the ipsilateral limb. This allows 
for a truer expression of weight bearing and inflammation across all animals 
regardless of the actual values. Data were subject to one-way ANOVA with repeated
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measures followed by a Holm-Sidak post-hoc test using the software package Sigma 
Stat 3.11. A P value equal to or less than 0.05 was considered statistically significant.
3.4 EXPERIMENTAL PROCEDURES
3.4.5 Seven day pilot study
Studies described in the previous chapter involved injection of small volumes of Fast 
green and FG into the rat knee joint (20 pi total volume). However, for the chronic 
joint inflammation study described in the current chapter it was necessary for the Fast 
green and FG to be injected with saline or FCA in a larger total volume (150 pi). 
Therefore, a pilot study was necessary to determine whether or not the quality of FG- 
labeling would be affected by this dilution. In addition, it was necessary to determine 
whether or not the procedure for weight bearing gave detectable and reproducible 
measurements of joint pain induced by the FCA and FG solution.
Six female Wistar rats were used in this seven day pilot study. Animals received an 
i.art injection of FCA, Fast green and FG (150 pi total volume; n = 3) or saline, Fast 
green and FG (150 pi total volume; n = 3) into the left knee joint.
Prior to injection on day zero, naive weight bearing readings were taken for each 
animal to provide a baseline for the study. Further weight bearing readings were taken 
on days 1 and 7 post-injection. All animals were euthanased on the final day of the 
study (day 7 post-injection).
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3.4.6 Identification of IB4-binding neurons and FG-labelled joint afferents in a 
model of knee joint monoarthritis.
Eight female Wistar rats were used in this sixteen day study of knee joint 
inflammation. Animals received an i.art injection of Fast green and FG (150 pi total 
volume; n = 4) or saline, Fast green and FG (150 pi total volume; n = 4) into the left 
knee joint.
Prior to injection on day 0, naive weight bearing readings were taken for each animal 
to provide a baseline for the study. Further weight bearing readings were taken on 
days 1 and 16 post-injection. On the final day of the study (day 16 post-injection) all 
animals were euthanased using a rising concentration of CO2 and DRG removed.
3.5 RESULTS
3.5.1 Seven day pilot study
3.5.1.2 Animals
No animals were excluded from any of the studies described in this chapter as a result 
of tracer or FCA leakage from the injection site. In addition, no animals showed any 
overt signs of distress or severe pain at any time during the study.
3.5.1.3 Measurement of hypersensitivity
Hypersensitivity was established after 24 hours and maintained up to the seventh day 
in all animals injected with FG and FCA (Figure 3.2). The hypersensitivity was 
greatest after 24 hours where the percentage difference in weight bearing measured an
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average of 21% (+/- 6 %) indicating a 79% shift in body weight to the contralateral 
(right) hind limb. However, the measurements taken at time points, day 1 and day 7 
post-FG and FCA injection, were significantly different to the FG and Saline injected 
animals (P <0.001; see appendix 1.1 and 2.2 for raw data and statistical analysis, 
respectively). None of the FG and saline injected group showed any hypersensitivity 
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Figure 3.2 Effect of i.art FCA on weight bearing (% ipsilateral/contralateral) over a 
7-day period. FG with FCA or saline (n = 3 per group) was injected on day 0. Error 
bars indicate +/- sem. One-way ANOVA with repeated measures indicate significant 
main effects of time and treatment and a significant interaction between treatment and 
time (P <0.001 in both cases, see appendix 2.2). Both post-FCA injection time points 
were significantly different compared to the saline control, (***) P <0.001, one-way 
ANOVA post hoc.
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3.5.1.4 Retrograde nerve tracing
Similar numbers of intense FG-labelled neuronal profiles were easily identifiable in 
the ipsilateral L3 and L4 DRG of animals from both experimental groups (FG and 
FCA, and FG and saline) receiving injections in to the knee joint (Figure 3.3).
Figure 3.3 Images of rat L3 DRG following fluoro-gold (FG) injection in to the knee 
joint. A: typical image from a rat lumbar DRG following FCA and FG injection. B: 
typical image from a rat lumbar DRG following saline and FG injection. Arrows 
indicate neurons labelled only with FG. Scale bar, 100 pm.
3.5.2 Identification of IB4-binding neurons and FG-labelled joint afferents in a 
model of FCA-induced joint pain.
3.5.2.1 M easurement of hypersensitivity
Hypersensitivity was established after 24 hours and maintained up to the 16th day in 
all animals injected with FG and FCA (Figure 3.4). Hypersensitivity was greatest 
after 24 hours where the percentage difference in weight bearing measured an average 
of 27% (+/- 4%) indicating a 73% shift in body weight to the contralateral (right) hind 
limb. Although the hypersensitivity appeared to improve by day 16 the percentage
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difference was still less than 60% (59% +/-2%) indicating that a 40% shift in body 
weight to the contralateral hind limb still remained. Measurements taken at time 
points, day 1 and day 16 post-FG and FCA injection, were both significantly different 
to the FG and Saline injected animals (P <0.001, see appendix 1.2 and 2.3 for raw 
data and statistical analysis, respectively). None of the FG and saline injected group 
showed any hypersensitivity at any stage during the study.
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Figure 3.4 Effect of i.art FCA on weight bearing (% ipsilateral/contralateral) over a 
16-day period. FG with FCA or saline (n = 4 per group) was injected on day 0. Error 
bars indicate +/- sem. One-way ANOVA with repeated measures indicate significant 
main effects of time and treatment and a significant interaction between treatment and 
time (P  <0.001 in both cases, see appendix 2.3). Both post-FCA injection time points 
were significantly different compared to the saline control, (***) P  <0.001, one-way 
ANOVA post hoc.
3.5.2.2 Retrograde nerve tracing
Intense FG-labelled neuronal profiles were easily identifiable in the ipsilateral L3 and 
L4 DRG of animals from both experimental groups (figure 3.5.A and 3.5.C).
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Figure 3.5 Images of rat L4 DRG following fluoro-gold (FG) injection into the knee 
joint and fluorescent histochemistry. Images A and B are the same section from an 
animal injected with FG and FCA, viewed under filters appropriate for FG and FITC 
respectively. Images C and D are the same section from an animal injected with FG 
and saline, viewed under filters appropriate for FG and FITC respectively. Arrows 
indicate neurons labelled only with FG. Scale bar, 100 pm.
3.5.2.3 IB4-fluorescent histochemistry
IB4-binding neurons labelled with FITC were readily identifiable in the lumbar DRG. 
However, none of the neurons were double-labelled with both FG and FITC in any of 
the animals that received a knee joint injection of FG and FCA (Figure 3.5.B) or FG 
and saline (figure 3.5.D).
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FCA knee 1 68 25 93 0 0
FCA knee 2 85 89 174 0 0
FCA knee 3 43 88 131 0 0
FCA knee 4 18 145 163 0 0
Totals 214 347 561 0 0
Table 3.1 Counts of FG-labelled cell bodies in L3 and L4 DRG from animals injected 
with FG and FCA.






Saline knee 1 58 81 139 0 0
Saline knee 2 60 57 117 0 0
Saline knee 3 26 97 123 0 0
Saline knee 4 28 89 117 0 0
Totals 172 324 496 0 0
Table 3.2 Counts of FG-labelled cell bodies in L3 and L4 DRG from animals injected 
with FG and saline.
3.5.2.4 Number and size of joint afferents
As with previous studies described in chapter 2 the total number of FG-labelled 
neurons per section and their mean diameter were calculated using the Zeiss KS300 
software package (Section 2.3.5). Although numbers of FG-labelled afferents varied 
between DRG, there was no difference in the total numbers of FG-labelled afferents 
counted in FCA and saline injected animals, 561 and 496 respectively (Table. 3.1 and
3.2 respectively). Moreover, the size distribution profiles of FG-labelled afferents 
from FG and FCA injected animals and FG and saline injected animals were very 
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Figure 3.6 Size distribution profile of FG-labelled knee joint afferent cell bodies in 
L3 and L4 DRG of animals injected with FG and FCA (n = 4).
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Figure 3.7 Size distribution profile of FG-labelled knee joint afferent cell bodies in 
L3 and L4 DRG of animals injected with FG and Saline (n = 4).
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3.6 DISCUSSION
Using retrograde nerve tracing, rat knee joint afferent neurons were labelled at the 
level of the L3 and L4 lumbar DRG in two groups of animals; a chronic joint 
inflammation group injected with FG and FCA (n = 4) and a control group injected 
with FG and saline (n = 4). None of the FG-labelled knee joint afferents identified in 
any animal from either group were also labelled with IB4-FITC. This suggests that 
IB4-binding neurons are completely absent in the rat knee joint during normal and 
pathophysiological conditions. These findings support those described in chapter 2 
(Ivanavicius et al., 2004) and are in accordance with previous investigations that have 
examined the IB4-binding neuron innervation of deep somatic structures under 
normal and inflammatory conditions. Aoki et al. (2004) noted that in normal 
physiological and inflammatory states less than 1 % of neurons that innervate the rat 
lumbar discs are IB4-binding (Aoki et al., 2004). Thus, no phenotypic switching of 
peptidergic neurons to IB4-binding neurons appears to occur during a sixteen day 
joint inflammation.
In contrast, trkA-expressing neurons have been identified in the rat (Salo and 
Theriault, 1997) and cat (Hanesch et al., 1997) knee joints and undergo a variety of 
changes during inflammatory conditions. Hanesch et al. (1997) used retrograde nerve 
tracing with FB to label knee joint afferent neurons in cats. They identified that under 
normal conditions approximately 42% and 22% of FB-labelled joint afferents in the 
L5 and L7 DRG were positive for CGRP and SP respectively. Following a 32 hour 
joint inflammation, induced by kaolin and carrageenan, the proportion of neurons 
expressing CGRP increased to 52% in joint afferents. Joint afferent co-localization 
with SP did not alter significantly. This implies that joint specific trkA-expressing
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neurons undergo phenotypic switching in response to acute joint inflammation and 
are involved in the inflammatory processes. This is supported by the observations that 
trkA expression is significantly increased in the rat synovium (Wu et al., 2000) and 
DRG (Pezet et al., 2001) in experimental models of chronic inflammatory pain. The 
current study suggests that IB4-binding neurons are completely absent from the knee 
joint during a model of monoarthritis. Thus, IB4-binding neurons are unlikely to have 
a prominent role in joint nociception and conditions of chronic joint pain.
Weight bearing measurements indicated that FCA-induced hypersensitivity was 
significant in both the seven day and sixteen day studies (figures 3.2 and 3.4 
respectively). Monoarthritis studies conducted in-house at GSK using volumes of 
FCA between 100-150 pi have shown only monophasic profiles of hypersensitivity 
which remain significant up to ninety days (data unpublished). Thus, for both, seven 
and sixteen day time courses in the current study, only two time points were recorded 
post-FCA injection.
Injections of FG into the tail vein and skin over the medial aspect of the knee joint 
were deemed unnecessary for this study as these routes of administration and analysis 
of afferent cell bodies in the L3 and L4 DRG have been examined previously in 
Chapter 2. Contralateral DRG were examined for control purposes. No FG-labelled 
cell bodies were identified in any contralateral DRG (data not shown).
Total counts of FG-labelled afferent neurons from the ipsilateral L3 and L4 DRG of 
FCA and saline injected animals were similar (561 and 496 respectively), but 
somewhat lower than those seen previously (Salo and Theriault, 1997; Ivanavicius et
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al., 2004). This maybe due to the administration of FG with FCA or saline (130 pi), at 
a much greater overall volume than used in previous experiments, thus, diluting the 
FG. Although, no obvious leakage of the solution was seen from the injection site 
following administration of FG and FCA/saline it is possible that not all of the FG 
was taken up by joint afferents. Animals were free to explore the recovery cages 
following surgery and subsequent movement of the joint may have caused some 
leakage at this time. Despite the low cell counts, the quality of labelling was 
consistent with that seen previously and FG-labelled cell bodies were easily identified 
by the image analysis software. Size distribution profiles constructed from the total 
number of FG-labelled neurons in FCA and saline injected animals (figures 3.5 and
3.6 respectively) were also similar and no obvious increase in the number of large 
diameter joint afferents was seen in the FCA injected group, a feature that has been 
associated with inflammatory conditions (Ohtori et al., 2001).
Of trkA-expressing neurons, 29% and 57% show intense and weak labelling with 
IB4, respectively and 24% of c-ret positive neurons are IB4-negative (Kashiba et al., 
2001). If the joint afferents identified in the current study are not IB4-binding neurons 
as the data suggest, it is reasonable to infer that they are peptidergic neurons. Double­
labelling with a trkA antibody would have left little doubt regarding the nature of the 
IB4-negative FG-labelled joint afferents and ultimately provided a more 
comprehensive study. Therefore, the current study may conclusively demonstrate that 
IB4-binding neurons are not present in the rat knee joint under normal and 
pathophysiological conditions, but does not demonstrate unequivocally the phenotype 
of the IB4-negative FG-labelled joint afferents.
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It is also debatable whether or not a sixteen day FCA-induced monoarthritis is 
chronic enough to induce a switch from a peptidergic population of neurons to a non- 
peptidergic population. Whilst unlikely, it is possible that by increasing the time 
course of hypersensitivity and inflammation that a switch may occur. In contrast, a 
switch from peptidergic to non-peptidergic neurons may occur at much earlier time 
points and switch back shortly afterwards thus, may not have been observed in the 
current study. Therefore, a more conclusive examination of a potential phenotypic 
switch may be more appropriately determined at intervals over a time course. 
Moreover, the possibility exists that only certain characteristics of IB4-binding 
neurons may undergo a phenotypic switch, for example, an increased expression of 
c-ret may occur in neurons without those neurons actually expressing cell surface 
a-D-galactose groups and therefore not binding IB4.
Although the current study suggests that IB4-binding neurons are not significantly 
involved in chronic inflammatory joint pain and joint nociception, it is possible that 
these neurons may play a secondary role in such disease states. Mounting evidence 
implies that IB4-binding neurons subserve an acute pain function (Magerl et al., 
2001; Vulchanova et al., 2001), which is supported by the observations that almost 
half of all cutaneous afferent neurons are IB4-binding (Ambalavanar et al., 2003; 
Bennett et al., 1996b; Ivanavicius et al., 2004). Moreover, evidence suggests that 
transitions from inflammatory to neuropathic pain may occur in experimental models 
of arthritis (Calza et al., 1998). This may suggest a putative transition from pain 
mediated by trkA-expressing neurons to pain mediated by IB4-binding neurons 
during the progression of chronic inflammation. Thus, it is possible that IB4-binding 
neurons may influence chronic joint pain from superficial areas outside of the joint
83
and may provide a potential therapeutic avenue using topical based treatments 
targeting IB4-binding neurons or receptors located on these neurons such as P2 X3, 
VR1 and VGSCs.
In conclusion none of the FG-labelled joint afferents examined in animals injected 
with FCA or saline were also positive for IB4-binding. The absence of IB4-binding 
neurons in the rat knee joint, in both physiological and inflammatory states, suggests 
that this population of C-fibres have little if any significant role in chronic 
inflammatory joint diseases. These findings also indicate that no phenotypic switch 
from peptidergic to non-peptidergic afferents occurs in the knee joint during a sixteen 
day inflammation.
It is probable that the IB4-negative FG-labelled afferents identified in this study are 
trkA-expressing, and therefore express CGRP, and that they are the only population 
of C-fibres present in the rat knee joint. Thus, future studies described in this thesis 
have focused on CGRP-expressing neurons within the normal and pathophysiological 
rat knee joint.
CHAPTER 4
Alterations in CGRP-expressing neurons in a model of chronic joint 
pain and the effect of celecoxib
4.1 INTRODUCTION
Levels of peptides, peptide mRNA and numbers of peptide-expressing neurons are 
known to fluctuate within the joint, DRG and dorsal horn during the course of chronic 
inflammatory joint pain (Mapp et al., 1990; Calza et al., 1998). In normal knee joints 
the synovium is richly innervated with SP- and CGRP-expressing neurons which are 
present throughout the synovial membrane and synovial blood vessels (Mapp et al., 
1990; Hukkanen et al., 1992; Theriault et al., 1993). However, evidence from rat and 
human tissue indicates that peptidergic innervation of the synovium becomes 
significantly depleted during conditions of chronic inflammatory joint pain (Mapp et 
al., 1990; Hukkanen et al., 1992). Although, peptidergic innervation of the cat knee 
joint appears to maintain its integrity following a chronic joint inflammation 
(Theriault et al., 1993).
A number of different hypotheses have been proposed to explain the loss of 
peptidergic neurons in the inflamed synovium of rat and man (Hukkanen et al., 1992). 
One possibility is that intensively proliferating cells that are recruited to the synovium 
during pannus formation may outgrow the peptidergic nerve fibres, thus rendering the 
neurons further away from the synovium than in normal physiology (Hukkanen et al., 
1992). Another more probable theory is that metabolic enzymes and free radicals 
produced by inflammatory cells may modify and degrade the neuropeptides within 
the neurons to such an extent that their detection by specific antibodies may not be 
possible (Hukkanen et al., 1992). Finally, it is possible that the increased release of 
pro-inflammatory peptides at the sites of inflammation may have resulted in depleted 
levels within the neurons at the time of histological examination.
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The effects of chronic joint inflammation are also detectable in the cell bodies of 
peptidergic neurons located in the DRG. Under normal physiological conditions 
approximately 10% and 33% of joint afferent cell bodies in rat are positive for SP and 
CGRP respectively (Salo and Theriault, 1997). During the course of chronic joint 
inflammation in experimental models, the levels of SP and CGRP fluctuate. The early 
stages of the inflammation are associated with an overall increase in the numbers of 
peptide expressing neurons in the DRG, in particular an increase in CGRP-expressing 
neurons (Ahmed et al., 1995; Walker et al., 2000). In addition the levels of SP and 
CGRP mRNA have been shown to decrease significantly in the dorsal horn by the 
fifth day of a chronic inflammation (Calza et al., 1998) which may imply an increase 
in their peripheral release by C-fibres at the site of inflammation. The increases in 
peptide content seen in the DRG are clearly a response to chronic inflammation. 
However, it is not entirely understood whether or not the changes occur in all peptide- 
expressing cell bodies within the DRG as a systemic response or only in joint specific 
neuronal cell bodies. Hanesch et al. (1998) found that the number of joint specific 
CGRP-immunopositive cell bodies in cat lumbar DRG increased from 42% to 52% 
thirty-two hours after induction of joint monoarthritis. However, evidence detailing 
the effects of more chronic inflammation on the expression of CGRP in joint specific 
afferent neurons is relatively sparse and not entirely understood. Therefore, 
investigating the potential changes in CGRP peptide levels in joint specific afferent 
neurons over a time course of chronic inflammation will certainly contribute to the 
understanding of this feature of neurogenic inflammation.
Current treatments for RA and OA such as NSAIDs and coxibs which provide 
symptomatic relief of pain are well characterised both clinically and in models of
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chronic pain. Central and peripheral release of CGRP and other neuropeptides during 
an inflammatory response promotes the synthesis and release of prostaglandins 
(Trang et al., 2002). Prostaglandins in turn activate prostaglandin receptors on 
primary afferent neurons and influence further release of several neuropeptides, 
including CGRP, forming a positive feedback mechanism. However, it is not 
currently understood whether or not prostaglandins also increase the CGRP content at 
the level of the DRG, in joint specific afferent neurons, during a model of 
inflammatory joint pain. Thus, the effect of coxibs on CGRP levels in joint specific 
neurons during a model of inflammatory joint pain is also unknown.
4.2 AIMS
For the current study retrograde nerve tracing with FG was utilized to label rat knee 
joint afferents at the level of the ipsilateral L3 and L4 DRG and FCA was used to 
induce a chronic (seventeen day) monoarthritis in the same joint. The COX-2 
inhibitor, celecoxib was dosed for the final five days of the seventeen day 
inflammation. Immunofluorescence was carried out using an anti-CGRP antibody and 
Alexa 488. The overall aim of this study was to determine whether or not there are 
joint specific increases in CGRP-expressing neurons during the early (day one), 
intermediate (day seven) and latter (day seventeen) stages of a chronic joint 
inflammation and to determine if celecoxib has any significant effect on joint specific 
CGRP expression during chronic joint inflammation.
In addition, a series of preliminary experiments were performed using an acute 
footpad model of pain (section 4.4.1) and a chronic joint pain model (section 4.4.2) in 




Due to the spread of a parvovirus in a number of GSK animal housing facilities and 
housing restrictions, female Wistar rats could not be used for the series of studies 
described in this chapter.
Male random hooded (RH) rats (Bantin & Kingman, UK) in the weight range of 150- 
200g and aged between 5 and 6  weeks were used in the studies described in this 
chapter (number of animals used per investigation is given in Section 4.4). Animals 
were housed in cages of 3 or 4 in a room with a 12 hour light/dark cycle (06.00h- 
18.00h) and were maintained at 21°C (+/- 3°C) and 55% (+/- 15%) humidity. All 
animals had access to tap water and a standard rat diet ad libitum. A period of 5 days 
was given for animals to acclimatize to new surroundings following movement from 
cages and rooms before any experimentation commenced. These experiments were 
carried out at GSK, Ware (PPL 80/1688; PIL 80/9066) and were in accordance with 
the Animals (Scientific Procedures) Act 1986 (UK)
4.3.2 Retrograde nerve tracing and FCA injection
4.3.2.1 Retrograde nerve tracing
The technique used for retrograde nerve tracing of knee joint afferent neurons is 
described in section 2.3.2.1.
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4 3 .2.2 Intra-articular injection of FCA or saline
A chronic unilateral inflammation was induced in the left knee joint via i.art injection 
of FCA (150 pi). Animals were anaesthetized with isoflurane (3%; O2 at 1.51/min) 
and had their knees shaved. The left knee area was swabbed with Hibiscrub and 
industrial methylated spirit (IMS) providing a sterile injection site. Using a sterile 29- 
gauge needle and insulin syringe combination (BD Consumer Healthcare, USA), 
FCA (150 pi) was injected through the patellar ligament into the joint space between 
the patellar groove of the distal femur. Following this procedure animals were given 
time to recover from the anesthetic in a heated recovery cage with soft paper bedding 
before being returned to their original cage. Saline (150 pi) was administered using 
the same technique in control animals.
4.3.2.3. Intra-plantar injection
Chronic unilateral inflammation was induced in the footpad of the left hind limb by 
injection of FCA. Animals were restrained using a cloth loosely wrapped around their 
body with their left hind limb protruding. A sterile 29-gauge needle connected to a 
1 ml syringe was inserted into the footpad, with the bevel pointing in the heel 
direction and 100 pi FCA administered. Following this procedure animals were 
returned to their original cages.
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4.3.3 M easurement of hypersensitivity and inflammation
4.3.3.1 M easurement of hypersensitivity
Hypersensitivity derived from FCA joint and intra-plantar injection was measured 
using the weight bearing method described in Section 3.3.3.
4.3.3.2 M easurement of inflammation
The degree of knee joint inflammation was quantitatively measured using handheld 
digital calipers which were opened over the joint and closed until the metal arms 
loosely contacted the joint (see figure 4.1). Joint diameter measurements were taken 
from both hind limbs before and during conditions of chronic joint inflammation.
Figure 4.1, Image of the digital calipers used to measure joint inflammation in rat 
with a unilateral knee joint inflammation.
4.3.4 Histology
Animals were euthanased using a rising concentration of CO2 and DRG were 
removed and post-fixed in PFA as described in Section 2.3.3
4.3.5 Immunofluorescence
The indirect method of labelling is a multi-phase process which involves an unlabeled 
primary antibody raised against specific tissue antigens, and a labeled secondary
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antibody to react with the primary. However, the secondary antibody must be against 
the immunoglobulin G (IgG) of the animal species in which the primary antibody was 
raised in. This method is more sensitive than the direct method (described in section
2.3.4) due to signal amplification through secondary antibody reactions with different 
antigenic sites on the primary antibody (Van Noorden, 1986).
4.3.5.1 CGRP: Indirect method of immunofluorescence
Tissue sections were cut and placed on microscope slides as described in Section 
2.3.4.1. Slides were immersed in acetone for 3-5 minutes and rehydrated in PBS 
twice, 5 minutes per wash. Blocking solution containing normal goat serum (NGS; 
10%), bovine serum albumin (BSA; 1%) and PBS was applied to slides, covering 
each tissue section, for 1 hour. After 1 hour, excess blocking solution was removed 
from the slide and a CGRP polyclonal rabbit antibody (Sigma, UK) diluted at 1:1000 
with blocking solution was applied to the slide, covering each tissue section and left 
overnight at 4°C. Following the primary phase, slides were rinsed in PBS 3 times, 10 
minutes per rinse. Goat anti-rabbit Alexa 488 (Molecular probes, UK) diluted at 
1:200 with PBS was then applied to the slide, covering each tissue section and left at 
room temperature for 1.5 hours. Following the secondary phase, slides were rinsed in 
PBS 3 times, 10 minutes per rinse. Slides were mounted with fluorescent mounting 
medium (DAKO, US), covered with glass cover slips and left to dry. Incubations 
using primary anti-sera in the absence of secondary anti-sera and vice versa were also 
performed on lumbar DRG tissue sections, as negative controls.
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4.3.6 Drugs
Celecoxib was made in-house at GSK, Harlow, and was dissolved in DMSO, 
PEG400 and distilled water in the ratio of 1:66:33. All doses were administered orally 
in a volume of 5ml/kg.
4.3.7 Microscopic analysis
Microscopic analysis was carried out as described in Section 2.3.5.
4.3.8 Analysis of hypersensitivity from joint injection
Data derived from weight bearing measurements taken from joint injections were 
analysed by one way ANOVA with repeated measures followed by a Holm-Sidak 
post-hoc test (as described in Section 3.3.7) during the dosing period only 
(experimental days 13-17).
4.3.9 Analysis of hypersensitivity from foot pad injection
Data derived from the established FCA model were expressed as percentage reversal 
of hypersensitivity using the formula:
% reversal = Post-dose threshold -  Pre-dose threshold x 100 
Baseline threshold -  Pre-dose threshold
Data were subject to one-way ANOVA followed by a Dunnett’s post-hoc test. 
A P value equal to or less than 0.05 was considered statistically significant.
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4.3.10 Analysis of inflammation
Joint diameter data derived from joint injection studies were expressed as percentage 
difference (ipsilateral over contralateral values; +/- SEM). No difference between 
ipsilateral and contralateral joint diameter measurements equated to 100%. Therefore, 
higher percentage values correspond to greater degrees of joint inflammation. These 
data were analysed as for joint hypersensitivity data (see Section 4.3.8). No joint 
diameter measurements were taken for any studies using injection of FCA into the 
footpad.
4.4 EXPERIMENTAL PROCEDURES
4.4.1 Dose response to celecoxib in an established FCA model of hypersensitivity
In order to ensure that celecoxib would provide a significant reversal of 
hypersensitivity it was necessary to validate the celecoxib in an established animal 
model of acute hypersensitivity. The footpad model of FCA-induced pain was chosen 
in order to establish the appropriate dose selection for the subsequent joint pain 
validation model as the footpad model can be conducted over a relatively short 
duration (24 hour) and can be performed using fewer animals.
Two FCA-induced footpad hypersensitivity studies were carried out. For each study 
28 male RH rats were used. All animals received intra-plantar injection of 100 pi 
FCA. Prior to injection naive weight bearing readings were taken for each animal to 
provide a baseline for the study. Weight bearing readings were taken again 23 hr 
post-FCA injection. Animals were ranked in ascending order according to the 
pre-dose weight bearing readings and then randomized into four dosing groups
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(n = 7) using a Latin square format. This ensured a uniform spread of inflammatory 
hypersensitivity throughout the groups.
At 23 hours post-FCA injection animals were orally administered vehicle or 
celecoxib (1 ,3 and 10 mg/kg). Weight bearing readings were then taken 1 hr post­
dose (24 hr post-FCA injection). All dosing was blinded and dose groups were 
blinded from the observer during measurement of hypersensitivity. At the end of the 
experiment all animals were euthanased using a rising concentration of CO2 followed 
by cervical dislocation.
4.4.2 Dose response to celecoxib in FCA-induced joint pain model
Established FCA studies examined the influence of celecoxib on an acute (24 hr) 
inflammation. However, this chapter ultimately aimed to examine the role of 
celecoxib on joint afferents in a chronic joint pain model, at a behavioural and 
histological level. Therefore, it was necessary to validate celecoxib in the FCA- 
induced chronic joint pain model to ensure that a reversal in hypersensitivity could be 
measured and to confirm the appropriate dose selection of celecoxib for use in the 
main study of this chapter.
Forty-four male RH rats were used in this 17 day study. Four animals remained naive 
throughout the study, all other animals received an i.art injection of 150 pi FCA in the 
left knee joint. Prior to injection on day zero, naive weight bearing readings and joint 
diameter measurements were taken for each animal to provide baselines for the study. 
Further weight bearing and joint diameter measurements were taken on days 1, 3 and 
9 post-injection. Animals were ranked in ascending order according to the day 9
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weight bearing readings and then randomized into four groups (n = 10) using a Latin 
square format, for oral administration with vehicle or celecoxib (1,3 and 10 mg/kg) 
twice a day (09.00 hr and 21.00 hr) for five days on days 13 to 17 inclusive. During 
this period weight bearing and joint diameter measurements were taken every day 2  
hours after the 09.00 hr dose. All dosing was blinded and dose groups were blinded 
from the observer during measurement of hypersensitivity. On day 17 post-FCA 
injection all animals were euthanased using a rising concentration of CO2 followed by 
cervical dislocation.
4.4.3 Effect of celecoxib on CGRP expression in joint afferent neurons in a 
model of joint pain.
Experiments described in the previous chapter examined DRG following injection of 
FG and FCA or saline together as one solution, since the terms of the project licence 
(PPL 80/1688) stated that only a single i.art injection of substance could be 
administered in any experiment. Therefore, in these studies no lumbar DRG were 
removed until after seven days post-FG injection, this was to remain consistent with 
earlier studies of retrograde nerve tracing. Also, FG takes at least four days post 
injection to show robust labelling, with the best labelling observed between days four 
and 28 post-administration (Schmued and Fallon, 1986). To generate DRG over a 
suitable time course for the examination of joint afferents and co-localization with 
inflammatory markers an amendment to the project licence (PPL 80/1688) was made, 
which allowed two i.art injections to be administered for the current study, providing 
they were at least seven days apart.
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Forty male RH rats were used in this 24 day study. All animals received i.art injection 
of 15 pi Fast green (0.1%) and 5 pi FG (2%) in the left knee joint. Seven days later 
animals received a second i.art injection in the left knee joint of 150 pi FCA or saline, 
enabling the effects of inflammation on previously labelled and identified joint 
specific sensory neurons to be examined over a time course, encompassing early (one 
day), intermediate (seven days), and later (seventeen days) time points, post-i.art 
FCA.
Prior to the first injection naive weight bearing readings and joint diameter 
measurements were taken for each animal to provide appropriate baselines for the 
study. A second set of measurements were taken 24 hours post-FG injection to ensure 
that no hypersensitivity or joint inflammation had occurred due to FG injection. Prior 
to the second injection a final set of baseline measurements were taken. Based on 
these measurements animals were ranked in ascending order and randomised into two 
groups (FCA or saline; n = 20). In order to remain consistent with other studies 
described in this thesis the day of the second injection was considered as day zero for 
this study. Further weight bearing and joint diameter measurements were taken on 
days 1, 7 and 10 post-FCA/saline injection.
Eight animals (FCA; n = 4 and saline; n = 4) were euthanased using a rising 
concentration of CO2 on days 1 and 7 post-FC A/saline injection and ipsilateral L3 and 
L4 DRG removed.
The remaining FCA injected animals were ranked in ascending order according to the 
day 1 0  weight bearing readings and then randomized into 2  dosing groups using a
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Latin square format. Bi-daily, oral administration of vehicle or celecoxib (10 mg/kg; 
n = 6 ) was performed as described in Section 4.4.2.
Weight bearing and joint diameter data during the dosing period were based on saline 
(n = 12), FCA + vehicle (n = 6 ) and FCA + celecoxib groups (n = 6 ). On day 17 post- 
second injection all animals were euthanased using a rising concentration of CO2 . 
Ipsilateral L3 and L4 were removed from twelve animals (n = 4, per group) for 
immunofluorescence.
4.5 RESULTS
4.5.1 Dose response to celecoxib in an established FCA model of hypersensitivity
4.5.1.2 Effect of celecoxib on hypersensitivity
Prior to intraplantar FCA injection the weight of the rat was distributed evenly 
between both hind paws. Hypersensitivity was established 23 hours later as shown by 
a decrease in the ability to bear weight on the injected (left) paw.
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■  Vehicle 13 1 mg/kg ■  3mg/kg □  10mg/kg
Figure 4.2 Percentage reversal of hypersensitivity in established (intra-plantar) FCA 
study 1. No dose group showed any significant reversal of hypersensitivity compared 
to vehicle treated controls (n = 7 per group). P >0.05, one-way ANOVA.
■  Vehicle ED 1 mg/kg U  3 mg/kg □  10 mg/kg
Figure 4.3 Percent reversal of hypersensitivity in established (intra-plantar) FCA 
study 2. Animals dosed with celecoxib at 1 and 10 mg/kg showed significant reversal 
of hypersensitivity, compared to vehicle treated controls (n = 7 per group). P  <0.05, 
One-way ANOVA, followed by a Dunnetf s post hoc. (*) P<0.05 compared to vehicle 
treatment.
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Following oral administration of vehicle or celecoxib (1, 3 or 10 mg/kg) no 
significant reversal of hypersensitivity was seen in any celecoxib dose group 
compared to vehicle dosed animals in study 1, (P >0.05, one way ANOVA; figure 
4.2) and the study was repeated. In study 2, significant reversal of FCA-induced 
hypersensitivity was identified in the 1 and 1 0  mg/kg celecoxib dose groups 
compared to vehicle (P <0.05, one-way ANOVA followed by a Dunnett’s post hoc; 
figure 4.3; see appendix 1.3 and 2.4 for raw data and statistical analysis, respectively).
4.5.2 Dose response to celecoxib in FCA-induced joint pain model
4.5.2.1 Effect of celecoxib on hypersensitivity
Prior to i.art FCA injection the weight of the rat was distributed evenly between both 
hind paws. Hypersensitivity was established 24 hours later as shown by a decrease in 
the ability to bear weight on the injected (left) paw. Hypersensitivity was maintained 
until the beginning of the dosing period (day 13) in all FCA injected animals (Figure
4.4). Nai've animals showed no hypersensitivity at any point during the study.
Celecoxib (1,3 and 10 mg/kg) gave a dose related reduction in hypersensitivity. With 
the exception of day 17 for the 1 mg/kg treated animals all weight bearing 
measurements for celecoxib treated animals during the dosing period were 
significantly different to the vehicle treated group (P <0.05, one-way ANOVA with 
repeated measures, followed by a Holm-Sidak post-hoc, see appendix 1.5 and 2.5 for 
raw data and statistical analysis, respectively). Animals dosed with vehicle showed no 
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Figure 4.4 Effect of celecoxib (1, 3 and 10 mg/kg) on FCA induced joint hypersensitivity compared to vehicle, as measured by weight bearing 
(% ipsilateral/contralateral). FCA or saline was injected on day 0. With the exception of day 17 in the 1 mg/kg dose group, all celecoxib treated 
animals showed significantly improved weight bearing compared to vehicle treated animals during the dosing period (P <0.05, one-way 
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Figure 4.5 Effect of celecoxib (1,3 and 10 mg/kg) on FCA induced joint inflammation compared to vehicle, as measured by joint diameter (% 
ipsilateral/contralateral). FCA or saline was injected on day 0. Both 3 and 10 mg/kg dose groups showed significant reductions in joint 
inflammation compared to the vehicle treated controls (P <0.05, one-way ANOVA with repeated measures, followed by a Holm-Sidak post-hoc 
test, see appendix 2.6). No significant difference was measured between the 1 mg/kg dose group and vehicle controls.
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4.S.2.2 Effect of celecoxib on joint inflammation
Joint inflammation was established 24 hours post-FCA injection in all FCA injected 
animals (Figure 4.5). An increase of approximately 30% in ipsilateral joint diameter 
was seen on days 1 and 3. This dropped to approximately 20% by day 9. Joint 
inflammation was never entirely diminished during the study. However, both 3 mg/kg 
and 10 mg/kg doses of celecoxib produced a sustained and significant reduction in 
joint inflammation compared to vehicle treated animals throughout the dosing period 
(.P <0.05, one-way ANOVA with repeated measures, followed by a Holm-Sidak post- 
hoc test, see appendix 1.6 and 2.6 for raw data and statistical analysis, respectively). 
The 1 mg/kg dose group showed no significant reduction in inflammation compared 
to vehicle treated animals (P >0.05, one-way ANOVA with repeated measures).
4.5.3 Effect of celecoxib on CGRP expression in joint afferent neurons in a 
model of joint pain.
4.5.3.1 Effect on hypersensitivity
Injection of FG on day -7 produced no changes in weight bearing measurements in all 
animals. Hypersensitivity was established 24 hours post-FCA injection and 
maintained until the beginning of the dosing period (day 13) in all FCA injected 
animals (Figure 4.6). Saline injected animals showed no hypersensitivity at any point 
during the study.
Celecoxib (10 mg/kg) gave a significant reduction in hypersensitivity. Weight bearing 
was significantly improved in celecoxib treated animals on every day during the 
dosing period compared to the vehicle treated group (.P <0.05, one-way ANOVA with
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repeated measures, followed by a Holm-Sidak post-hoc, see appendix 1.7 and 2.7 for 
raw data and statistical analysis, respectively). Animals injected with FCA and dosed 
with vehicle showed no significant reduction in hypersensitivity.
4.5.3.2 Effect on joint inflammation
Joint inflammation was also established 24 hours post-FCA injection in all FCA 
injected animals (Figure 4.7). Increases of approximately 30% in ipsilateral joint 
diameter were seen on day 1. This dropped to approximately 15% by day 10. No 
inflammation was seen in any animal following injection of FG on day -7.
Joint inflammation dropped to approximately 10% in vehicle dosed animals by 
day 17. Celecoxib (10 mg/kg) dosed animals also showed a significant decrease in 
inflammation. Joint diameter was significantly reduced in celecoxib treated animals 
on every day during the dosing period compared to the vehicle treated group 
(P <0.05, one-way ANOVA with repeated measures, followed by a Holm-Sidak post- 
hoc, see appendix 1.8 and 2.8 for raw data and statistical analysis, respectively). 
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Figure 4.6 Effect of celecoxib (10 mg/kg) on FCA induced joint hypersensitivity compared to vehicle, as measured by weight bearing 
(% ipsilateral/contralateral). FG was injected on day -7 and FCA or saline injected on day 0. Celecoxib treated animals showed significantly 
improved weight bearing every day during the dosing period, compared to the vehicle treated group (P <0.05, one-way ANOVA with repeated 
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Figure 4.7 Effect of celecoxib (10 mg/kg) on FCA induced joint inflammation compared to vehicle, as measured by joint diameter (% 
ipsilateral/contralateral). FG was injected on day -7 and FCA or saline injected on day 0. Celecoxib treated animals showed significantly reduced 
joint inflammation every day during the dosing period, compared to the vehicle treated group (P <0.05, one-way ANOVA with repeated 
measures, followed by a Flolm-Sidak post-hoc, see appendix 2.8). Error bars indicate +/- sem.
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4.5.3.3 Retrograde nerve tracing
Intense FG-labelled neuronal profiles were easily identifiable in the ipsilateral L3 and 
L4 DRG of animals from all experimental groups, FCA-injected (figure 4.8 .A) and 
saline-injected (figure 4.8.C) at every time point, days 1, 7 and 17. Contralateral L3 
and L4 DRG were also removed and used as work-up tissue for optimizing IHC 
techniques. No FG-labelled profiles were seen in any of the contralateral DRG (data 
not shown).
4.5.3.4 Immunofluorescence
CGRP-immunopositive neuronal profiles were easily identifiable in the ipsilateral L3 
and L4 DRG of animals from all experimental groups, FCA-injected (figure 4.8.B) 
and saline-injected (figure 4.8.D) at every time point, days 1, 7 and 17. Double­
labelled FG and CGRP-immunopositive cell bodies were seen in all ipsilateral DRG.
On day 1, FG-labelled and CGRP-immunopositive cell bodies in DRG removed from 
saline injected animals showed 34 +/- 3% (mean +/- SEM) co-localization. 
Significantly more co-localization was seen in DRG from FCA-injected animals, 
45 +/- 4% at the same time point (P <0.01, one-way ANOVA, see appendix 1.9 and
2.9 for raw data and statistical analysis, respectively). On day 7, FG-labelled and 
CGRP-immunopositive cell bodies in DRG removed from saline injected animals 
showed 29 +/- 1% co-localization. Significantly more co-localization was seen in 
DRG from FCA-injected animals, 38 +/- 2% at the same time point (P <0.05, one­
way ANOVA). On day 17, FG-labelled and CGRP-immunopositive cell bodies in 
DRG removed from saline injected animals, FCA-injected animals dosed with vehicle
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and FCA-injected animals dosed with celecoxib showed no significant difference 
between groups (P >0.05, one-way ANOVA; table 4.1 and figure 4.9, see appendix
1.9 and 2.9 for raw data and statistical analysis, respectively). No CGRP- 
immunopositive cell bodies were identified in any negative control studies, which 
examined the use of primary and secondary anti-sera used separately with blocking 
(NGS and BSA) solution (data not shown).
Figure 4.8 Images of rat L4 DRG following injection of FG with FCA (A and B) or 
saline (C and D) into the knee joint and immunofluorescence. The two sections were 
each photographed alternately under filters appropriate for FG (A and C) and Alexa 
488 (B and D). Arrows indicate FG- and CGRP-immunopositive double-labelled 
neurons. Scale bar, 100 pm.
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Group Total FG-labelled




Day 1. Saline 463 154 33
Day 1. FCA 618 269 43 (**)
Day 7. Saline 476 146 30
Day 7. FCA 388 147 38 O
Day 17. Saline 320 95 30
Day 17. FCA + vehicle 353 140 40
Day 17. FCA +
celecoxib 186 67 36
Table 4.1 Total cell counts of FG-labelled and CGRP-immunopositive cell bodies 
identified in ipsilateral L3 and L4 DRG from all FCA-injected, saline-injected and 
celecoxib-treated animals taken at three time points with percentage co-localization. 
Percentage co-localization between saline and FCA+vehicle was significantly 
different on days 1 and 7, (**) P <0.01 and (*) P  <0.05, one-way ANOVA, 
respectively.




Day 1 Day 7 Day 17
Time (Days post-FCA injection)
Figure 4.9 Proportion of CGRP-immunopositive FG-labelled joint afferents in saline 
injected animals, FCA injected animals and FCA injected animals treated with 
celecoxib (n = 4 per group per time point) during a 17 day unilateral monoarthritis of 
the right knee joint. Saline and FCA injected animals were significantly different on 
days 1 and 7, (**) P <0.01 and (*) P <0.05, one-way ANOVA, respectively. No 
significant difference was measured between groups on day 17.
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4.6 DISCUSSION
Preliminary studies using FCA injection into the footpad and knee joint established 
the behavioural effects of celecoxib dosed orally at 1, 3 and 10 mg/kg. Studies 
performed using the footpad model of FCA-induced pain confirmed dose selection 
for the joint pain validation study in an acute model using a relatively small number 
of animals. Celecoxib showed varied responses in the footpad model of acute pain. In 
study 1 none of the dose groups showed any significant difference in the percentage 
reversal of hypersensitivity compared to the vehicle control group (figure 4.2), 
whereas in study 2 , significant differences were seen in the 1 and 1 0  mg/kg dose 
groups compared to the vehicle dose group (figure 4.3). It is likely that data derived 
from study 1 may reflect initial difficulties in either the dosing of the animals or the 
personal expertise in the use of weight bearing equipment. Despite supervision, this 
was the first study where oral dosing had been performed, thus, error could have 
occurred. Moreover, this was the first study during which weight bearing 
measurements were taken from animals with acute footpad inflammation. It is 
possible that animals with this type of superficial hypersensitivity may behave 
differently whilst settling on the weight bearing apparatus compared to animals with 
joint hypersensitivity, used in chapter three, especially after oral dosing only one hour 
before. In addition, it is possible that an error may have occurred during the dose 
formulation or dose preparation with DMSO, PEG 400 and water. However, this is 
unlikely as the same batch of celecoxib and dose preparations were also used during 
study 2 , which produced a more reliable set of data and suggested a robust and 
significant effect of celecoxib on footpad hypersensitivity.
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Administration of celecoxib at 1, 3 and 10 mg/kg during the final five days of a 
seventeen day FCA-induced joint pain model produced a dose-response effect in both 
hypersensitivity and inflammation (figures 4.4 and 4.5 respectively). The 10 mg/kg 
dose group produced the greatest resolution of hypersensitivity and inflammation and 
the 1 mg/kg group produced the least resolution. Thus, for the final study (Effect of 
celecoxib on CGRP expression in joint afferent neurons in a model of joint pain) 
celecoxib was dosed at 1 0  mg/kg to ensure that optimal behavioural responses would 
be attained.
For the final study conducted in this chapter weight bearing and joint diameter 
measurements demonstrated a sustained and significant joint hypersensitivity and 
inflammation in all FCA-injected animals (figures 4.6 and 4.7). FCA-injected animals 
treated with celecoxib showed a significant reduction in hypersensitivity and 
inflammation on every day during the dosing period compared to FCA-injected 
animals treated with vehicle. No joint hypersensitivity or inflammation was seen in 
any of the saline injected control animals.
A significant increase in CGRP-immunopositive joint afferents was measured in 
FCA-injected animals compared to saline injected animals on day one, 43% and 33% 
respectively and day seven, 38% and 30% respectively. No significant difference in 
the co-localization of CGRP-immunopositive FG-labelled neurons was seen between 
groups on day 17.
These histological and behavioural data suggest that the early stages of a chronic joint 
inflammation, day one, when joint hypersensitivity and inflammation are at their
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peak, correspond with an increased number of joint specific CGRP-expressing 
neurons. The increase in CGRP-expressing joint afferents was still significant by the 
intermediate phase, day seven, when joint hypersensitivity and inflammation were 
still pronounced. However, by day seventeen, when there was some resolution in 
hypersensitivity and considerable reduction in joint inflammation, the number of joint 
specific CGRP-expressing neurons in inflamed animals did not differ significantly 
from control animals. Moreover, dosing with celecoxib appeared to have no 
significant effect on the expression of CGRP in joint afferents despite significantly 
reducing joint hypersensitivity and inflammation. Whilst these data appear to suggest 
that inhibition of prostaglandin synthesis provides relief from pain and inflammation, 
via mechanisms that do not exert a significant effect on the expression of CGRP in 
the DRG, administration of celecoxib at an earlier interval during the study, when the 
increased number of joint specific CGRP-expressing neurons was more pronounced, 
may have demonstrated otherwise.
Previous investigations also identify increased CGRP expression during the early 
stages following joint inflammation. In monoarthritis studies of the rat tarsal joint, 
levels of CGRP mRNA are elevated in the DRG after only eight hours following 
injection of adjuvant (Donaldson et al., 1992). In the inflamed cat knee joint the 
number of CGRP-immunopositive joint afferents increased by approximately 10% 
after thirty-two hours post-injection of adjuvant (Hanesch et al., 1997). Whilst early 
increases in CGRP content following a joint inflammation appear to be well founded 
additional studies have noted a more prolonged elevation of CGRP-expression in the 
whole DRG following joint inflammation. In polyarthritis models the level of CGRP 
in the DRG has been shown to double by days fifteen and twenty-six post inoculation
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(Kuraishi et al., 1989). Although the widespread systemic effects of a polyarthritis 
model may account for the prolonged elevation of CGRP levels in the whole DRG it 
is also likely that some of the increased peptide content is located in joint specific 
afferent cell bodies.
The rapid increase in CGRP, mRNA and peptide, in the DRG as a consequence of 
joint inflammation may occur in order to enhance blood flow to the site of 
inflammation. CGRP is a potent vasodilator, thus, peripheral release of CGRP at the 
site of inflammation may dilute and remove noxious substances, such as FCA or 
inflammatory mediators, from the inflamed area (Hanesch et al., 1997). In the case of 
FCA injection into the joint, non-metabolisable oil in a poorly perfused structure, the 
noxious substance is likely to reside indefinitely and may account for prolonged 
increases in CGRP expressing joint afferents.
Joint afferent neurons identified in saline-injected control animals showed consistent 
levels of CGRP expression on days one, seven and seventeen, 33%, 30% and 30% 
respectively. These levels of CGRP expression in joint afferents are in agreement 
with previous studies, as Salo and Theriault (1997) also identified that 33% of rat 
knee joint afferents were CGRP-immunopositive under normal physiological 
conditions.
Although CGRP-expressing joint afferents were comprehensively examined in 
several experimental groups and at a number of time points in the current study, the 
inclusion of other markers such as trkA would have provided a more thorough 
examination of the joint afferents. Prior to work-up experiments with antibodies for
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CGRP, numerous work-up experiments were performed using two different 
antibodies for trkA (Chemicon, UK; Santa Cruz, US), as trkA had been the original 
marker of interest for the current study. In addition, a series of amended 
immunofluorescence protocols were applied including, altered durations of 
incubation, rinses with different buffer solutions such as tris buffered saline (TBS) 
and PBS and different secondary antisera, including Alexa 488 (Molecular Probes, 
UK) and Alexa 633 (Molecular Probes, UK). Unfortunately, work-up experiments 
using antibodies specific for trkA failed to demonstrate any good quality or reliable 
labelling of neuronal cell bodies in the rat DRG (data not included). Thus, CGRP, 
which was originally used as a control antibody to validate an immunofluorescence 
protocol, was used as a contingency marker, as approximately 92% of trkA- 
expressing neurons are CGRP-immunopositive (Averill et al., 1995). Therefore it is 
possible that the increase in CGRP-expressing joint afferents seen in the current study 
may also represent an increase in trkA-expressing neurons as increases in trkA 
expression have also been identified in the DRG during models of chronic 
inflammatory joint pain (Pezet et al., 2001). However, confirmation of such a 
correlation has yet to be unequivocally identified and requires further investigation.
In conclusion, the hypersensitivity and inflammation measured behaviourally, 
following injection of FCA into the rat knee joint, appears to be correlated with an 
increase in knee joint specific CGRP-expressing neurons. The increase in CGRP- 
expressing neurons remains substantial up to seventeen days post-FCA injection. The 
exact function of this increase in joint specific CGRP-expressing neurons is not 
known. However, it is probable that one aspect of this increase represents a
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vasodilatory effect within the joint in order to dilute and remove offending substances 





The results obtained in this thesis have shown that IB4-binding neurons are 
completely absent from the rat knee joint under normal and pathophysiological 
conditions induced by i.art administration of FCA. The same subtype of C-fibre has 
also been shown to contribute almost half of the afferent innervation from the skin 
surrounding the medial knee joint. Furthermore, the final collection of studies in this 
thesis have illustrated a significant increase in joint specific CGRP-expressing 
neurons at a number of intervals during an FCA-induced monoarthritis of the knee 
joint which appear to match behavioural responses. These findings support the 
hypotheses that IB4-binding neurons are not present in the rat knee joint during 
normal or pathophysiological conditions and that knee joint specific peptidergic 
neurons increase in number during a model of chronic inflammatory joint pain. The 
findings of this thesis contribute to the understanding of knee joint innervation and 
provide an insight into the responses of joint specific neuronal populations in 
conditions of chronic joint inflammation.
The absence of IB4-binding neurons in the normal and pathophysiological rat knee 
joint were confirmed through the application of retrograde nerve tracing, 
experimental models of pain, behavioural measures and histological examination. The 
absence of IB4-binding neurons in this deep somatic structure and abundance in 
cutaneous structures is in accordance with numerous other findings. Previous authors 
have noted low numbers of IB4-binding neurons in other deep somatic structures, 
such as the rat masticatory muscle (Ambalavanar et al., 2003) and the rat lumbar 
disks (Aoki et al., 2004). Moreover, almost half of the afferent neurons from skin
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surrounding the vibrissal pad area and medial ankle in rat are IB4-binding (Bennett et 
al., 1996b; Ambalavanar et al., 2003).
The relative contribution of IB4-binding neurons in the mediation of chronic pain 
during normal and pathophysiological conditions is unknown. However, the current 
study suggests that any functional role in chronic inflammatory joint pain occurs from 
outside of the joint. A number of studies have suggested that IB4-binding neurons 
may be involved with the processes of chronic pain derived from nerve injury and 
chronic pain derived from tissue inflammation may be more associated with trkA- 
expressing neurons (Malmberg et al., 1997a; Malmberg et al., 1997b). Additional 
investigations have proposed that transitions from inflammatory to neuropathic pain 
may occur in experimental models of arthritis (Calza et al., 1998). This may suggest a 
putative transition from pain mediated by trkA-expressing neurons to pain mediated 
by IB4-binding neurons during the progression of chronic inflammation. Thus, it is 
possible that IB4-binding neurons may influence chronic joint pain from superficial 
areas outside of the joint, possibly due to a secondary inflammation of the skin 
surrounding the joint or due to surrounding nerve damage.
A growing body of evidence has implicated IB4-binding neurons in acute pain 
sensation. When IB4-binding neurons are selectively destroyed in rats using nerve 
toxin, animals show behavioural signs of decreased sensitivity to acute thermal and 
mechanical stimuli (Vulchanova et al., 2001). Although acute pain is mainly ascribed 
to the larger diameter A8 -fibres, C-fibres are still thought to contribute, as some pain 
can still be felt following a pin prick to the skin even after loss of A8 -fibre function 
(Magerl et al., 2001). The abundance of EB4-binding neurons in the skin suggests that
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this subtype of C-fibre may be responsible for the remaining pain sensation following 
the loss of A8 -fibre function. In addition, the almost exclusive expression of P2 X3 
receptors on IB4-binding neurons and the abundance of this C-fibre subtype in the 
skin support the observations that cutaneous nerves are more sensitive to ATP in 
conditions of acute inflammation (Hamilton et al., 2001).
Whilst it is possible that IB4-binding neurons mediate both chronic pain derived from 
nerve injury and some aspects of acute pain, the current studies do not demonstrate 
this. What can be concluded, with a great degree of certainty, is that IB4-binding 
neurons are not present in the rat knee joint. Therefore, this implies that trkA- 
expressing neurons are the only subtype of C-fibre present in the rat knee joint and 
that it is these neurons that have been associated with conditions of chronic 
inflammatory joint disease. The final study in this thesis appears to support this.
The histological profile of joint specific CGRP-expressing neurons was also 
determined using retrograde nerve tracing in a model of rat knee joint monoarthritis, 
in conjunction with behavioural profiles of hypersensitivity and inflammation. The 
effects of celecoxib treatment on monoarthritis-induced changes were also 
determined, both behaviourally and histologically. Significant increases in joint 
specific CGRP-expressing neurons were present during the early and intermediate 
phases of monoarthritis, when hypersensitivity and inflammation were at their most 
pronounced. However, by the final day of the study when some resolution of 
hypersensitivity and inflammation could be seen the number of joint specific CGRP- 
expressing neurons in the monoarthritis animals did not differ significantly from 
control animals. This might imply that the slight resolution of hypersensitivity and
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inflammation is correlated with a reduction of CGRP-expression in joint specific 
afferents. Although, celecoxib treated animals showed significant improvements on a 
behavioural scale this was not reflected on a histological scale, as the number of joint 
specific CGRP-expressing neurons did not differ from the vehicle treated group.
The current findings are in agreement with previous authors who have also noted 
increased levels of CGRP expression during the early stages of a monoarthritis. 
Increases in CGRP expression have been noted in the inflamed joint, the dorsal horn, 
the whole DRG (Donaldson et al., 1992; Calza et al., 1998) and in joint specific 
afferent cell bodies in the DRG (Hanesch et al., 1997). Additional studies have also 
identified a more prolonged elevation of CGRP-expression, 15 and 26 days post­
induction of chronic joint inflammation (Kuraishi et al., 1989).
CGRP performs a multitude of roles which are known to potentiate an inflammatory 
response. These include inducing the release of PGE2 and acting as a chemotactic 
agent for endothelial cells and fibroblasts. Thus, there are a host of reasons why the 
number of joint specific CGRP-expressing neurons increase as a consequence of a 
monoarthritis. However, it is likely that one major reason for this increase is due to 
the potent vasodilatory function of CGRP. Peripheral release of CGRP increases local 
blood flow to the joint and potentially dilutes or removes any offending substances 
from the inflamed area.
5.2 FUTURE WORK AND CONCLUSIONS
Experiments described in this thesis have answered certain questions and raised 
several others. One of the main unanswered questions is whether or not IB4-binding
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neurons present any significant contribution in the pathogenesis of chronic 
inflammatory joint diseases from areas outside of the joint. The use of retrograde 
nerve tracing could again be applied in order to give an insight into such a possibility. 
By labelling afferent neurons in the skin surrounding the knee joint and inducing a 
monoarthritis in the same joint, any changes in the number of IB4-binding skin 
afferents could be examined over time in the lumbar DRG. This may indicate any 
influence of IB4-binding neurons on the pathogenesis of chronic inflammatory joint 
disease, thus supporting or contradicting the notion of a transition from pain mediated 
by trkA-expressing neurons to IB4-binding neurons during the progression of 
experimental arthritis.
Clearly the examination of other markers would have strengthened the results in this 
thesis, in particular, trkA. For studies described in chapters 2 and 3 double-labelling 
with a trkA antibody would have confirmed unequivocally the nature of the IB4- 
negative joint afferents. For the final study in chapter 4, double labelling with a trkA 
antibody may have identified a correlation between the increases in joint specific 
CGRP-expressing neurons and the increases in trkA-expression in experimental 
models of arthritis (Pezet et al., 2001). Unfortunately, despite numerous attempts to 
examine trkA-expressing neurons, work up experiments using two trkA antibodies 
failed to produce any reliable results, discussed in section 4.6. Thus, the main 
question that remains is the correlation between increases in joint specific CGRP- 
expressing neurons and joint specific trkA-expressing neurons. This could be 
answered by simply repeating the final study described in this thesis and using a 
reliable immunofluorescence protocol with a suitable trkA antibody. In addition, 
contralateral joints could also be labelled with FG to determine whether or not the
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increases in joint-specific peptide expressing neurons in the ipsilateral side are 
reflected on the contralateral side.
The results described in this thesis have contributed to the understanding of knee joint 
innervation and have illustrated behavioural and histological changes that occur in 
joint specific afferent neurons during inflammatory conditions. However, a number of 
questions have been raised throughout this thesis which currently remain unanswered. 
Until more investigations are performed in this area of applied neuroscience, 
including studies such as those described above, it will not be possible to conclude 
what the exact nature and contributions provided by C-fibre subtypes are in the 
normal physiology of the joint or how their separate functions influence the 
pathogenesis of chronic inflammatory joint diseases. Determining a more complete 
picture of how these neuronal influences are involved in physiology and 
pathophysiology may provide a host of therapeutic avenues for the treatment of 
chronic inflammatory joint disease.
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APPENDIX 1
Raw data used for statistical analysis
Appendix 1.1. Raw da ta  for figure 3.2
Saline
Baseline I I I
Animal Mean Ipsi Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C
FCA 1 78 102 76 95 97 98 93 100 94
FCA 2 99 91 109 111 129 86 93 103 90
FCA 3 91 96 95 137 146 94 94 99 95
_____ I  . . . . .  _ _  J
mean 90 96 94 114 124 93 93 101 93
sem 6 3 10 12 14 . . .  4 0 1 1
FCA
Baseline Day 1 Day 7
Animal Mean Ipsi Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C
Saline 1 94 93 100 44 132 33 48 115 42
Saline 2 78 82 95 20 136 14 21 130 16
Saline 3 93 111 84 23 157 15 45 139 32
mean 88 96 93 29 142 21 38 128 30
sem 5 9 5 8 8 6 9 7 8
124
Appendix 1.2. Raw data  for figure 3.2
Saline
Baseline L Day 1 Day 16
Animal Mean Ipsi Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C
FCA 1 78 81 96 82 73 113 118 112 105
FCA 2 69 77 90 69 77 89 102 105 97
FCA 3 89 81 109 82 81 101 121 124 98
FCA 4 83 81 103 89 89 100 103 114 90
! i i -
mean 80 80 ! ' I 81 80 101 111 114 98
sem 4 1 4 4 3 5 5 4 3
FCA
Baseline Day Day 16
Animal Mean Ipsi Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C
Saline 1 107 100 107 42 125 34 73 127 58
Saline 2 70 71 100 41 123 33 63 119 53
Saline 3 70 60 116 22 106 21 82 132 62
Saline 4 92 99 93 25 114 22 65 104 63
mean 85 82 104 32 27 71 121 59
sem 9 : . : 5
_
_ 4 4 6 2
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Vehicle
Animal Mean Ipsi I Mean Contra difference Ratio l/C Mean Ipsi Mean Contra difference Ratio l/C Mean Ipsi Mean Contra difference Ratio l/C %reversal5 74 69 -5 107 25 104 79 24 38 81 43 47 4311 71 75 4 95 39 98 60 39 34 99 65 34 -1014 71 62 -9 114 52 76 24 68 45 82 37 55 -3719 76 75 -1 101 41 85 44 48 52 69 18 75 5920 87 93 5 94 28 110 81 26 37 99 62 37 2521 89 83 -6 108 44 102 57 44 37 114 77 32 -3122 96 96 0 100 43 82 39 52 56 84 28 67 29
mean 81 I 79 -2 103 39 94 55 43 43 90 47 50 11sem 4 | 5 2 3 4 5 8 6 3 6 8 6 14
1 mg/kg
2 70 60 -10 116 24 89 65 27 53 77 24 69 554 54 70 16 77 50 78 28 64 72 71 -1 101 24410 77 84 7 92 44 94 50 47 47 72 24 66 5913 81 75 -6 108 26 107 81 24 52 88 36 59 5218 90 85 -5 106 46 95 49 48 25 115 91 21 -7723 77 80 3 96 48 87 38 56 53 73 20 73 5324 6^ 83 7 92 35 105 71 33 62 89 27 70 69
mean 75 77 2 98 39 94 55 43 52 83 31 66 65sem 4 3 3 5 4 4 7 6 6 6 11 9 35
3 mg/kg3 76 '4 103 31 85 54 36 319 88 49 I 45 96 72 60 -12 119 33 109 76 30 67 68 1 98 859 80 78 -1 102 14 115 101 12 84 35 59 6512 79 82 3 97 51 83 31 62 : 80 37 54 -2017 90 104 14 86 35 80 45 43 3.7 78 41 48 1525 81 89 8 91 48 100 52 48 53 73 20 73 7327 101 84 -17 120 60 90 29 I 67 612 81 19 77 22
mean 83 82 -1 i 103 39 94 M  1 4 9 5.0 | 79 23 j 65 j 36sem 4 I 4 I 5 6 1 2 i  6 | 7 j 15
10 mg/kg1 70 61 -10 116 37 92 56 I 40 45 86 41 53 237 87 84 -3 103 50 96 46 52 63 85 22 74 498 88 83 -6 107 26 91 65 28 31 91 60 34 715 75 58 -17 130 52 80 28 65 59 63 3 95 5416 79 74 -5 107 23 93 69 25 57 78 21 73 6526 78 80 3 97 44 78 33 57 52 54 2 97 10328 87 89 2 97 35 97 62 36 41 91 50 45 21
mean 81 76 -5 108 38 90 51 43 50 78 28 67 46sem 3 5 3 4 4 3 6 6 4 5 9 9 12
Appendix 1.3. Raw weight bearing data for vehicle, 1 mg/kg, 3 mg/kg and 10 mg/kg dosed animals used for figure 4.2. Mean (+/- sem) percentage reversal were used to plot figure 4.2 and to determine statistical significance between groups
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Post-doseAnimal Mean Ipsi Mean Contra difference Ratio l/C Mean Contra difference Ratio l/C Mean Contra difference Ratio l/C %reversal2 89 77 -11 115 28 109 81 26 19 135 116 14 -386 99 91 -8 108 30 121 91 25 45 114 69 40 238 95 99 4 96 46 110 64 42 23 125 102 19 -6411 88 73 -15 121 54 111 57 48 28 128 100 22 -6012 80 96 16 84 38 98 60 39 64 87 23 74 8421 82 86 4 95 21 140 119 15 17 144 127 12 -725 75 80 4 95 33 97 64 34 32 95 63 34 2
mean 87 I 36 112 33 33 119sem 3 4 ............. 4 . 5 4 6 9 4 8 8 20
1 mg/kg1 7 89 95 6 94 43 102 59 42 62 92 30 67 5415 76 77 1 99 52 79 27 65 71 74 3 96 9116 79 82 3 96 33 111 79 29 67 92 25 73 7117 88 91 2 97 39 100 61 39 96 122 26 79 6018 82 81 -1 101 34 139 105 25 69 88 19 78 8123 74 79 5 94 29 111 82 26 54 95 41 57 5324 99 107 7 93 19 108 89 18 60 80 20 75 84
mean 84 87 3 ! 35 107 72 35 68 92sem 3 4 1 1 4 7 9 6 5 6 4 5 6
3 mg/kg1 79 86 7 92 32 77 46 41 61 90 29 68 434 72 81 9 89 41 108 67 38 61 94 33 65 5910 84 88 A 96 25 113 88 22 58 81 23 72 7714 81 78 -3 104 55 79 24 70 59 85 26 69 -719 88 95 7 93 41 121 80 34 54 114 60 47 2722 94 95 1 99 30 111 81 27 34 120 86 28 -628 84 84 0 100 17 118 101 15 50 109 59 46 42
mean 83 87 3 96 34 104 99 45sem 3 2 2 2 5 7 .. 10 . 7 6 s 6 12 I
10 mg/kg3 87 82 -5 107 41 93 52 44 80 77 -3 103 955 92 97 5 95 28 108 79 26 72 73 1 98 1059 84 70 -14 119 29 118 89 25 64 99 35 65 5213 88 88 1 99 35 110 75 32 64 91 27 70 6420 89 91 2 97 40 112 71 36 51 100 49 51 3226 98 103 5 95 15 130 116 11 71 87 16 82 9027 114 122 8 94 79 119 41 66 78 75 -3 104 132
mean 93 93 0 38 113 34 68 86 1Ssem 4 6 3 3 8 4 9 7 4 4 8 8 13
Appendix 1.4. Raw weight bearing data for vehicle, Img/kg, 3 mg/kg and 10 mg/kg dosed animals used for figure 4.3. Mean (+/- sem) percentage reversal were used to plot figure 4.3 and to determine statistical significance between groups
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Vehicle
Day 13 Day 14
Mean Ipsi
Day 15 ■ Day 16
Mean Ipsi
Day 1 r m
Antmal Mean Ipsi I Mean Contra I Ratio l/C Mean Contra Ratio l/C Mean Ipsi | Mean Contra | Ratio l/C Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C
1 17 72 24 25 90 28 16 69 23 11 41 27 29 63 46
2 36 100 36 27 93 29 30 78 38 45 85 53 31 70 44
426 40 96 42 16 100 16 32 76 42 50 80 63 30 71
10 30 99 30 36 85 42 40 75 53 37 64 58 44 81 54
13 23 78 29 21 89 24 48 92 52 38 77 49 42 64 66
14 54 88 61 50 86 58 50 119 42 52 88 59 39 77 51
27 38 72 53 42 96 44 40 94 43 35 77 45 27 53 51
30 50 99 51 42 102 41 31 122 25 45 98 46 40 61 66
38 40 84 48 36 96 38 35 72 49 37 64 58 41 69 59
39 38 96 40 24 100 24 51 110 46 72 40 46 99 46
Mean
SEM
33 | 89 U  37 H  29 | 91 H  33 m  36 I 85 K  42 ■  39 I 73 I f  51 S I  Jb 71 ! 51
5 I 5 | 5  1 5 | 2 ■  6 |  5 I 8 DV 4 1 6 I 7 ■  5 ] 3 3 4
1 mg/kg
Day 13 Day 14 Day 15 | Day 16 Day 17
Animal Mean Ipsi Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C
3 20 47 43 24 59 41 36 67 54 45 80 56 18 40 45
5 45 81 56 30 100 30 53 66 80 54 78 69 47 91 52
8 46 101 46 55 99 56 60 117 51 60 91 66 68 93 73
18 49 102 48 44 101 44 58 80 73 42 59 71 70 93 75
20 40 78 51 48 102 47 55 100 55 50 70 71 41 90 46
21 43 83 52 40 92 43 46 93 49 - 41 59 52 88 59
24 35 89 39 42 106 40 45 100 45 52 88 59 60 89 67
31 53 101 52 64 97 66 62 94 66 47 77 61 57 91 63
36 64 87 74 49 100 49 57 96 59 62 91 68 30 51 59
37 60 102 59 40 80 50 55 79 70 45 79 I 57 59 86 69
Mean
SEM
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4 Mean Ipsi Mean Contra Ratio l/C 1 Mean Ipsi Mean Contra Ratio l/C Mean Ipsi Mean Contra] Ratio l/C Mean Ipsi Mean Contra I Ratio M/C Mean Ipsi Mean Contra Ratio l/C
7 36 49 73 53 68 78 78 71 110 ~ B o - 84 105 62 81 77
9 45 65 69 60 64 94 52 63 83 74 94 79 88 80 110
12 67 89 75 69 94 73 81 106 76 75 91 82 70 87 80
15 94 107 88 66 79 84 53 65 82 98 95 103 90 91 99
19 64 98 65 90 97 93 61 84 73 85 79 108 81 90 90
23 54 87 62 61 80 76 54 80 68 55 62 89 62 67 93
29 62 92 67 64 103 62 59 85 69 60 70 86 60 65 92
32 61 101 60 64 88 73 73 97 75 68 68 I X 74 69 107
34 39 110 35 59 77 77 64 71 90 56 69 81 59 68 I 87
58 111 52 60 90 67 80 90 89 71 85 84 68 82 | 83
Mean
SEM
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10 mg/kg
Day 13 Day 14 Day 15 Day 16 Day 17
Animal Mean Ipsi Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C
11 55 87 63 69 77 90 69 65 106 95 96 99 88 93 95
16 63 83 76 48 45 107 69 74 93 65 69 94 66 70 94
17 62 90 69 60 69 87 90 85 106 87 84 104 59 66 89
22 65 85 76 84 73 115 91 94 97 71 66 108 83 76 109
25 64 77 83 96 88 109 46 47 98 61 77 79 100 91 110
26 64 86 74 69 82 84 57 70 81 46 49 94 90 96 94
28 68 74 92 70 72 97 67 77 87 61 70 87 59 70 84
33 63 88 72 61 90 68 67 74 91 65 66 98 77 79 97
35 60 99 61 45 60 75 68 78 87 49 62 79 49 52 94
40 69 76 91 61 70 87 68 76 89 51 60 85 83 84 99
SEM
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Appendix 1.5. Raw weight bearing data for vehicle, 1 mg/kg, 3 mg/kg and 10 mg/kg dosed animals used for figure 4 4. Mean (+/- sem) of ratio l/C were used to plot figure 4.4 and each Ratio l/C colum per day used to determine 




Day 14 B 08y 15 Day 16 Day 17
Mean IpsiAnimal Mean Contra Ratio l/C Mean Ipsi | Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C Mean Contra Ratio l/C
1 1 22 9 9 123 2 126 10 3 1223 11 6 1 0 0 1160 11 3 101 1119 11.0 10 0 1 10 0
2 12 0 101 1188 11 5 10 0 115.0 1 12 1 00 1120 11 2 10 1 1109 11.5 10 0 115 0
6 12.6 10 0 126 0 12 0 10 0 120 0 1 20 1 02 1176 12 0 100 120 0 11 7 10 0 117 0
10 1 13 9.8 115.3 1 16 9 9 117.2 1 0 9 1 00 1090 1 0 6 9 9 107 1 11 0 10 0 1100
13 11.3 10 0 1130 11 9 101 1178 1 10 9 8 1122 111 10 0 1110 11 3 101 11 19
14 1 13 10.0 1130 1 13 9 9 114 1 111 100 111 0 1 1 3 9.9 114 1 11 4 102 1118
27 1 15 10 0 115 0 11.7 9 9 118 2 1 13 9 9 114 1 1 1 3 10 0 113 0 111 10 2 1088
30 1 10 9 9 1111 1 13 10.0 113 0 1 12 1 00 1120 1 1 3 10 0 113 0 10 9 9 9 110.1
38 11.3 9.9 114 1 114 9 9 115.2 11.2 9.9 113 1 11 5 10 0 115 0 112 10 1 1109
39 11.0 9 8 112 2 1 13 9 9 114 1 11.0 | 9  9 1111 1 1 2 9.9 1131 11.2 1 00 112 0
Mean
SEM
1 17  100  1 18  I 1 00  113  I t o o
Day 13 ■
-
Day 14 Day 16
Animal Mean Ipsi Mean Contra Ratio l/C Mean Ipa Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C Mean Ipei Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C
3 1 16 9.9 117.2 11 2 9 9 113 1 113 100 113 0 1 1 3 10 1 1119 1 10 10 0 110 0
5 12 5 9 8 127 6 1 20 1 00 1200 12 0 1 03 116 5 1 1 6 101 114 9 11 8 101 116 8
8 1 2 8 10 0 128 0 120 10 0 120.0 12 2 1 02 1196 1 22 10 2 1196 1 16 10 3 1126
18 1 16 9 8 1184 11.3 9.9 11 0 1 00 110 0 1 09 9.9 110.1 11.3 10 2 1108
20 11.1 10 0 1110 1 14 101 1129 11.6 104 1115 1 1 4 10 2 1118 114 10 3 110 7
21 1 14 10.1 1129 121 1 0 4 1163 1 09 1 02 1069 1 1 3 1 00 1130 112 1 00 1120
24 11.3 10 0 113.0 110 10.1 108 9 110 1 0 0 1100 11 1 1 00 1110 1 17 1 03 113 6
31 11.1 10.0 1110 11.5 10 2 112 7 1 09 9 8 1112 1 1 2 1 00 1120 11.0 1 0 2 107 8
36 11.7 9 9 1182 11 4 1 00 114 0 11.3 1 00 11 3 0 11.2 10.2 1098 11 0 10.1 108 9
37 11.3 1 0 0  I 113.0 111 10.0 111 0 1 1 2  | 100 1120 1 1 2 1 0 0  | 1120 109 9 9 110.1
se m  I 0 2  I o o H a i W  0 2  I o i  0 2  1 01  0 2  1 0 0  ■  112 1 1 01  | 01  0.9
Day 13 Da iv ' f Day 17 ■
4 Mean Ipsi Mean Contra I Ratio l/C Mean Ipsi Mean Contra Ratio l/C Mean Ipsi Mean Contra Mea*r Ipsi Ratio l/C Mean Ipsi Mean Contra Ratio l/C
7 11.3 9 9  1141 1 08 9 9 109 1 1 07 1 02 104 9 1 0 8 10 2 105.9 109 101 107 9
9 1 0 7 9 9 108 1 1 07 9 9 108.1 107 1 0 2 104 9 1(D 6 10 2 1039 107 1 02 104 9
12 10 6 9.8 108 2 110 9 9 111.1 1 09 101 107 9 1 0 6 10 1 1050 11.0 1 03 1068
15 12 0 10 3 116 5 1 15 10 2 1127 11 1 1 00 1110 1 1 1 1 02 108 8 11.5 10 1 113 9
19 11 7 101 1158 111 101 1099 11 0 101 108 9 t© 9 100 1090 10 6 1 02 103 9
23 11.4 1 0 2 1118 11 4 1 0 3 110.7 11 2 10 3 108 7 11.2 1 03 108 7 11 0 102 107 8
29 11.1 10.0 111 0 10.9 9 9 110.1 1 07 10 1 105 9 11 .2 101 1109 109 10 1 107 9
32 11.3 9 9 114 1 111 101 1099 11 4 1 03 1107 11.0 10 1 108 9 1 08 1 02 105 9
34 11 6 10.2 1137 11.2 10 2 1098 10 7 10 0 107 0 1 0 8 100 108 0 10 9 1 03 1058
11.1 1 0 0 1110 11.3 I 101 111 9 1 1 0 1 0 3 1068 11.1 103 1078 111 I 10 4 | 106 7
Mean
SEM
1 13  I 1 00  h i  112.4 t 111 10 1 1 1 1 0 . 3 109  1 1 02  ■ 1 1 0 7 /  1  1 0 9  1 1 02  11 0  102  B  107.5
1 1 H .  0 .7 K  1 1 1 1.0 1 1 H T I  i
I^ T i^ k g
Day 13 Day 14 W Day 15 B ^ Day f ^ B Day 17
Animal Mean Ipsi Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C Mean Ipsi Mean Contra Ratio l/C
11 10.8 10.1 1069 10 9 1 00 109 0 1 09 10 2 1069 1 0 4 1 00 1040 108 1 0 2 105 9
16 1 1 0 1 00 110 0 10 8 10.0 108 0 108 1 02 1 059 1 0 8 10.2 105 9 107 10 1 105 9
17 10 9 10 0 109 0 11.3 10.1 111.9 10 7 9.9 108 1 1 0 9 10 0 109 0 108 1 03 104 9
22 11.3 10 2 11 0 8 1 0 9 103 1058 1 06 1 02 103 9 107 10 2 1049 10 9 1 03 1058
25 10 8 100 108 0 11.0 10 1 108 9 108 10 1 1069 1 0 4 10.0 1040 10 6 1 00 1060
26 11 8 10 0 1180 11 4 10.2 1118 1 1 2 1 02 1 098 1 1 0 101 1089 11.0 1 04 1058
28 11.2 1 0 0 1120 11 0 1 0 0 110.0 107 1 02 1 049 10 8 1 02 1059 10 6 10 2 1039
33 11.5 1 02 1127 111 10 1 1099 11.1 1 05 105 7 11 0 1 02 107 8 10 5 1 03 101.9
35 ! 1 08 10 1 106 9 11 0 10 0 110.0 10.8 1 02 105 9 10 8 1 02 105 9 11.0 1 02 107 8
40 12 1 10 1 1198 1 10 9 9 111.1 114 10 2 1 118 1 1 0 1 02 107 8 10 9 1 02 1069
Mean
SEM
111 101 111 I m  1 108 I m i
I H B H  | L i ' W a H ^ H  I ^ ■ B S r . l  I H  0  9 B
A p p en d ix  1.6. Raw joint diameter data for vehicle, Img/kg, 3 mg/kg and 10 mg/kg dosed animals used for figure 4.5. Mean (+/- sem) of ratio l/C were used to plot figure 4.5 and each Ratio l/C per day used to determine 
statistical significance between groups
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Saline
Day 13 Day 14 Day 15 Day 16 Day 17
Animal Mean Left Mean Right Ratio L/R Mean Left Mean Right Ratio L/R Mean Left Mean Right Ratio L/R Mean Left Mean Right Ratio L/R Mean Left Mean Right Ratio L/R
1 79 87 91 65 64 102 63 71 89 79 85 93 77 70 110
6 86 79 109 96 86 112 88 84 105 77 75 103 93 88 106
7 65 75 87 71 70 101 72 79 91 62 70 89 93 96 97
8 77 78 99 77 79 97 62 71 87 90 82 110 92 91 101
13 79 76 104 77 85 91 89 81 110 88 96 92 64 70 91
14 89 96 93 85 73 116 85 85 100 85 77 110 85 89 96
15 71 80 89 69 74 93 79 84 94 69 80 86 89 96 93
17 93 87 107 90 96 94 91 87 105 87 92 95 68 74 92
18 81 84 96 81 90 90 99 93 106 81 80 101 88 85 104
19 90 82 110 90 92 98 72 79 91 99 94 105 94 86 109
20 74 79 94 85 88 97 51 60 85 88 84 105 87 95 92
26 83 90 92 64 71 90 77 69 112 75 83 90 79 80 99
mean 81 83 97 79 81 98 77 79 98 82 83 84 85 99
sem 2 2 2 3 3 2 4 3 3 ■ 2 I 2
FCA+Vehicle
Day 13 Day 14 Day 15 Day 16 Day 17
Animal Mean Left Mean Right Ratio L/R Mean Left Mean Right Ratio L/R Mean Left Mean Right Ratio L/R Mean Left Mean Right Ratio L/R Mean Left Mean Right Ratio L/R
2 51 125 41 42 101 42 47 110 43 46 91 51 49 96 51
5 34 80 43 40 95 42 52 111 47 32 90 36 42 103 41
9 33 98 34 37 89 42 44 98 45 51 109 47 39 89 44
10 42 101 42 47 109 43 31 94 33 44 101 44 45 92 49
11 37 112 33 34 99 34 48 107 45 55 89 62 47 107 44
12 41 109 38 53 126 42 50 112 45 50 110 45 48 98 49
mean 40 104 38 42 103 41 45 105 43 46 98 4? 45 98 46
sem 3 6 2 3 5 I 1 3 3 2 3 4 4 3 2
FCA+Celecoxib
Day 13 Day 14 Day 15 Day 16 Day 17
Animal Mean Left Mean Right Ratio L/R Mean Left Mean Right Ratio L/R Mean Left Mean Right Ratio L/R Mean Left Mean Right Ratio L/R Mean Left Mean Right Ratio L/R
3 61 110 55 75 89 84 67 79 85 79 89 89 82 93 88
4 48 91 53 73 96 76 54 73 74 65 81 80 73 78 94
21 63 86 73 55 75 73 63 83 76 80 94 85 69 81 85
23 66 94 70 75 88 85 78 82 95 51 61 84 83 94 88
24 65 101 64 82 90 91 81 89 91 73 80 91 92 95 97
37 70 112 63 73 113 65 72 83 87 64 79 81 69 83 83
mean 62 99 63 72 92 79 69 82 85 69 81 85 78 87 89
sem 3 4 3 5 . 3 4 5 2 4 3 2
Appendix 1.7. Raw weight bearing data for vehicle and 10 mg/kg celecoxib dosed animals used for figure 4.6. Mean (+/- sem) of ratio I/C were used to plot figure 4.6 and each Ratio l/C per day used to determine 
statistical significance between groups
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Saline
Day 13 1 Day 14 1 Day 15 ■ Day 16 ■ Day 17 |
Animal Mean Left Mean Right Ratio L/R Mean Left Mean Right Ratio L/R Mean Left Mean Right Ratio L/R Mean Left Mean Right Ratio L/R Mean Left Mean Right Ratio UR
1 10.3 10.3 100 10.2 10.2 100 103 10 2 101 10 2 10 3 99 10.3 10.2 101
6 102 10.3 99 102 103 99 10.2 10.2 100 10 3 10.2 101 10.2 104 98
7 102 10.2 100 10.2 10.2 100 10.2 102 100 10.2 102 100 10.3 10.2 101
8 10 3 10.3 100 103 10.3 100 10.2 10.2 100 10 3 10 3 100 104 10 3 101
13 10.3 10.3 100 10.3 10.3 100 103 102 101 103 10.3 100 10.2 102 100
14 10.3 10 3 100 10.3 10.2 101 10.3 102 101 102 103 99 10.3 103 100
15 10.3 10.2 101 10.2 10.2 100 103 10.3 100 10.3 102 101 10.3 103 100
17 10.3 103 100 10.3 10.3 100 10.3 103 100 10.3 103 100 10.2 10.3 99
18 10.3 10.3 100 103 10.3 100 10.3 103 100 10.3 103 100 10.2 10.2 100
19 10.2 10.2 100 10.3 10.3 100 10.2 10.3 99 10 3 10.4 99 10.2 10.2 100
20 10.2 10.2 100 103 10.3 100 10.3 103 100 10.3 10.3 100 10.2 10.3 99
I 26 102 10 102 10.3 103 100 10.3 10 3 100 10.2 10 3 99 10 3 10.3 100
mean I 10 10 100 10 10 100 10 10 100 10 10 100 10 10 100
{ sem | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1
|FCA+Vehicle
i Day 13 Day 14 ■ Day 15 Day io Day 17
I Animal Mean Left Mean Right Ratio L/R Mean Left Mean Right Ratio L/R Mean Left Mean Right I Ratio L/R Mean Left Mean Right Ratio L/R Mean Left Mean Right Ratio UR
I 2 11.8 10 118 11.4 10.2 112 11 3 101 112 11.3 10.1 112 11 10.1 109
I 5 11.7 10.2 115 11.5 10 115 11.3 10 | 113 11.2 10.1 111 11.2 10.2 110
9 114 10 2 112 11.1 10.2 109 11.1 10.1 110 I 11.1 102 109 10.9 10 2 10710 11 10 110 11.1 10.2 109 11.1 10.1 110 11 10.1 109 10.9 10.2 107
11 11.3 10.2 111 11.6 10.2 114 115 10.2 | 113 114 10.1 113 11.3 102 111
I 12 10 112 11.2 10 1 111 11.3 101 | 112 -  - 10.2 109 11.2 10.2 110
mean 11 113 11 112 11 J 112 11 10 110 . _ 10 109sem 0 _ L. L . 1 o 1 0 1 . . .. 1
FCA+Celecoxib
Day 13 Day 14 Day 1 5 ■ Day 16 ■ Day 1 7 ■
Animal Mean Left Mean Right Ratio L/R Mean Left Mean Right Ratio L/R Mean Left Mean Right Ratio UR Mean Left Mean Right Ratio UR Mean Left Mean Right Ratio UR
3 10 8 10.2 106 10.8 102 106 108 102 106 10 5 102 103 106 102 104
4 11.11 103 108 11 10.3 107 10.7 10.3 104 108 103 105 10.7 10.2 105
21 10.9 10.2 107 109 10.3 106 10.8 103 105 109 103 106 10.9 10.3 106
23 11.5 10.3 112 11.1 10.2 109 11 10.3 107 108 10.2 106 10 9 10.2 107
24 11.8 10.3 115 11.5 10.3 112 11.3 10.3 110 11.1 103 108 10.7 102 105
37 11 10.3 107 109 10.2 107 10.8 10.2 106 106 103 103 10 7 10.2 105
mean 11 10 109 11 10 108 11 10 106 11 10 105 11 10 105
sem 0 0 1 0 0 1 0 0 1 0 0 1 0 0 0
Appendix 1.8. Raw weight bearing data for vehicle and 10 mg/kg celecoxib dosed animals used for figure 4.7. Mean (+/- sem) of ratio l/C were used to plot figure 4.7 and each Ratio l/C per day used to determine 
statistical significance between groups
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Appendix 1.9. Cell count data for FG-labelled and CGRP-immunopositive cell 
bodies from individual animals, experimental groups and time points used to 
comprise table 4.1, figure 4.9 and appendix 2.9.
Day 1.







Day 1. Saline rat 1 39 81 120 44 37
Day 1. Saline rat 2 35 83 118 37 31
Day 1. Saline rat 3 66 77 143 48 34
Day 1. Saline rat 4 35 47 82 25 30
Totals 175 288 463 154 33







Day 1. FCA rat 1 75 76 151 74 49
Day 1. FCA rat 2 104 79 183 75 41
Day 1. FCA rat 3 64 90 154 71 46
Day 1. FCA rat 4 77 53 130 49 38
Totals 320 298 618 269 44
Day 7.







Day 7. Saline rat 1 49 66 115 37 32
Day 7. Saline rat 2 65 79 144 44 31
Day 7. Saline rat 3 54 51 105 27 26
Day 7. Saline rat 4 37 75 112 38 34
Totals 205 271 476 146 31







Day 7. FCA rat 1 30 66 96 39 41
Day 7. FCA rat 2 50 49 99 36 36
Day 7. FCA rat 3 38 55 93 37 40
Day 7. FCA rat 4 71 29 100 35 35
Totals 189 199 388 147 38
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Day 17.







Sal+Vehicle 1 19 50 69 24 35
Sal+Vehicle 2 20 59 79 28 35
Sal+Vehicle 3 17 77 94 27 29
Sal+Vehicle 4 62 16 78 16 21
Totals 118 202 320 95 30







FCA+Vehicle 1 32 138 170 66 39
FCA+Vehicle 2 11 39 50 21 42
FCA+Vehicle 3 39 16 55 22 40
FCA+Vehicle 4 15 63 78 31 40
Totals 97 256 353 140 40







FCA+celebrex 1 18 22 40 10 25
FCA+celebrex 2 17 43 60 23 38
FCA+celebrex 3 22 22 44 17 39
FCA+celebrex 4 23 19 42 17 40




Appendix 2.1. Statistical analysis to determine whether or not the medians of day 7 
and day 28 FG-labelled cell bodies differ significantly. Analysis derived using L3 and 
L4 count data from tables 2.1 and 2.3.
Mann-Whitney Rank Sum Test.
Group N Missing Median 25% 75%
Day 28 8 0 55.000 23.000 82.500
Day 7 8 0 108.000 62.500 224.000
T = 48.500 ntsmall)^ 8 n(big)= 8 P(est.)= 0.046 P(exact)= 0.038
The difference in the median values between the two groups is greater than would be expected by 
chance; there is a statistically significant difference (P = 0.038).
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Appendix 2.2. Statistical analysis o f weight bearing data for pilot study (figure 3.2).
One Way Repeated Measures ANOVA
Source of Variation DF SS MS F P
Group 1 9157.556 9157.556 65.698 0.001
Sub(Group) 4 557.556 139.389
Day 2 4716.778 2358.389 23.990 <0.001
Group xD ay 2 4572.111 2286.056 23.255 <0.001
Residual 8 786.444 98.306
Total 17 19790.444 1164.144
All Pairwise Multiple Comparison Procedures (Holm-Sidak method): 
Overall significance level = 0.05
Comparisons for factor: Group within day 0 
Comparison D iff o f Means t
Saline vs. FCA 0.333 0.0386
Comparisons for factor: Group within day 1 
Comparison Diff o f Means t
Saline vs. FCA 72.000 8.332
Comparisons for factor: Group within day 7 
Comparison Diff o f Means t





















Appendix 2.3. Statistical analysis o f weight bearing data for figure 3.4.
One Way Repeated M easures ANOVA
Source of Variation DF SS MS F P
Group 1 7733.719 7733.719 113.763 <0.001
Sub(Group ) 6 407.885 67.981
Day 2 5807.609 2903.804 48.911 <0.001
Group xD ay 2 6073.828 3036.914 51.153 <0.001
Residual 12 712.436 59.370
Total 23 20735.477 901.542
All Pairwise Multiple Comparison Procedures (Holm-Sidak method): 
Overall significance level = 0.05
Comparisons for factor: Group within day 0 
Comparison D iff o f Means t
FCA vs. Saline 4.429 0.794
Comparisons for factor: Group within day 1 
Comparison D iff o f Means t
Saline vs. FCA 73.345 13.148
Comparisons for factor: Group within day 16 
Comparison D iff o f Means t



















Note: where unadjusted P is 0.000, this corresponds to <0.001
Appendix 2.4. Established FCA model (intra-plantar) statistical analysis data
Study 1. Established FCA model (intra-plantar) - One Way Analysis of Variance
Source of Variation DF SS MS F P
Between Groups 3 10661.754 3553.918 1.111 0.364
Residual 24 76752.029 3198.001
Total 27 87413.783
The differences in the mean values among the treatment groups are not great enough to exclude the 
possibility that the difference is due to random sampling variability; there is not a statistically 
significant difference (P = 0.364).
Study 2. Established FCA model (intra-plantar) - One Way Analysis of Variance
Source of Variation DF SS MS F P
Between Groups 3 34986.222 11662.074 9.120 <0.001
Residual 24 30690.459 1278.769
Total 27 65676.681
The differences in the mean values among the treatment groups are greater than would be expected by 
chance; there is a statistically significant difference (P = <0.001).
Power o f performed test with alpha = 0.050: 0.984
Multiple Comparisons versus Control Group (Dunnett's Method):
Comparisons for factor:
Comparison D iff o f Means q’ P P<0.050
vehicle vs. 1 Omg/kg 90.173 4.718 - Yes
vehicle vs. lmg/kg 79.192 4.143 - Yes
vehicle vs. 3 mg/kg 41.988 2.197 - No
Note: The P values for Dunnett's and Duncan's tests are unavailable except for reporting that the P's are 
greater or less than the critical values of .05 and .01.
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Appendix 2.5. Statistical analysis for effect of celecoxib on weight bearing data 
(figure 4.4).
One Way Repeated Measures ANOVA
Source o f Variation DF SS MS F p
Group 4 81947.626 20486.907 80.316 <0.001
Subjects(Group) 39 9948.107 255.080
Day 5 22795.560 4559.112 38.579 <0.001
Group x Day 20 18550.120 927.506 7.849 <0.001
Residual 195 23044.169 118.175
Total 263 166324.883 632.414
Multiple Comparisons versus Control Group (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor: Group within day 9
Comparison Diff o f Means t Unadjusted P Critical Level
Vehicle vs. Naive 54.660 7.781 0.000 0.013
Vehicle vs. 3 mg/kg 1.532 0.288 0.773 0.017
Vehicle vs. lOmg/kg 1.326 0.250 0.803 0.025
Vehicle vs. 1 mg/kg 0.509 0.0959 0.924 0.050
Comparisons for factor: Group within day 13
Comparison D iff o f Means t Unadjusted P Critical Level
Vehicle vs. Naive 61.196 8.711 0.000 0.013
Vehicle vs. lOmg/kg 34.398 6.478 0.000 0.017
Vehicle vs. 3mg/kg 23.578 4.440 0.000 0.025
Vehicle vs. 1 mg/kg 10.605 1.997 0.047 0.050
Comparisons for factor: Group within day 14
Comparison Diff of Means t Unadjusted P Critical Level
Vehicle vs. lOmg/kg 57.536 10.835 0.000 0.013
Vehicle vs. Naive 60.130 8.560 0.000 0.017
Vehicle vs. 3 mg/kg 43.250 8.145 0.000 0.025
Vehicle vs. 1 mg/kg 12.161 2.290 0.023 0.050
Comparisons for factor: Group within day 15
Comparison Diff o f Means t Unadjusted P Critical Level
Vehicle vs. lOmg/kg 52.138 9.818 0.000 0.013
Vehicle vs. 3mg/kg 39.995 7.532 0.000 0.017
Vehicle vs. Naive 49.828 7.093 0.000 0.025
Vehicle vs. 1 mg/kg 18.801 3.541 0.000 0.050
Comparisons for factor: Group within day 16
Comparison Diff o f Means t Unadjusted P Critical Level
Vehicle vs. lOmg/kg 42.908 8.080 0.000 0.013
Vehicle vs. 3mg/kg 41.778 7.867 0.000 0.017
Vehicle vs. Naive 48.557 6.912 0.000 0.025



























Comparisons for factor: Group within day 17
Comparison Diff o f Means t Unadjusted P Critical Level Significant?
Vehicle vs. lOmg/kg 44.038 8.293 0.000 0.013 Yes
Vehicle vs. 3mg/kg 39.212 7.384 0.000 0.017 Yes
Vehicle vs. Naive 49.312 7.020 0.000 0.025 Yes
Vehicle vs. 1 mg/kg 8.159 1.537 0.126 0.050 No
Note: where unadjusted P is 0.000, this corresponds to <0.001
Appendix 2.6. Statistical analysis for effect of celecoxib on joint diameter data 
(figure 4.5).
One Way Repeated Measures ANOVA
Source of Variation DF SS MS F P
Group 4 4811.085 1202.771 39.451 <0.001
Subjects(Group) 39 1189.007 30.487
Day 5 1465.319 293.064 45.322 <0.001
Group x Day 20 345.373 17.269 2.671 <0.001
Residual 195 1260.913 6.466
Total 263 9805.935 37.285
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05
Comparisons for factor: Group within day 9
Comparison Diff o f Means t Unadjusted P Critical Level Signifies
Vehicle vs. Naive 19.963 10.428 0.000 0.013 Yes
Vehicle vs. lOmg/kg 3.132 2.164 0.032 0.017 No
Vehicle vs. 3mg/kg 2.215 1.531 0.128 0.025 No
Vehicle vs. 1 mg/kg 0.150 0.103 0.918 0.050 No
Comparisons for factor: Group within day 13
Comparison Diff o f Means t Unadjusted P Critical Level Significant?
Vehicle vs. Naive 15.680 8.191 0.000 0.013 Yes
Vehicle vs. lOmg/kg 4.765 3.293 0.001 0.017 Yes
Vehicle vs. 3 mg/kg 3.748 2.590 0.011 0.025 Yes
Vehicle vs. 1 mg/kg 0.830 0.573 0.567 0.050 No
Comparisons for factor: Group within day 14
Comparison Diff of Means t Unadjusted P Critical Level Significant?
Vehicle vs. Naive 17.665 9.228 0.000 0.013 Yes
Vehicle vs. lOmg/kg 7.055 4.875 0.000 0.017 Yes
Vehicle vs. 3mg/kg 6.364 4.398 0.000 0.025 Yes
Vehicle vs. 1 mg/kg 2.379 1.644 0.102 0.050 No
Comparisons for factor: Group within day 15
Comparison Diff o f Means t Unadjusted P Critical Level Significant?
Vehicle vs. Naive 12.818 6.696 0.000 0.013 Yes
Vehicle vs. lOmg/kg 5.853 4.045 0.000 0.017 Yes
Vehicle vs. 3mg/kg 5.149 3.558 0.001 0.025 Yes
Vehicle vs. lmg/kg 0.454 0.314 0.754 0.050 No
Comparisons for factor: Group within day 16
Comparison Diff o f Means t Unadjusted P Critical Level Significant?
Vehicle vs. Naive 12.426 6.491 0.000 0.013 Yes
Vehicle vs. lOmg/kg 6.497 4.490 0.000 0.017 Yes
Vehicle vs. 3 mg/kg 5.223 3.609 0.000 0.025 Yes
Vehicle vs. lmg/kg 0.311 0.215 0.830 0.050 No
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Comparisons for factor: Group within day 17
Comparison D iff of Means t Unadjusted P Critical Level Significant?
Vehicle vs. Naive 11.737 6.131 0.000 0.013 Yes
Vehicle vs. lOmg/kg 6.262 4.327 0.000 0.017 Yes
Vehicle vs. 3mg/kg 4.586 3.169 0.002 0.025 Yes
Vehicle vs. lmg/kg 0.410 0.283 0.777 0.050 No
Note: where unadjusted P is 0.000, this corresponds to <0.001
Appendix 2.7. Statistical analysis for weight bearing data during the celecoxib dosing 
period (figure 4.6).
One Way Repeated Measures ANOVA
Source of Variation DF SS MS F P
Group 2 76289.086 38144.543 488.227 <0.001
Subject(Group) 21 1640.701 78.129
Day 5 4123.800 824.760 9.308 <0.001
Group x Day 10 6484.438 648.444 7.318 <0.001
Residual 105 9303.575 88.605
Total 143 96112.830 672.118
All Pairwise Multiple Comparison Procedures (Holm-Sidak method): 
Overall significance level = 0.05
Comparisons for factor: Group within day 10 
Comparison Diff of Means t
vehicle vs. FCA+V 60.800 13.047
vehicle vs. celecoxib 55.605 11.933
celecoxib vs. FCA+V 5.194 0.965




Comparisons for factor: Group within day 13
Comparison D iff o f Means t Unadjusted P Critical Level Significant?
vehicle vs. FCA+V 59.251 12.715 0.000 0.017 Yes
vehicle vs. celecoxib 34.365 7.375 0.000 0.025 Yes
celecoxib vs. FCA+V 24.886 4.625 0.000 0.050 Yes
Comparisons for factor: Group within day 14
Comparison Diff o f Means t Unadjusted P Critical Level Significant?
vehicle vs. FCA+V 57.591 12.359 0.000 0.017 Yes
celecoxib vs. FCA+V 38.299 7.118 0.000 0.025 Yes
vehicle vs. celecoxib 19.291 4.140 0.000 0.050 Yes
Comparisons for factor: Group within day 15
Comparison D iff o f Means t Unadjusted P Critical Level Significant?
vehicle vs. FCA+V 55.063 11.816 0.000 0.017 Yes
celecoxib vs. FCA+V 41.769 7.763 0.000 0.025 Yes
vehicle vs. celecoxib 13.294 2.853 0.005 0.050 Yes
Comparisons for factor: Group within day 16
Comparison Diff o f Means t Unadjusted P Critical Level Significant?
vehicle vs. FCA+V 50.923 10.928 0.000 0.017 Yes
celecoxib vs. FCA+V 37.713 7.009 0.000 0.025 Yes
vehicle vs. celecoxib 13.211 2.835 0.005 0.050 Yes
Comparisons for factor: Group within day 17
Comparison Diff o f Means t Unadjusted P Critical Level Significant?
vehicle vs. FCA+V 52.786 11.328 0.000 0.017 Yes
celecoxib vs. FCA+V 42.961 7.984 0.000 0.025 Yes
vehicle vs. celecoxib 9.826 2.109 0.037 0.050 Yes
Note: where unadjusted P is 0.000, this corresponds to <0.001
144
Appendix 2.8. Statistical analysis of joint diameter data during celecoxib (10 mg/kg) 
administration (figure 4.7).
One Way Repeated Measures ANOVA
Source o f Variation DF SS MS F p
Group 2 3736.026 1868.013 141.323 <0.001
Subject(Group) 21 277.579 13.218
Day 5 391.286 78.257 23.725 <0.001
Group x Day 10 269.924 26.992 8.183 <0.001
Residual 105 346.350 3.299
Total 143 4878.312 34.114
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor: Group within day 10
Comparison D iff of Means t Unadjusted P Critical Level
FCA+V vs. vehicle 15.471 13.905 0.000 0.017
celecoxib vs. vehicle 14.306 12.858 0.000 0.025
FCA+V vs. celecoxib 1.165 0.907 0.367 0.050
Comparisons for factor: Group within day 13
Comparison D iff of Means t Unadjusted P Critical Level
FCA+V vs. vehicle 12.708 11.422 0.000 0.017
celecoxib vs. vehicle 8.769 7.881 0.000 0.025
FCA+V vs. celecoxib 3.939 3.066 0.003 0.050
Comparisons for factor: Group within day 14
Comparison D iff o f Means t Unadjusted P Critical Level
FCA+V vs. vehicle 11.504 10.339 0.000 0.017
celecoxib vs. vehicle 7.639 6.866 0.000 0.025
FCA+V vs. celecoxib 3.865 3.008 0.004 0.050
Comparisons for factor: Group within day 15
Comparison D iff of Means t Unadjusted P Critical Level
FCA+V vs. vehicle 11.387 10.235 0.000 0.017
celecoxib vs. vehicle 6.004 5.396 0.000 0.025
FCA+V vs. celecoxib 5.384 4.190 0.000 0.050
Comparisons for factor: Group within day 16
Comparison D iff o f Means t Unadjusted P Critical Level
FCA+V vs. vehicle 10.526 9.461 0.000 0.017
celecoxib vs. vehicle 5.190 4.665 0.000 0.025
FCA+V vs. celecoxib 5.336 4.154 0.000 0.050
Comparisons for factor: Group within 17
Comparison Diff o f Means t Unadjusted P Critical Level
FCA+V vs. vehicle 8.916 8.013 0.000 0.017
celecoxib vs. vehicle 5.297 4.761 0.000 0.025

























Note: where unadjusted P is 0.000, this corresponds to <0.001
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Appendix 2.9. Statistical analysis of FG-labelled and CGRP-immunopositive cell 
bodies percentage co-localization (table 4.1 and figure 4.9).
Day 1. Percentage co-localization, One Way Analysis of Variance
Group Name N Missing Mean Std Dev SEM
Saline 4 0 33.019 2.755 1.378
FCA 4 0 43.447 5.071 2.536
Source of Variation DF SS MS F P
Between Groups 1 217.461 217.461 13.057 0.011
Residual 6 99.931 16.655
Total 7 317.392
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor:
Comparison Diff o f Means t Unadjusted P Critical Level Significant? 
FCA vs. Saline 10.427 3.613 0.0112 0.050 Yes
Day 7. Percentage co-localization, One Way Analysis o f Variance
Group Name N Missing Mean Std Dev SEM
Saline 4 0 30.593 3.532 1.766
FCA 4 0 37.943 2.692 1.346
Source o f Variation DF SS MS F P
Between Groups 1 108.054 108.054 10.957 0.016
Residual 6 59.170 9.862
Total 7 167.224
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor:
Comparison Diff o f Means t Unadjusted P Critical Level Significant?
FCA vs. Saline 7.350 3.310 0.0162 0.050 Yes
Day 17. Percentage co-localization, One Way Analysis o f Variance
Group Name N Missing Mean Std Dev SEM
Saline 4 0 23.750 5.439 2.720
FCA+Vehicle 4 0 35.000 21.150 10.575
FCA+celecoxib 4 0 16.750 5.315 2.658
Source o f Variation DF SS MS F P
Between Groups 2 678.167 339.083 2.014 0.189
Residual 9 1515.500 168.389
Total 11 2193.667
The differences in the mean values among the treatment groups are not great enough to exclude the 
possibility that the difference is due to random sampling variability; there is not a statistically 
significant difference (P = 0.189).
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Abstract—Small-diameter sensory neurons are key contribu­
tors in joint pain and have been implicated in the pathogen­
esis of rheumatoid arthritis (RA). Small-diameter sensory 
neurons can be separated into at least two distinct popula­
tions, which include isolectin B4 (IB4)-binding and tyrosine 
receptor kinase (trk) A-expressing. While trkA-expressing 
neurons have been identified in the rat knee joint there are no 
data, we are aware of, to suggest that IB4-binding neurons 
are also present. We aimed to determine whether or not there 
exists a population of IB4-binding neurons in the rat knee 
joint.
Retrograde nerve tracing with fluoro-gold (FG) was used 
to identify the complete population of knee joint afferents in 
the lumbar dorsal root ganglia (DRG) L3 and L4 of female 
Wistar rats. IB4 conjugated to fluorescein isothiocyanate 
(FITC) was used to identify the cell bodies of IB4-binding 
neurons in the DRG. Of 1096 FG-labeled cell bodies in the 
DRG of knee joint injected animals (n=4), none were double 
labeled with FITC. Injection of FG into skin over the medial 
aspect of the rat knee (n=3) showed 48% of these cutaneous 
afferents in L3 and L4 DRG were double-labeled with FG and 
FITC.
A complete absence of IB4-binding neurons in the rat 
knee joint makes it unlikely that this predominantly cutane­
ous, IB4-binding population of afferent neurons could have 
any significant influence in chronic inflammatory joint dis­
ease. This suggests that trkA-expressing neurons are the 
sole population of small-diameter sensory neurons in the 
knee joint and implies a significant role for these afferents in 
the progression of RA. © 2004 IBRO. Published by Elsevier 
Ltd. All rights reserved.
Key words: DRG, FG, RA, trkA.
Sm all-d iam eter sen so ry  n eu ro n s  of the  dorsal root ganglia 
(DRG) d e tec t noxious stimuli, which often resu lts  in pain 
sen sa tio n . In the  early  1980s N agy and  Hunt (1982) su g ­
g e s te d  tha t sm all-d iam eter sen so ry  neu ro n s could be  s e p ­
a ra ted  into two distinct populations b a se d  on their neuro ­
chem ical profile. O ne group of neu ro n s con ta ined  the  neu-
‘Corresponding author. Tel: +44-1225-383825.
E-mail address: mppspi@bath.ac.uk (S. P. Ivanavicius). 
Abbreviations: CGRP, calcitonin gene-related peptide; DRG, dorsal 
root ganglion; FG, fluoro-gold; FITC, fluorescein isothiocyanate; 
GDNF, glial-derived neuronal factor; IB4, isolectin B4; NGF, nerve 
growth factor; PBS, phosphate-buffered saline; RA, rheumatoid arthri­
tis; SP, substance P; trk, tyrosine receptor kinase.
ropeptides calcitonin gene-re la ted  pep tide (C G RP) and  
su b s tan ce  P (SP), w h e re a s  th e  o ther group lacked n eu ­
ropeptides but con ta ined  th e  enzym e fluoride-resistant 
acid p h o sp h a ta se  and  selectively bound th e  lectin Griffonia 
simplicifolia isolectin B4 (IB4; N agy an d  Hunt, 1982; Sil­
verm an and K ruger, 1990). T h e se  tw o populations of 
sm all-d iam eter se n so ry  neu ro n s a lso  differ in their trophic 
dependency . T he peptidergic neu ro n s a re  regu lated  by 
nerve growth factor (NGF) and  ex p re s s  th e  high-affinity 
NGF recep tor ty rosine recep to r k inase (trk) A (Averill e t al., 
1995; Michael e t al., 1997), w h e rea s  IB4-binding n eu rons 
respond  to glial-derived neurotrophic factor (GDNF) and  
ex p re ss  th e  GDNF recep to r com plex, including G F R a su b ­
units and c-ret (Molliver e t al., 1997; B ennett e t al., 1998, 
2000; O rozco e t al., 2001; Zwick e t al., 2002). Recently, 
th e  different regulatory  facto rs and  neurochem ical c la ss i­
fications of th e s e  tw o populations h av e  led to speculation  
over their potential functional d ifferences. E vidence for 
possib le functional d ifferences com e from th e  fact tha t the  
purine recep to r P2X 3, which h a s  b een  a sso c ia te d  with 
nociception, is a lm ost exclusively localized in IB4-binding 
neurons, few a re  found in th e  trkA -expressing population 
(V ulchanova e t al., 1998; Burnstock, 2002; H onore e t al., 
2002). Furtherm ore, th ere  a re  a  num ber of neuroanatom i- 
cal d ifferences th a t strongly imply functional d ifferences. 
T he trkA -expressing neu rons term inate  in lam ina I and  
ou ter lam ina II of th e  superficial dorsal horn, w h e rea s  
IB4-binding n eu ro n s  predom inantly  project to inner lam ina 
II (Silverm an and  K ruger, 1990; M antyh e ta l . ,  1997; Ju lius 
and  B asbaum , 2001). Also, th e  trkA -expressing population 
generally  innervate v isceral ta rg e ts , w h e re a s  IB4-binding 
neu rons generally  innervate  m ore superficial struc tu res  
(Lu e t al., 2001; A m balavanar e t al., 2003).
Further functional d ifferences betw een  th e  two popu­
lations of sm all-d iam eter sen so ry  neu ro n s a re  illustrated 
by their contributions to inflam m atory re sp o n se s . E xp res­
sion of pro-inflam m atory neu ro p ep tid es  S P  and  C G R P by 
trkA -expressing fibers implies a  m ore significant involve­
m en t in neurogen ic  inflam m ation com pared  with the  non- 
peptidergic IB4-binding neu rons. M oreover, o ther stu d ies  
have  su g g es ted  th a t th e  two populations of sm all-d iam eter 
sen so ry  n eu rons m ay re p re se n t different m odalities of 
chronic pain. C hronic pain derived from tissu e  inflam m a­
tion h as  been  asso c ia te d  with trkA -expressing neurons, 
w h e rea s  IB4-binding neu ro n s have  b een  a sso c ia te d  with 
chronic pain derived from nerve  injury (M alm berg e t al., 
1997a,b).
T he painful n a tu re  an d  p ro g re ss io n  of ch ron ic  inflam ­
m atory  cond itions su c h  a s  rh eu m ato id  arth ritis (RA) h a s  
b een  a s s o c ia te d  with in c re a se d  sensitiv ity  of sm all-
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d ia m e te r  s e n s o ry  n e u ro n s  (Kidd e t al., 1990; M app e t 
al., 1990). T h e  likelihood of functional d iffe ren ces  b e ­
tw een  th e  tw o p o p u la tio n s of sm a ll-d iam ete r se n s o ry  
n e u ro n s  m ay  a lso  imply s e p a ra te  ro les for them  in th e  
p a th o g e n e s is  of RA an d  a s s o c ia te d  d is e a s e s .  D etail 
reg a rd in g  th e  tw o p o p u la tio n s in d e e p  so m a tic  s tru c ­
tu re s  su c h  a s  th e  k n e e  jo in t is lim ited. S a lo  an d  T heriau lt 
(1997) found  th a t 33%  an d  10%  of all k n ee  jo in t affer- 
e n ts  in ra t w e re  positive for C G R P  an d  S P  respec tive ly , 
indicating  th a t app rox im ate ly  one-th ird  of all ra t k n ee  
joint a ffe re n ts  a re  trkA -expressing  n eu ro n s . W hile the  
w ork of S a lo  an d  T heriau lt (1997) im plies th a t trkA- 
e x p re s s in g  n e u ro n s  a re  p re s e n t in th e  ra t k n ee  joint 
th e re  a re  no  d a ta , w e a re  aw a re  of, to  s u g g e s t  th a t 
IB 4-binding n e u ro n s  a re  a lso  p re se n t.
In this investigation w e have  u sed  re trog rade  nerve 
tracing to label all ra t knee  joint afferen ts and  fluorescen t- 
histochem istry  tech n iq u es to identify sm all-d iam eter s e n ­
sory  n eu ro n s  a t th e  level of th e  lum bar DRG to determ ine 
w h eth er or not th e re  is a  population of IB4-binding neu rons 
in th e  rat k n ee  joint.
EXPERIMENTAL PROCEDURES
Animals
Eleven fem ale Wistar rats (2 5 0 -3 0 0  g) w ere u sed  in this study. 
Animals w ere obtained in h ou se  and maintained under a 12-h 
light/dark cycle, two or three per ca g e . All experim ents w ere  
carried out in accordance with Hom e Office guidelines on the 
ethical u se  of anim als. Also, every effort w as m ade to minimize 
animal suffering and reduce the number of anim als used .
Retrograde nerve tracing
Retrograde labeling of knee joint afferents w as carried out using a 
technique described previously (Salo and Theriault, 1997; Catre 
and Salo, 1999). Briefly, four anim als w ere put under isoflurane 
an esth esia  and using a sterile technique a small (approximately 
5 mm) skin incision w as m ade over the patellar ligament of the 
right hind limb. A ga u g e  27  need le, a s  part of a SURFLO winged  
infusion se t  (Terumo, NJ, USA), connected  to a 100 |xl Hamilton 
syringe w as introduced into the sp a ce  betw een the tendon and the 
patellar groove of the distal femur. 15 |xl Fast Green (Sigm a, UK) 
dissolved  in 0.1 M phosphate-buffered saline (PBS) and 5 jjlI of 
2% fluoro-gold (FG) (Fluorochrome LCC, CO, USA) w as then  
injected into the joint. Following injection the n eed le w a s with­
drawn and the incision sea led  with non-toxic glue.
R etrograde labeling of cu taneous afferents w as carried out in 
three anim als a s  described above, the need le being inserted into 
skin over the medial a sp ec t of the knee joint. Three animals 
received a 5 (xl injection of 2% FG into the tail vein and on e animal 
rem ained naive a s  a blank control.
Preparation of tissue
All rats w ere killed 7 days after FG injection. Animals w ere deeply  
anesthetized  with sodium  pentobarbital (R hone Merieux, E ssex , 
UK; 120 mg, i.p.) and perfused with 500  ml 0.1 M PB S followed by 
5 00  ml ice-cold, fresh 4% paraformaldehyde in 0.1 M PBS. After 
perfusion, ipsilateral and contralateral lumbar DRG L3 and L4 
w ere rem oved and im m ersed in paraformaldehyde for 4  h. Tis­
s u e s  w ere then rinsed in 0.1 M PB S and im mersed in 20%  
su cro se  solution for another 48  h. After cryoprotection DRG w ere 
longitudinally oriented and mounted in Tissue-Tek (Raymond A.
Lamb, London, UK) and rapidly frozen in liquid nitrogen and stored  
at - 8 0  °C until sectioning.
Fluorescent-histochemistry
T issu es w ere cut at - 2 0  °C on a Bright cryostat (section  thickness 
10 |xm). Section s w ere thaw -m ounted onto BDH superfrost micro­
sc o p e  slides. S lid es w ere then briefly incubated in 0.1 M PBS, 
followed by incubation at 4  °C in a humid environm ent with 
an IB4-fluorescein isothiocyanate (FITC) conjugate (Sigm a), 
10 p,g/ml or non-conjugated FITC (Sigm a), 10 (xg/ml for 4 0  min. 
After rinsing in 0.1 M PB S, slid es w ere mounted with fluorescent 
mounting medium (DAKO, CA, USA) and left to dry at 4  °C over 
night.
Analysis
All slid es w ere observed  under a Z e iss m icroscope using filters 
appropriate for FG illumination (excitation: 365 /12  nm; em ission: 
397  nm) and FITC illumination (excitation: 4 5 0 - 4 9 0  nm; em is­
sion: 5 1 5 -5 6 5  nm). Digital im ages w ere generated  of every third 
section  for all DRG. The outline of all FG-labeled neurons w as  
digitized using pre-programmed im age analysis software (Z eiss  
KS 300 im age analyzer). The im age analysis software calculated  
the total number of FG-labeled neurons per section  and their 
m ean, feret diam eter (diam eter m easured every 10° with the 
m ean recorded). Only neurons with a nucleus show ing w ere in­
cluded in the counts.
RESULTS
Animal observations
No an im als show ed  any  overt sig n s of d is tre s s  during th e  
period betw een  FG injection and  term ination. No an im als 
w ere  excluded from this study  a s  a  resu lt of injection into 
struc tu res  o th e r th an  th e  knee  joint, skin an d  tail vein or 
d u e  to ex travasation  of tra ce r from th e  injection site.
Retrograde nerve tracing
Only L3 and  L4 DRG w ere  analyzed , a s  approxim ately  
88%  of knee  joint a fferen ts a re  found h e re  (S alo  and  
Theriault, 1997). In tense  FG -labeled  neuronal profiles 
w ere  easily  identifiable in th e  ipsilateral L3 and  L4 DRG of 
an im als w ho received  FG injections to th e  kn ee  joint (Fig. 
1a and  1c). C ontralateral L3 and  L4 DRG w ere  a lso  re ­
m oved and  exam ined  for control p u rp o ses. No FG -labeled  
profiles w ere  s e e n  in any  of th e  con tralateral DRG (data  
not show n).
In tense F G -labeled  neuronal profiles w ere  a lso  s e e n  in 
the  ipsilateral L3 and  L4 DRG of th e  an im als th a t received  
a  skin injection of FG (Fig. 2a, c). No FG -labeled  neuronal 
profiles w ere  s e e n  in th e  con tralateral DRG of skin injected 
an im als or in th e  tail vein-in jected  an im als an d  naive co n ­
trol anim al (data  not show n).
Fluorescent-histochemistry
IB 4-binding n e u ro n s  lab e led  with FITC w e re  read ily  
identifiable. N one of th e  n e u ro n s  w e re  d o u b le - lab e led  
with both FG an d  FITC in an y  of th e  an im a ls  th a t r e ­
ce ived  a  k n ee  jo in t in jection  of FG (Fig. 1b, d). FG a n d  
FITC d o u b le -lab e led  n e u ro n s  w ere  easily  identifiab le  in 
DRG from th e  skin in jec ted  an im al (Fig. 2b , d). Forty-
S. P. Ivanavicius et al. / Neuroscience 128 (2004) 555-560 557
o < 4 -
a<«-
A
Fig. 1. Images of rat L4 DRG following FG injection into the knee joint and fluorescent histochemistry. The two sections were each photographed 
alternately under filters appropriate for FG (A and C) and FITC (B and D). Arrows indicate neurons labeled only with FG. Scale bar=100 pm.
e i g h t  p e r c e n t  o f  F G - l a b e l e d  sk in  a f f e r e n t s  w e r e  d o u b l e ­
l a b e l e d  w ith  FIT C  ( T a b l e  1). N o  la b e l i n g  w a s  s e e n  with  
a n y  n e g a t i v e  c o n tr o l  s e c t i o n s  u s i n g  n o n - c o n j u g a t e d  
FITC ( d a t a  n o t  s h o w n ) .
N u m b e r a n d  s i z e s  o f jo in t  a f f e re n ts
All F G - l a b e l e d  k n e e  jo int  a n d  sk in  a f f e r e n t s  w ith  a  n u ­
c l e u s  s h o w i n g  w e r e  c o u n t e d  u s i n g  Z e i s s  K S  3 0 0  i m a g e  
a n a l y s i s  s o f t w a r e .  N u m b e r s  o f  F G - l a b e l e d  a f f e r e n t s  v a r ­
i e d  b e t w e e n  D R G  ( T a b l e  2 ) .  S o m a l  d i a m e t e r s  o f  jo int  
a f f e r e n t s  w e r e  b r o a d ly  d i s t r ib u te d  a c r o s s  a  r a n g e  o f  
s i z e s  (F ig .  3 ) .
DISCUSSION
U s in g  r e tr o g r a d e  n e r v e  trac ing  w e  b e l i e v e  w e  h a v e  la b e le d  
all rat k n e e  joint a f f e r e n t s  a t  t h e  l ev e l  o f  t h e  L3 a n d  L4 
D R G . N o n e  o f  t h e  k n e e  joint a f f e r e n t s  w e  identif ied  w e r e  
IB 4-b in d in g  n e u r o n s .  P r e v i o u s  s t u d i e s  e x a m i n in g  t h e  in­
n e r v a t io n  o f  d e e p  s o m a t i c  s t r u c tu r e s  h a v e  a l s o  n o te d  low  
n u m b e r s  o f  IB 4-b ind ing  n e u r o n s .  In t h e  rat tr ig em in a l  m a s ­
t ica tory  m u s c l e  o n ly  5%  o f  s e n s o r y  a f f e r e n t s  s h o w  IB4 
b in d in g  (A m b a la v a n a r  e t  al. , 2 0 0 3 ) .  O ur f inding that  4 8 %  o f  
c u t a n e o u s  a f f e r e n t s  a r e  IB 4-b in d in g  n e u r o n s  is  a l s o  in 
a g r e e m e n t  with p r e v io u s  r e su l ts .  A p p r o x im a te ly  4 4 %  a n d  
4 3 %  o f  c u t a n e o u s  a f f e r e n t s  from  t h e  v ib r issa l  p a d  a r e a  a n d  
m e d ia l  a n k le  r e s p e c t iv e ly ,  s h o w  IB4 b inding  ( A m b a l a v a n a r  
e t  al. , 2 0 0 3 ;  B e n n e t t  e t  al. , 1 9 9 6 ) .  A ls o ,  this  s u g g e s t s  that
IB 4-b ind ing  n e u r o n s  tra n sp o rt  F G  at  a  s im ilar  rate  a s  o th e r  
s e n s o r y  a f fe r e n t  n e u r o n s .  T h u s ,  it is un l ike ly  that  F G  a n d  
FITC d o u b le - l a b e l e d  n e u r o n s  h a v e  not  b e e n  identif ied  in 
t h e  rat k n e e  joint d u e  to s l o w e r  tr a n sp o r t  o f  F G  to t h e  
lu m b a r  D R G . M o r e o v e r ,  w e  h a v e  identif ied  n o  F G  a n d  
FITC d o u b le - l a b e l e d  n e u r o n s  in lu m b a r  D R G  r e m o v e d  2 8  
d a y s  s u b s e q u e n t  to  rat k n e e  joint in jection  with F G  (da ta  
not  s h o w n ) .  A s  e x p e c t e d  with a  s y s t e m i c  injection  of  FG  
w e  s a w  n o  la b e l in g  o f  lu m b a r  D R G  s o m a t a  fo l low in g  t h e  
tail v e in  in je c t io n s  o f  F G , in d ica t in g  that  t h e  la b e l in g  w e  
s a w  fo l lo w in g  k n e e  joint a n d  skin  in je c t io n s  w a s  from  t h e  
s i t e  o f  in jection  o n ly  a n d  not  d u e  to s y s t e m i c  s p r e a d  o f  FG.
T h e  n u m b e r  o f  F G - l a b e l e d  a f fe r e n t  n e u r o n s  in th e  L3 
a n d  L4 D R G  w e r e  s o m e w h a t  l o w e r  th a n  n u m b e r s  c o u n t e d  
in p r e v io u s  s t u d i e s  ( S a l o  a n d  T her iault ,  1 9 9 7 ) .  T h is  m ight  
b e  d u e  to  d i f f e r e n c e s  in c o u n t in g  t e c h n i q u e s  a n d  t h e  i m a g e  
a n a l y s i s  s o f t w a r e  u s e d .  A l th o u g h  m o s t  l a b e l e d  n e u r o n s  
w e r e  brightly l a b e l e d  with F G , s o m e  a p p e a r e d  to b e  faintly  
l a b e le d ,  g iv ing  a  m o r e  g r a n u la r  a p p e a r a n c e .  It is p o s s i b l e  
that  by  u s in g  d ifferent  c o lo r  t h r e s h o l d s  to  identify  F G -  
l a b e l e d  n e u r o n s  s o m e  s o f t w a r e  m a y  o u t l in e  c e l l s  that  w e  
d e e m e d  a s  b ord er l in e .  T h e r e fo r e ,  w e  o n ly  c o u n t e d  n e u ­
r o n s  that  w e r e  brightly l a b e le d .  In a d d it ion ,  t h e  lo w  c o u n t s  
m a y  a l s o  r e p r e s e n t  d iff icu lt ies  with t h e  reproducib il ity  o f  
m a n u a l  in je c t io n s  into t h e  rat k n e e  joint. A lth o u g h  th e  
n u m b e r s  o f  F G - l a b e l e d  k n e e  joint a f f e r e n t s  d if fered  b e ­
t w e e n  t h e  individual g a n g l ia ,  t h e  s i z e  distribution profile  
(Fig. 3)  c o n s t r u c t e d  from  t h e  total  n u m b e r  o f  F G - la b e le d
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Fig. 2. Images of rat L4 DRG following FG injection into the skin over the medial aspect of the knee joint and fluorescent histochemistry. The two 
sections were each photographed alternately under filters appropriate for FG (A and C) and FITC (B and D). Arrows indicate FG and FITC 
double-labeled neurons. Scale bar=100 |j.m.
n e u r o n s  w a s  c o n s i s t e n t  with p r e v io u s  s i z e  distribution pro­
f i le s  o f  k n e e  joint a f fe r e n ts  ( S a l o  a n d  Ther iault ,  1 9 9 7 ) .
T h e  p r e s e n t  r e s u l t s  fur th er  s u p p o r t  t h e  n o t io n  of  
d if feren t  fu n c t io n a l  r o l e s  for t h e  s m a l l - d i a m e t e r  s e n s o r y  
n e u r o n  p o p u l a t i o n s  in n o r m a l  p h y s i o l o g y  a n d  d i s e a s e  
p a t h o l o g y .  If, a s  t h e  d a t a  s u g g e s t ,  t r k A - e x p r e s s i n g  n e u ­
r o n s  a r e  t h e  o n ly  s m a l l - d i a m e t e r  s e n s o r y  n e u r o n s  in t h e  
rat k n e e  joint,  it b e c o m e s  i n c r e a s i n g l y  l ike ly  th a t  trkA- 
e x p r e s s i n g  n e u r o n s  a r e  t h e  p o p u la t io n  o f  s m a l l - d i a m e t e r  
s e n s o r y  n e u r o n s  a s s o c i a t e d  w ith  c h r o n i c  in f la m m a to r y  
c o n d i t i o n s  s u c h  a s  RA.
A n u m b e r  o f  s t u d i e s  h a v e  s u g g e s t e d  th a t  t h e  tw o  
p o p u la t i o n s  o f  s m a l l - d i a m e t e r  s e n s o r y  n e u r o n s  m a y  r e p ­
r e s e n t  d i f fe r e n t  m o d a l i t i e s  o f  c h r o n i c  p a in .  C h r o n ic  pain  
d e r iv e d  from  t i s s u e  i n f la m m a t io n  h a s  b e e n  a s s o c i a t e d
Table 1. Counts of FG-labeled and FG and FITC double-labeled skin 
afferents in the lumbar DRG
with  t r k A - e x p r e s s i n g  n e u r o n s ,  w h e r e a s  I B 4 -b in d in g  n e u ­
r o n s  h a v e  b e e n  a s s o c i a t e d  w ith  c h r o n i c  p a in  d e r i v e d  
f r o m  n e r v e  injury ( M a l m b e r g  e t  a l . ,  1 9 9 7 a , b ) .  In a d d i t io n ,  
I B 4 -b in d in g  n e u r o n s  h a v e  a l s o  b e e n  i m p l i c a t e d  in t h e  
n o c i c e p t i o n  o f  a c u t e  p a in .  W h e n  I B 4 -b in d in g  n e u r o n s  
a r e  s e l e c t i v e l y  d e s t r o y e d  w ith  n e r v e  to x in ,  a n i m a l s  
s h o w  b e h a v i o r a l  s i g n s  o f  d e c r e a s e d  s e n s i t i v i t y  to  a c u t e  
p a in  ( V u l c h a n o v a  e t  a l . ,  2 0 0 1 ) .  A l t h o u g h  a c u t e  p a in  is  
m a in ly  a s c r i b e d  to  l a r g e r  d i a m e t e r  s e n s o r y  n e u r o n s  
(A -A  f ib e r s ) ,  s m a l l - d i a m e t e r  s e n s o r y  f i b e r s  a r e  still 
t h o u g h t  to  c o n t r ib u t e ,  a s  a  d e g r e e  o f  p a in  c a n  still b e  fe l t  
f o l lo w in g  a  pin prick to  t h e  sk in  e v e n  a f t e r  l o s s  o f  A -A  
f ibe r  f u n c t io n  (M a g e r l  e t  a l . ,  2 0 0 1 ) .  T h u s ,  it i s  p o s s i b l e  
th a t  I B 4 -b in d in g  n e u r o n s  m e d i a t e  b o th  c h r o n i c  p a in  d e ­
r iv ed  fro m  n e r v e  injury a n d  a c u t e  p a in ,  a lb e i t  s e c o n d a r y  
to  A - f ib e r s .
Animal Ganglia Total FG-labeled FG/FITC double­ Table 2. Counts of FG-labeled knee joint and skin afferents in the
cell bodies labeled cell bodies (%) lumbar DRG
Rat skin 1 L3 96 30 (31) Animal L3 L4 Total FG/FITC double­
Rat skin 1 L4 111 41 (37) labeled cell bodies
Rat skin 2 L3 76 3 0(39)
Rat skin 2 L4 197 97 (49) Rat knee joint 1 36 34 70 0
Rat skin 3 L3 42 13(31) Rat knee joint 2 109 107 216 0
Rat skin 3 L4 263 164 (62) Rat knee joint 3 89 237 326 0
Average% 48 Rat knee joint 4 273 211 484 0
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Fig. 3. Distribution of cell body diameters of FG-labeled knee joint afferents.
CONCLUSIONS
W e  p r o p o s e  th a t  t h e  a b s e n c e  o f  I B 4 -b in d in g  n e u r o n s  
a n d  a b u n d a n c e  o f  t r k A - e x p r e s s i n g  n e u r o n s  in t h e  rat 
k n e e  jo in t  i n d i c a t e  c r u c ia l  d i f f e r e n c e s  b e t w e e n  t h e  f u n c ­
t ion o f  t h e s e  t w o  p o p u l a t i o n s  a n d  p o te n t ia l l y  in t h e  
p a t h o g e n e s i s  o f  R A. With n o  I B 4 -b in d in g  n e u r o n s  in t h e  
rat k n e e  jo int  it is  u n c e r t a in  w h e t h e r  th i s  p r e d o m i n a n t l y  
c u t a n e o u s ,  I B 4 -b in d in g  p o p u la t i o n  o f  a f f e r e n t  n e u r o n s  
c o u ld  h a v e  a n y  s ig n i f i c a n t  i n f l u e n c e  in c h r o n i c  in f la m ­
m a to r y  jo in t  d i s e a s e .  T h e  n e u r o g e n i c  i n f la m m a to r y  p r o p ­
e r t i e s  o f  t r k A - e x p r e s s i n g  n e u r o n s  a n d  p r e s e n c e  a s  t h e  
s o l e  p o p u la t i o n  o f  s m a l l - d i a m e t e r  s e n s o r y  n e u r o n s  in 
t h e  k n e e  jo int  s u g g e s t  a  s i g n i f i c a n t  r o le  for t h e s e  a f f e r ­
e n t s  in t h e  p r o g r e s s i o n  o f  R A  a n d  o t h e r  c h r o n i c  in f la m ­
m a to r y  jo in t  d i s e a s e .
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